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Preface  
General Introduction, aims and organization of this 
thesis 
1. GENERAL INTRODUCTION 
In expert opinions, nanobiotechnology is expected to revolutionize or at least 
significantly improve the pharma and life science market within the next 15 years 
(Rehm & Schueler 2005). However, imaginations concerning what exactly will be 
possible in future are rather divergent. Visions, such as the ones of the 
controversially discussed American physicist K. E. Drexler, that one day it will be 
possible to build nanorobots, which will be able to assemble atom-by-atom 
anything mankind needs (Drexler et al. 1993), appear rather like utopian illusions 
from a science fiction novel. Nevertheless, nanotechnology is the rage of today’s 
research world that forces the American government to spend 1.3 billion $ for 
funding in 2006 alone (www.nano.gov/html/about/funding.html).  
Concerning nanodevices suitable for drug delivery, there has already been 
tremendous progress within the last 30 years, from the first liposomal approach 
(Gregoriadis et al. 1974) to various present colloidal systems that enable temporal 
and spatial site-specific delivery. Typical properties of these novel nanocarriers are 
(Couvreur & Vauthier 2006):  
a) Protection of the drugs from degradation  
b) Enhancement of the drug absorption by facilitating the diffusion through 
the epithelium 
c)  Modification of the pharmacokinetics and the drug tissue distribution profile
d) Improvement of the intracellular penetration and distribution 
One very popular subtype of these colloidal delivery systems are nanoparticles. 
They are by definition solid, submicron-sized particles that possess a matrix 
structure typically based on polymers or macromolecular substances (Kreuter 
1978). Drugs or tracers to be delivered with these particles can either be adsorbed 
onto the surface, entrapped in the particle matrix or dissolved in the particle core 
(Allemann et al. 1993). When searching for potential matrix-molecules, good 
particle preparation properties are just one aspect. Aside from this, potential 
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candidates should ideally be highly biocompatible and biodegradable, feature 
various accessible sites to e.g. attach targeting ligands, and finally, be easy to obtain 
and cheap in production. Due to this, approaches based on natural macromolecules 
and proteins that originally go back to the early days of colloidal carrier system 
development (Speiser & Pharmaceutical Society of Victoria 1974; Marty et al. 1978), 
have performed a certain renaissance within the last years. Back in time, these 
approaches failed due to limited reproducibility as well as instabilities and 
inhomogeneities of the produced nanoparticles. Nowadays, technological and 
scientific progress offer new and highly precise tools that facilitate the development 
of new preparation procedures for high quality nanoparticles based on the 
originally old approaches.   
 
2. AIMS OF THIS THESIS 
The present thesis deals with the development of nanoparticles based on the 
proteinaceous macromolecule gelatin as delivery system for various nucleotide-
based drugs. Since a method to produce homogenous nanoparticles was already 
described in principle (Coester et al. 2000), it was the first approach to characterize, 
optimize, and standardize this manufacturing process.  
The next goal was to advance these plain gelatin nanoparticles via modification of 
the surface towards a delivery system for nucleotide-based drugs. Subsequent to 
this, the newly established carrier system should be evaluated in preclinical trials.  
In addition to these main projects, it was also an aim of this study to investigate 
and influence the biodistribution of gelatin nanoparticles.  
 
3. ORGANIZATION OF THIS THESIS 
Due to the multitude of independent projects, the present work is divided into five 
self-contained chapters.  
In Chapter I, fundamental research data concerning the preparation of gelatin 
nanoparticles is described. Thereby, the work was focused on process optimization 
of the existing preparation procedure. Moreover, new analytical tools to 
characterize gelatin and the gelatin nanoparticles are introduced.   
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Chapter II features the data that were produced in cooperation with the 
Department of Pharmaceutical Biotechnology at Ludwig-Maximilians-University 
Munich. In this cooperation, plasmid DNA was bound onto the surface of 
previously modified gelatin nanoparticles by electrostatic interactions. Subsequent 
preparation optimization, this simple non-viral gene delivery system was 
investigated in vitro on murine melanoma cells.  
The major project of this work, the development and evaluation of gelatin 
nanoparticles as carrier system for immunogenic so called CpG oligonucleotides is 
presented in Chapter III and Chapter IV. The data has been generated in 
cooperation with the Department of Internal Medicine at the Ludwig-Maximilians-
University Munich and initially during a 3-month research stay at the Faculty of 
Pharmacy at the University of Alberta in Edmonton, Canada. 
Chapter III features extensive in vitro investigations on the respective primary 
murine and human target cells such as dendritic cells and B cells, whereas in 
Chapter IV, the results of in vivo experiments are presented. Here, the 
immunogenic effects of CpG oligonucleotide-loaded nanoparticles alone and their 
adjuvant activity in combination with the model protein antigen ovalbumin (OVA) 
were explored. 
In the final chapter, Chapter V, first PEGylation experiments of gelatin 
nanoparticles are described, with special emphasis on the establishment of new 
analytical tools for the quality control of the PEGylation process. In the second 
part of this chapter, radiolabeling strategies were developed in cooperation with the 
Department of Nuclear Medicine (TU Munich) to enable real-time in vivo tracking 
of the gelatin nanoparticles via positron emission tomography (PET). 
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Chapter I 
Optimized preparation of gelatin nanoparticles 
1. INTRODUCTION 
In the development process of a nanoparticulate drug delivery system for in vivo 
application, biodegradability without toxic by-products is one of the major claims, a 
potential matrix molecule has to fulfill. Within the past decades, a multitude of 
protocols described in literature used synthetic or natural base products for the 
preparation of biodegradable nanoparticles. Instead of a complete listing of all 
approaches, only a selection of the most significant biodegradable nanoparticle 
types will be reviewed here.  
With regards to nanoparticles based on synthetic polymers, polylactide (PLA), 
polyglycolide (PLG), and poly(D,L-lactide-co-glycolide) (PLGA) nanoparticles 
represent the most extensively investigated ones (Panyam & Labhasetwar 2003). 
Further polymers discussed as promising approaches are poly(cyanoacrylate) 
(PCA), poly(alkylcyanoacrylate) (PACA) (Vauthier et al. 2003), poly(ε-caprolactone) 
(PCL) (Potineni et al. 2003), and poly(ester-anhydride) (PEA) (Pfeifer et al. 2004).  
In addition to these polymers, natural biopolymers and macromolecules such as 
chitosan (Janes et al. 2001), sodium alginate (Rajaonarivony et al. 1993), albumin 
(Kreuter 1978), collagen (Lee et al. 2001) and gelatin represent a second 
fundamental class of base materials for nanoparticles. Among these, nanoparticles 
of proteinaceous origin, e.g albumin, collagen and gelatin have raised specific 
interest. Due to their intrinsic protein structure with the high number of different 
accessible functional groups, they bear multiple modification opportunities for 
coupling of e.g. targeting-ligands, crosslinkers, and shielding substances.  
In the present work, gelatin nanoparticles have been chosen as promising drug 
delivery system candidate. Typically, this natural biopolymer is present in other 
fields of our daily life. It gives gummi bears consistency and without gelatin 
containing icing, ingredients such as fruits would not stick to a cake. Consequently, 
the foodstuff industry is the major purchaser of the tonnages of gelatin that are 
produced every year. However, the amount of gelatin being applied in 
pharmaceutical industry is not negligible, as far as capsules and ointments are 
concerned (Djagny et al. 2001). But also for current research in fields of delivery 
Chapter I. Optimized preparation of gelatin nanoparticles 
- 6 - 
published by Verlag Dr. Hut, Munich, www.dr.hut-verlag.de, ISBN: 3-89963-451-9 
vehicles for the controlled release of biomolecules such as proteins and nucleotides, 
gelatin has generated increased interest (Young et al. 2005). While gelatin and the 
delivery systems based on this polymer are biocompatible and biodegradable 
without toxic degradation products (Ward et al. 1977; Tabata & Ikada 1998; Kawai 
et al. 2000; Yamamoto et al. 2001), they are furthermore known for high 
physiological tolerance and low immunogenicity since decades (Schwick & Heide 
1969). However, rare ethnologically caused cases of hypersensitivity reactions in the 
Japanese population have been described in literature (Kelso 1999; Saito et al. 
2005). But the basically beneficial properties of gelatin contributed to its proven 
record of safety which is also documented by the classification as “Generally 
Recognized as Safe” (GRAS) excipient by the US Food and Drug Administration 
(FDA). So, gelatin derivatives are even constituent of intravenously administered 
applications as plasma expanders (e.g. Gelafundin™, Gelafusal™) and used as 
sealant for vascular prostheses (Kuijpers et al. 2000).  
The natural source of gelatin are animals. It is obtained by mainly acidic or alkaline, 
but also thermal or enzymatic degradation of the structural protein collagen. 
Collagen represents 30% of all vertebrate body protein. More than 90% of the 
extracellular protein in the tendon and bone and more than 50% protein in the skin 
consist of collagen (Friess 1998). The characteristic molecular feature of collagen 
being responsible for its high stability is the unique triple-helix structure consisting 
of three polypeptide α-chains. Among the 27 collagen types that have been isolated 
so far (Brinckmann et al. 2005), only collagen type I (skin, tendon, bone), type II 
(hyaline vessels) and type III are utilized for the production of gelatin (Babel 1996).  
According to origin and pretreatment of the utilized collagen, two major types of 
gelatin are commercially produced (Fig. 1). Gelatin type A (acid) is obtained from 
porcine skin with acidic pre-treatment prior to the extraction process. The second 
prevalent gelatin species, type B (basic), is extracted from ossein and cut hide split 
from bovine origin. Thereby, an alkaline process, also known as “liming” is applied. 
During this extraction also the amide groups of asparagine and glutamine are 
targeted and hydrolyzed into carboxyl groups, thus converting many of the residues 
to aspartate and glutamate (Tabata & Ikada 1998; Young et al. 2005). Consequently, 
the electrostatic nature is affected, in contrast to collagen and gelatin type A having 
an isoelectric point (IEP) of pH 9.0, the higher number of carboxyl groups per 
molecule reduces the IEP to pH 5.0.  
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Fig. 1: Preparative process for acidic and basic gelatins from collagen (Tabata & 
Ikada 1998) 
Aside from the two major gelatin types, mixtures of both, resulting in specific 
intermediate IEPs and cold water fish gelatin do exist. Latterly, FibroGen (South 
San Francisco, CA, USA) offers synthetic gelatin produced by recombinant DNA 
technology via a yeast system (pichia pastoris). Thus, the potential theoretical 
hazards of animal-derived materials do no longer exist. However, the current price 
of 750$ per g (www.fibrogen.com) is immense in comparison to the low price of 
commercially available highly purified, sterile, and pyrogen-free natural gelatin.   
The amino acid composition of collagen and hence of gelatin is dominated by 
about 33% glycine and a further 22% proline and 4-hydroxyproline; the remaining 
45% comprise 17 amino acids. This specific distribution profile can be attributed to 
the characteristic triple-helical structure of collagen. Thus, Gly-X-Y represents the 
continuously repeating amino acid sequence. Since glycine does not possess a side 
chain, it is oriented into the core of the triple-helix, which represents the closest 
packed formation. Proline can typically be found in X-position and 4-
hydroxyproline in Y-position (Friess 1998). But they can be substituted by any 
other amino acid as well. In addition to these repetitive sequences, there are regions 
of 9-26 amino acids at each end flanking the helical structure. These non-helical 
regions are named telopeptides and show a high variation in amino acids. The 
overall amino acid composition (rounded per 1000) of type I collagen and gelatin is 
given in Table 1. 
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Table 1: Amino acid composition of collagen type I and gelatin. (rounded per 1000) 
(Babel 1996)  
Amino acid Type I collagen Type A gelatin Type B gelatin 
Alanine 
Arginine 
Asparagine 
Aspartic acid 
Glutamine 
Glutamic acid 
Glycine 
Histidine 
Hydroxylysine 
Hydroxyproline
Isoleucine 
Leucine 
Lysine 
Methionine 
Phenylalanine 
Proline 
Serine 
Threonine 
Tyrosine 
Valine 
Total 
113
51
16
29
25
48
331
4
104
5
11
24
28
6
13
114
35
17
4
22
1000
111
49
16
29
25
48
329
4
91
6
10
24
27
4
14
131
35
18
3
26
1000
117 
48 
- 
46 
- 
72 
335 
4 
93 
4 
11 
24 
28 
4 
14 
125 
34 
18 
1 
22 
1000 
 
 
During the extraction process of collagen, covalent intra- and intermolecular bonds 
responsible for the stability and insolubility of collagen undergo cleavage (Courts 
1959). The resulting tropocollagen is further denatured by the breakage of 
hydrogen- and hydrophobic bonds that stabilize the triple-helix structure (Flory & 
Weaver 1960). Instead of a homogeneous decomposition product, a heterogeneous 
proteinaceous material with a broad range of molecules with various molecular 
weights is generated since some peptide bonds remain stable and others, especially 
those with glycine are rather labile. Furthermore, partial renaturation can occur 
dependent on external factors such as pH or temperature (Farrugia & Groves 
1999). 
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The molecular heterogeneity of gelatin can be characterized via various molecular 
weight fractions (Farrugia 1998; Farrugia & Groves 1999): 
a) Low molecular weight fraction (< 50 kDa) and sub-α fraction (50-80 kDa); 
consisting of hydrolysis fragments (Steckert et al. 1992) 
b) α fraction (80-125 kDa); corresponding to the α-chains derived from 
tropocollagen (Piez et al. 1960)  
c) β fraction (125-230 kDa); corresponding to α-chain dimers, also  known as 
β-chain (Piez et al. 1960; Piez et al. 1961) 
d) γ fraction (230-340 kDa); corresponding to α-chain trimers, also known as γ-
chain (Veis et al. 1962) 
e) ε fraction (340-700 kDa); corresponding to γ-chain dimers  
f) ζ fraction (700-1000kDa); corresponding to γ-chain trimers  
g) δ fraction (1000-1800 kDa); corresponding to γ-chain tetramers with a high 
degree of crosslinking (Veis et al. 1962) 
h) Microgel (> 1800 kDa); corresponding to γ-chains multimers 
 
Due to this molecular heterogeneity of gelatin, the preparation of homogeneous 
micro- and especially nanoparticulate formulations is challenging. Nevertheless, 
there is a number of preparation techniques described since the 1970s, most of 
them adopted from other proteins such as albumin. Basically two major approaches 
can be described: 
a) Preparation via a biphasic system: emulsifying an aqueous solution of 
gelatin within an oily phase. 
b) Desolvation of the protein: adding a non-solvent, salting out, or adjusting 
the pH to the IEP of gelatin. 
 
Most of the emulsification techniques that are described in literature use simple 
W/O-emulsions. Thereby, e.g. sesame oil, chloroform, toluene or 
isopropylpalmitate are chosen as organic phase (Yoshioka et al. 1981; Tabata & 
Ikada 1989; Kreuter 1992; Cascone et al. 2002). The preparation itself is typically 
performed with emulsifiers, but in some cases also without surfactant (Esposito et 
al. 1995; Li et al. 1998).  
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Even though a lot of emulsion techniques are described in literature, all of them 
contain certain drawbacks, such as low yield (30%) or broad size distributions. 
Furthermore, complex and tedious purification procedures are necessary to get rid 
of the sometimes toxic organic phase and remaining emulsifier. Finally, high 
energetic methods, such as ultrasound, high-speed-, or high-pressure-
homogenization have to be applied to achieve adequate particle sizes. 
The first method using a desolvation technique was already described in the 1970s 
(Speiser & Pharmaceutical Society of Victoria 1974; Marty et al. 1978). Thereby, 
gelatin nanoparticles are prepared by the addition of sodium- or ammonium sulfate 
as salting-out agents or ethanol as non-solvent.  
This method is appropriate for the preparation of nanoparticles based on proteins 
with defined molecular weight such as albumin. For the use with bulk gelatin 
having a wide molecular weight spectrum, it lacks robustness in reproducibility and 
homogeneity of the produced particles. So it is described that different batches of 
nominally the same gelatin require different experimental conditions and even a 
slight excess of the dehydrating agent ethanol leads to mass aggregation and 
precipitation of the nanoparticles. Moreover, polydispersity indices obtained by 
dynamic light scattering analysis (DLS) are mostly unacceptably large, indicating the 
presence of a broad size distribution (Farrugia & Groves 1999).  
It is mandatory that problems like these get eliminated before gelatin nanoparticles 
gain attractiveness as alternative colloidal carrier system. An important step towards 
a solution was the development of the two-step desolvation technique (Coester et 
al. 2000); a higher molecular weight fraction is separated from a lower molecular 
weight fraction during a first desolvation step, before the particles are prepared in a 
second desolvation step. This new protocol enabled the production of 
homogeneous colloidal gelatin spheres.  
But thinking of the applicability of nanoparticles as future drug delivery systems, 
aside from uniformity, reproducibility in size is another prerequisite for commercial 
production. Hitherto, first investigations had been made, leading to a better 
understanding of the complexicity of the process and resulting nanoparticles 
(Coester 2000; Weber et al. 2000). 
It was the aim of the present study to further optimize the two-step desolvation 
technique and to characterize the utilized gelatin fractions, preparation conditions, 
and resulting nanoparticles. So, the gelatin fractions and the resulting nanoparticles 
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are scrutinized with well established analytical tools in comparison to novel 
approaches. Finally, the impact of several preparation parameters was investigated, 
to determine a size range where homogeneous gelatin nanoparticles can be 
reproducibly prepared within. 
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2. MATERIALS AND METHODS 
2.1 Reagents  
Reagent Description Supplier 
Acetone p.a. VWR International GmbH  
(Ismaning, Germany) 
Gelatin type A  175 Bloom Sigma-Aldrich GmbH  
(Taufkirchen, Germany) 
Glutaraldehyde  25% sol. in water Sigma-Aldrich GmbH  
(Taufkirchen, Germany) 
HCl 1 N VWR International GmbH  
(Ismaning, Germany) 
NaCl p. a. VWR International GmbH  
(Ismaning, Germany) 
Na2HPO4*2H2O p.a. Sigma-Aldrich GmbH  
(Taufkirchen, Germany) 
NaH2PO4 *H2O p.a. Sigma-Aldrich GmbH  
(Taufkirchen, Germany) 
NaOH 1 N VWR International GmbH  
(Ismaning, Germany) 
 
2.2 Preparation of gelatin nanoparticles by two-step desolvation   
The original preparation procedure is described as following (Coester et al. 2000): 
1.25g of gelatin type A (Bloom175) are dissolved in 25 mL water (5% w/w) under 
gentle heating. A first desolvation step is initiated by the addition of 25 mL 
acetone. After sedimentation of precipitated gelatin fractions for a certain time, the 
supernatant consisting of some desolvated gelatin as well as gelatin in solution has 
to be discarded. Now, the sediment is getting dissolved again by the addition of 25 
mL water under heating and the pH has to be adjusted to 2.5. In situ gelatin 
nanoparticles are formed during a second desolvation step by dropwise addition of 
50 mL acetone under stirring (500 rpm). After 10 min, 200 µl of glutaraldehyde 
(25%) are added to the reaction vessel to crosslink the nanoparticles. Finally, after 
stirring for 12 hours, the particles have to be purified by three-fold centrifugation 
(16000 g for 20 min) and redispersion in aceton/water (30/70). The purified 
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nanoparticles are stored as dispersion in highly purified water (conductivity < 0.04 
µs/cm) at 4-8 °C.  
Except stated otherwise, the following standard parameters were chosen for 
nanoparticle preparation: 
a) Temperature before the first and second desolvation step: 50°C 
b) stirring speed: 500-700 rpm  
c) precipitation time after the first desolvation step: 60 sec  
d) speed of acetone addition (second desolvation step): 3-5 mL/min  
2.3 Particle size determination  
Particle size determination was performed with three different methods. In 
addition to the two state-of-the-art techniques dynamic light scattering and 
scanning electron microscopy, a new sizing method was evaluated. The applied new 
analytical tool was an asymmetric flow field-flow fractionation unit with a multi-
angle light scattering detector. The asymmetrical flow field-flow fractionation data 
was generated in cooperation with my former colleague Dr. Wolfgang Fraunhofer. 
Dr. Norbert Stock (Physical Chemistry, LMU Munich) assisted at the scanning 
electron microscopy experiments.  
2.3.1 Dynamic light scattering (DLS) 
DLS is also often referred as photon correlation spectroscopy (PCS) or quasi-
elastic light scattering (QELS). In DLS experiments, the Brownian motion of the 
analytes within the dispersion medium is detected. More precisely,  this is done by 
measuring the angular distribution of time-dependent scattered light intensity due 
to density and/or concentration fluctuations (Chu & Liu 2000). From these 
fluctuations an autocorrelation function is derived, which is inverted to determine 
the diffusion coefficient of the analyzed sample. The diffusion coefficient in turn 
represents the velocity of the analyte’s Brownian motion. The size of the analyte is 
now calculated based on the measured velocity with respect to two further factors 
having significant impact on this calculation; medium viscosity and temperature 
(Hodgson 2000).  
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Thus, the hydrodynamic diameter ( )(Hd ) can be calculated by the Stokes-Einstein 
equation: 
D
kTHd πη3)( =  
d(H) = hydrodynamic diameter 
k = Bolzmann’s constant 
η = viscosity 
T = absolute temperature (K)
D = diffusion coefficient 
 
Thereby, the measured diameter d(H) describes how the particles move within a 
liquid, but cannot be set equivalent with the actual particle diameter.  
The calculated DLS results are displayed as average mean sizes. However, these 
mean sizes represent only intensity-based average values and do not further clarify 
the prevailing size distributions. For this purpose a second benchmark, the 
polydispersity index (PI) is stated to give information about the actual distortion of 
the monomodal light scattering signal. The PI can have values from 0-1 and  is 
equivalent to the variance σ2 of the distribution (Rawle 1993).   
DLS experiments were performed with a Zetamaster (Malvern Instruments, 
Worcestershire, England) detecting the scattered light at a fixed angle of 90°. 
Additionally, recent samples were analyzed with a Nanosizer ZS (Malvern 
Instruments, Worcestershire, England) using NIBS™-technology (Non Invasive 
Back Scattering) at a static detection angle of 173°. Except stated otherwise, the 
nanoparticles were diluted in sterile filtered, highly purified water and measured in 
concentrations between 30 and 100 µg/mL. Due to these low concentrations, the 
nanoparticles did not influence the viscosity of the dispersion, so that the viscosity 
was set as pure water (i.e. 0.8872 cP at 25°C). The experiments were performed at 
room temperature or set to 25°C in Nanosizer ZS experiments. 
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2.3.2 Asymmetrical flow field-flow fractionation (AF4) in combination with 
multi-angle light scattering (MALS) 
As novel analytical approach for size determinations we chose a combination of an 
asymmetrical flow field-flow fractionation (AF4) unit for analyte fractionation and 
a static light scattering (SLS) detector to determine the analyte’s size or molecular 
weight. SLS, also known as classic light scattering measures in contrary to DLS the 
angular distribution of time-averaged scattered light intensities (Chu & Liu 2000). 
Whereas DLS is the light scattering technique of choice, if no further fractionation 
of the analyte can be applied, it is inappropriate for on-line detection subsequent to 
a chromatographic separation, as autocorrelation and size calculation take too 
much time. On the other hand it is mandatory for accurate SLS detection to 
separate varying analytes before detection. However, SLS with a single photodiode 
to collect the scattered light intensity of analytes at a defined angle is not adequate 
for correct signal detection of gelatin nanoparticles. This experimental setup is only 
appropriate for analytes with diameters < λ/20. Solely these samples induce 
isotropic light scattering with the same intensity to every direction according to the 
Rayleigh theory. Analytes > λ/20 instead induce anisotropic light scattering, as the 
light is in correlation with increasing analyte size more and more forward scattered 
(Fig. 2). 
 
Fig. 2: Illustration of the particular light scattering profiles of various sized analytes 
Hence, these analytes that are best described by the theories of Rayleigh-Gans-
Debye (RGD), Mie, or Fraunhofer cannot be determined exactly by measuring only 
a single light intensity at a static angle. In consequence, a multi-angle measurement 
is necessary for correct analysis of samples within this size range. This is possible 
by the use of a 18-angle multi-angle light scattering (MALS) unit (DAWN EOS, 
Wyatt Technology, Santa Barbara, USA). For the present size calculation of gelatin 
nanoparticles, a Debye-based method was chosen.  
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The fractionation of the various sized nanoparticles was performed by an HRFFF-
10.000 AF4 system, comprising separation channel, pumps controlling the injection 
flow, forward flow, and cross-flow, in-line solvent filter (0.1 µm, PTFE), degasser 
(PN7505) and autoinjection system (PN5200) (all from Postnova Analytics, 
Landsberg, Germany). The channel height was 350 µm and the flow rate at the 
channel outlet was 1.0 mL/min. The applied regenerated cellulose ultrafiltration 
membrane (Nadir Filtration, Wiesbaden, Germany) had a cut-off of 5 kDa. 
The concentration signal, which is necessary to calculate the particle size, was 
obtained from on-line UV-spectrophotometrical detection at 280 nm wavelength 
(SpectraSystem UV 1000, Thermoquest, Darmstadt, Germany) and dn/dc values 
were determined with a deflection type differential RI detector (Δn-1000, λ = 620 
nm; WGE Dr. Bures, Dallgow, Germany).  
The experiments were performed at 24 °C, using a buffer with pH 7.4 (5 mM 
Na2HPO4*2H2O and 14 mM NaCl). 
2.3.3 Scanning electron microscopy (SEM) 
Gelatin nanoparticles were analyzed by SEM to characterize the surface 
morphology of dry, non-dispersed nanoparticles. The pictures were taken with a 
field emission scanning electron microscope (JSM-6500 F, Jeol, Ebersberg, 
Germany) at 5.0 kV and a working distance of 9.7 mm. For sample preparation 
gelatin nanoparticles were dispersed in acetone at a concentration of 20 µg/mL and 
applied on a specifically polished sample grid. The samples were vacuum-dried over 
12 hours and finally metallized with a 2 nm gold layer before microscopical 
analysis.  
2.4 Molecular weight analysis of gelatin 
Size exclusion HPLC and AF4 analytics of gelatin were performed under the 
technical guidance of my colleague Jan Zillies and my former colleague Dr. 
Wolfgang Fraunhofer.  
2.4.1 Size exclusion HPLC (SE-HPLC) analysis of various gelatin samples  
The molecular weight distribution of dissolved gelatin type A (Bloom 175) was 
analyzed using a TSKgel G 3000 SW column (7.5 mm x 30 cm; Tosoh Biosep, 
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Stuttgart, Germany). The further HPLC instrumentation consisted of a LKB 2248 
pump (Pharmacia Corp., Germany), a Spectra Series AS 100 (Thermoquest, 
Darmstadt, Germany) autosampler, and a vaccum in-line degasser (Thermoquest). 
Quantitative detection was performed with a UV detector (Thermoquest) at 280nm 
wavelength. The light scattering signal was measured by a MiniDawn™ (Wyatt 
Technology, Santa Barbara, USA) static light scattering detector.  
The separation experiments were performed at 24 °C, using a phosphate buffer pH 
6.0 (2 mM Na2HPO4*2H2O and 14 mM NaCl) as mobile phase. The refractive 
index increment dn/dc for molecular weight calculation of gelatin was set to 0.174 
mL/g and the second virial coefficient was set to 0. 
2.4.2 AF4 analysis of gelatin  
The molecular weight analysis of gelatin type A (Bloom 175) was performed with 
the identical AF4/MALS instrumentation as described for the nanoparticle 
characterization (see 2.3.2), except the RI detector. Analogous to the SE-HPLC 
analysis, we used 0.174 mL/g as dn/dc and set the second virial coefficient at 0. As 
mobile phase, the same phosphate buffer pH 6.0 as in the SE-HPLC experiments 
(see 2.4.1) was chosen.  
2.5 Zetapotential (ζ potential) determination of gelatin 
As the ζ potential can not be measured directly, it is calculated from the 
electrophoretic mobility of an analyte, according to the Debye-Hückel-theory and 
the Helmholtz-Smoluchowski-equation. 
For the present study, we used a NanoSizer ZS (Malvern Instruments, 
Worcestershire, UK) equipped with ZetaPals™ technology. Measurements were 
performed in specific disposable cuvettes at concentrations of 20 µg/mL. To 
provide sufficient ionic background, measurements were performed in 1 mM NaCl 
(conductivity:  0.7-1.0 mS/cm). 
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3. RESULTS AND DISCUSSION 
3.1 Comparison of different analytical tools for gelatin 
nanoparticle size determination 
As already mentioned in the introduction, the two-step desolvation method enables 
the preparation of homogeneous nanoparticles. Quality control of the resulting 
nanoparticles is done by DLS measurements, the state-of-the-art sizing technique 
for colloidal analytes. Typical narrow size distributions of gelatin nanoparticles are 
characterized by PIs below 0.1, so DLS analysis will suggest them to be 
monomodal. In Fig. 3 a size distribution as plotted by DLS is displayed 
(Zetamaster; fixed 90° detection angle). This nanoparticle batch (ZW030121-1) was 
prepared under the previously stated standard conditions (see 2.2), except for the 
pH value before the second desolvation step, which was adjusted to 3.0. The 
Zetamaster software calculated 255.7±1.8 nm as averaging mean size of these 
particles with a PI of 0.028±0.012 (mean of 3 measurements with 10 individual 
subruns each). 
 
Fig. 3: DLS results of batch ZW030121-1 (size distribution by intensity) 
We additionally analyzed this nanoparticle batch by SEM to visualize the particles 
and investigate their morphology. SEM revealed the sample as smooth spheres 
(Fig. 4), but a significant discrepancy could be seen between the visible size 
distribution of the nanoparticles in the SE micrograph (150-260 nm) and the DLS 
results. Obviously, the accuracy of DLS data needed to be reconsidered. Certainly, 
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according to the measurement principle of both analytical methods, the 
nanoparticles could not be measured under equal conditions. For DLS analysis, the 
particles need to be dispersed in sterile filtered water, whereas SEM detection has 
to be performed with dried analytes under vacuum conditions.  
 
Fig. 4: SE micrograph of gelatin nanoparticle batch ZW030121-1 
Consequently, a certain shrinking or even tendencies towards collapsing seem 
possible when preparing nanoparticles for SEM analysis. DLS in contrary measures 
the hydrodynamic diameter (d(H)) of analytes which is higher than their real 
diameter. Same observations were already described in literature for other polymer-
based nanoparticles (Finsy et al. 1992; Bootz et al. 2004).  
Exact knowledge of the nanoparticle size and a narrow size distribution are 
essential. However, the variety of appropriate analytical tools is rather limited. 
Solely analytical ultracentrifugation has been recently described as promising 
alternative tool to SEM and PCS (Bootz et al. 2004).   
Our attempt was to use MALS to determine the exact nanoparticle size. The multi-
angle geometry spacing 18 photodetectors around a flow cell ensures exact 
detection of colloidal anisotropic scattering analytes within shortest time. The 
second big advantage of this detector is its ability to determine molar masses 
without reference standards, as MALS is an absolute method and all necessary 
constants can be measured.  
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A requirement for the exact size determination via MALS is a sufficient previous 
fractionation of different nanoparticle populations. SE-HPLC as state-of-the-art 
separation unit being utilized in conjunction with MALS is inappropriate since no 
adequate columns are commercially available for the separation of nanoparticles. 
Typically, the upper threshold for samples that can be analyzed via SE-HPLC is 109 
kDa (~50 nm). Above this threshold, no separation occurs and finally columns are 
destroyed by clogging. For particles within this range other fractionation techniques 
as for example capillary hydrodynamic chromatography (CHDF) and field-flow 
fractionation (FFF) are presently the methods of choice (Dos Ramos & Silebi 1993; 
Wyatt 1998). 
So we chose the FFF sub-type AF4 as fractionation unit for the nanoparticles. AF4 
can easily be applied for insoluble analytes up to some micrometers because the 
fractionation is driven by specific flows in a channel instead of a package-material 
filled separation column.  
Dealing with nanoparticles with an expectable narrow size distribution, it has to be 
the goal to achieve a possibly high resolution. The key is to increase the separation 
force, i.e. the cross-flow (Wahlund et al. 1986). However, an increased cross-flow 
increases also the potential risk of sample-sample and sample-membrane 
interactions due to sample concentration at the ultrafiltration membrane 
(Andersson et al. 2001). Hence, we decided to apply a procedure of stepwise 
approximation to find optimal fractionation conditions. Thereby, we started with 
an initial cross-flow rate of 5% which was applied for 10 min and increased run by 
run in 5% intervals. At 5% cross-flow rate, the resolution was too low to enable 
accurate calculation of the nanoparticle size distribution. Very small analytes were 
not separated enough from each other to enable distinct detection in the MALS 
detector (Fig. 5). Moreover, their MALS signal is overpowered by stronger light 
scattering signal of simultaneously eluted bigger analytes at the beginning of the 
elution process. An increase to 10% cross-flow already led to adequate resolution 
with a separated elution profile according to the particle size. This could be proven 
as we exerted 15% cross-flow, indeed nanoparticle elution profile was further 
delayed, but no different size distribution data were calculated by MALS software. 
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Fig. 5: Characterization of gelatin nanoparticles via AF4/MALS using 5% cross-flow 
(light grey line), 10% cross-flow (grey line), and 15% cross-flow (black line) 
To further verify our data we finally increased the injected nanoparticle 
concentration (from 0.5 to 0.9 mg/mL). Thereby the assessed increase of UV’s 
AUC values was in sound agreement with the sample concentrations (from 
A=1.56-2.80). Size distribution data was not further affected, thus our new sizing 
method was further substantiated.  
MALS software calculates the original dimension data as root mean square (rms) 
radii (Fig. 5), also known as radii of gyration (RG). Anyways, these values can easily 
be converted into the hydrodynamic diameters (d(H)) by the following equation: 
2)(
3
20)( GRHd =  
  d(H)= hydrodynamic diameter 
 RG = radius of gyration or root mean square radius 
 
Calculating the size distribution based on the obtained MALS data with a cross-
flow rate of 10% (RG distribution 60-98 nm), resulted with a hydrodynamic 
diameter range between 155 and 253 nm. 
Comparing these data with the results of the other analytical methods it can be 
summarized, that DLS analysis using the Zetamaster system (Malvern, 
Worcestershire, United Kingdom) is obviously unable to produce data with the 
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same high accuracy as SEM or AF4/MALS. An explanation for this can be found 
in the sample measuring setup, since the plain probe is measured without further 
separation. According to the Rayleigh approximation, differences in particle size 
have an amplification factor of 106 on the scattered light intensity (Rawle 1993). 
Thus, it is quite difficult to detect small nanoparticles along with larger ones. 
During sample preparation special attention has to be paid to the avoidance of 
contaminations. Otherwise, DLS analysis is a method that requires no specific 
preparation and is performed in a short time.  
The big advantage of SEM is the detailed information about shape and morphology 
of the samples. A clear disadvantage is the complex sample preparation. Moreover, 
preparation steps like vacuum drying and contrasting feature a potential risk of 
changes in particle properties. The determination of size distributions demands 
further software. Although, only random samples can be captured, so that due to 
the low number of samples only poor statistical data are generated. 
Regarding to the calculated size distribution, AF4/MALS resulted with presumably 
more accurate data than DLS. In contrast to SEM, no tedious sample preparation 
with its potential risks is necessary and far more individual particles can be 
detected. A slight disadvantage of the method is, that it is not ready to use for any 
analyte at anytime, in contrast to DLS. So, sensitive tuning of the fractionation 
conditions is necessary to enable accurate sample analysis. Concerning time and 
effort, the new technique consumes more than the less precise DLS analysis, which 
produces sizing data within seconds, but is also far less complex than SEM analysis.  
Thus, DLS as quick state-of-the-art technique is acceptable as quality control for 
homogeneous samples as analyzed here. Nevertheless, it can be expected that the 
new hybrid will have great potential especially for heterogeneous samples. 
3.2 Molecular weight characterization of gelatin 
The present fundamental data concerning the molecular weight distribution of 
different gelatin fractions was generated under the major guidance of Dr. Wolfgang 
Fraunhofer. Parts of the presented data, such as the ones depicted in Fig. 6 –  Fig. 
8, are already published (Fraunhofer et al. 2004).   
SE-HPLC is the method of choice routinely used for process control and product 
development, to monitor the molecular mass distribution of gelatin (Meyer & 
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Morgenstern 2003). The use of a UV detector requires previous calibration of the 
retention times via globular molecular weight standards resulting in more or less 
straight calibration lines. The accuracy of these calibrations in connection with 
gelatin is rather questionable, since gelatin has no globular structure. Thus, previous 
molecular weight findings based on UV detection alone (Coester 2000; Weber et al. 
2000) have to be considered as approximations only. In the present study we 
additionally measured the light scattering signals of the separated gelatin fractions 
employing a static light scattering (SLS) detector. As soluble gelatin is below the 
diameter boundary of λ/20 (see 2.3.2), a 3-angle light scattering detector is 
sufficient for correct analysis. 
Investigating gelatin with our experimental settings, the resulting chromatogram 
(Fig. 6) of a bulk gelatin solution demonstrated the large molecular heterogeneity of 
this biopolymer. MALS determined a molecular weight range from about  
4 – 1000 kDa. Moreover, two distinct fractions could be identified at 280 nm 
wavelength.  The first fraction comprised high molecular weight (hmw) 
components >100 kDa and the second one low molecular weight (lmw) 
components < 100 kDa.  
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Fig. 6: SE-HPLC analysis via UV280 and MALS; flow rate: 0.7 mL/min  
Adopting the previously described classification scheme for the different gelatin 
molecular weight fractions (Farrugia 1998; Farrugia & Groves 1999), the borderline 
between both fractions corresponds to the α-fraction of gelatin (80-125 kDa), 
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which consists of soluble tropocollagen α-chains. Consequently, the first peak 
summarizes the higher molecular weight fractions (β-, γ-, ε-, ζ-, δ-, and microgel-
fraction) i.e. the multimers of the tropocollagen α-chain, whereas the hydrolysis 
products classified as sub-α and low molecular weight fraction are responsible for 
the second peak. The initial steepness of the first peak has to be attributed to an 
artifact of the separation column, because the molecular weight of the eluted 
protein was above the maximum separable molecular weight. Thus, these very large 
components were already eluted with the void volume. 
Based on these chromatographic data for bulk gelatin, we further analyzed 
solutions of the two phases after the first desolvation step: the precipitated 
sediment which would be further processed for nanoparticle preparation and the 
supernatant that has to be discarded (Fig. 7). Comparing the chromatograms, both 
gelatin samples revealed high and low molecular components as well. But as 
supposed, a higher amount of the hmw components could be found in the 
sediment. The percentage of hmw components was 58% in the sediment sample 
compared to 38% in bulk gelatin. A percentage of only 29% of hmw components 
remained in the supernatant.  
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Fig. 7: SE-HPLC chromatograms of bulk gelatin (black), sediment (grey) and 
supernatant (blue) before the first desolvation step 
 Even though SE-HPLC is the method of choice to characterize the molecular 
weight of gelatin  (Barth et al. 1994; Farrugia 1998), our experiments demonstrated 
that variations of the analytical settings have significant impact on the determined 
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ratios between the hmw and lmw components of the samples. Lowering the flow 
rate led to an intense reduction of the hmw component percentage throughout the 
analyzed samples; e.g. a reduction of the flow rate to 0.3 mL/min reduced the hmw 
component content to 24% (sediment), 15% (bulk), and 13% (supernatant). 
Apparently, the change of the flow rate prohibits to state absolute quantitative 
values for the molecular weight distribution of gelatin.  
Since our major interest was to get a more detailed idea about the actual molecular 
weight distributions of the gelatin samples, we evaluated AF4/MALS as alternative 
analytical tool. Applying mild cross-flow conditions (5%), a separation of the bulk 
gelatin into two fractions was not observed (Fig. 8). However, the molecular weight 
results, calculated from these experiments, differed remarkable from the results 
obtained with SE-HPLC. With a molecular weight distribution of 20 – 10,000 kDa, 
the calculated maximal molar mass was about one order of magnitude higher.  
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Fig. 8: AF4 fractogram of bulk gelatin (5% cross-flow) 
However, these results seem to describe more precisely the actual molar mass 
distribution of gelatin solutions. It is supposable that these very hmw components 
could either not pass the separation column in SE-HPLC or got degraded by 
abrasive shear forces caused by the column package material (Barth et al. 1994). In 
AF4 experiments, this problem does not occur because the separation channel 
itself is free of package material. Additionally, the field of force that is exerted on 
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the sample can be minimized by reducing the cross-flow. So, even very delicate 
analytes can be kept from degradation during the analytical run. 
If higher cross-flows are applied, the fractograms of gelatin reveal two populations 
analogous to the SE-HPLC chromatogram. These two separated fractions can 
already be generated with 40% initial cross-flow. The molecular weight borderline 
between these two fractions was not 100 kDa but approximately 450 kDa, thus the 
the hmw peak represented a lower amount of total gelatin than in SE-HPLC 
experiments. Nevertheless, most hmw components could be detected in the 
sediment (27%), followed by 17 % in bulk gelatin and 10% in the supernatant 
sample (Fig. 9) 
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Fig. 9: AF4 fractograms of bulk gelatin (black), sediment (grey), and supernatant 
(blue) after the first desolvation step (40% cross-flow) 
Even though augmentations of the cross-flow intensity influenced the absolute 
values of the hmw ratios, the relative proportions of the individual samples to each 
other concerning the hmw content remained constant (data not shown). Thus, no 
sample degradation occurred.  
So, it can be summarized that AF-4 analysis exceeded SE-HPLC in the present 
study, as it delivered more accurate molecular weight distributions of the applied 
gelatin solutions. This can be attributed to the milder and more flexible separation 
conditions the samples were committed to. 
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3.3 Optimization of the two-step desolvation technique 
To achieve pre-defined settings for the reproducible preparation of specifically 
sized nanoparticles, we had to characterize the influence of diverse variables in the 
manufacturing process. We expected the following factors to be most important 
and decided to investigate their impact on the resulting nanoparticles: 
a) temperature at the first and second desolvation step  
b) amount of sediment after the first desolvation step  
c) pH value before the second desolvation step  
d) speed of acetone addition during the second desolvation  
e) amount of crosslinking reagent applied  
Batch size, geometry and size of the reaction vessel, and the applied 
homogenization speed were not further varied or investigated.  
3.3.1 Temperature at the first and second desolvation step 
The first parameters we investigated were the prevailing temperatures before the 
induction of the first respectively the second desolvation step. It is well known 
from literature, that temperature has significant impact on the apparent molecular 
weight distribution of gelatin, due the occurrence of denaturation or renaturation 
processes (Farrugia 1998; Farrugia & Groves 1999). Gelatin solutions incubated at 
56°C and above exhibit partially reversible denaturation of the higher molecular 
weight fractions. Enhanced renaturation occurs at lower temperatures, which 
results in sol-gel transition of gelatin solutions. The sol-gel transition temperature 
of gelatin solutions is typically at 35-40°C (Peyrelasse et al. 1996). In addition to the 
temperature, the pH of the solution does also have an impact on these 
denaturation/renaturation phenomena. Thus, denaturation is suppressed and 
renaturation favored by the lack of net charge on the individual polypeptide units 
(Farrugia 1998).  
As we performed our experiments according to the standard preparation protocol, 
we chose 35-60°C as temperature range to be tested. The upper limit of the tested 
temperature spectrum was constituted with respect to the boiling temperature of 
the later applied desolvation reagent acetone. The lower limit was constituted with 
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respect to the expected sol-gel transition temperature. Each condition was tested in 
triplicate. 
Contrary to our expectance, variations of the gelatin solutions’ temperatures did 
not induce significant differences in the resulting particles. At least, concerning the 
temperature before the first desolvation step a slight trend could be seen. The 
highest (60°C) and the lowest (35°C) temperature conditions led to the biggest and 
most inhomogeneous particles (Fig. 10A). In terms of the temperature at the 
second desolvation step, only a minimal trend could be observed favoring 50-55°C 
as optimal temperature for the production of small nanoparticles (Fig. 10B). So it 
can be concluded that the chosen standard conditions (50°C for both) also seem to 
represent the ideal setup as well.   
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Fig. 10: Correlation between the temperature of the gelatin solutions before each 
desolvation step and the resulting nanoparticles; A: temperature before the first 
desolvation step; B: temperature before the second desolvation step (n=3)  
 
3.3.2 Amount of sediment after the first desolvation step 
As described in the original protocol, the quick addition of acetone causes a rapid 
precipitation of gelatin. Within seconds a highly viscous, hydrogel-like gelatin 
sediment appears, which can easily be separated from its supernatant by 
decantation. Waiting for 10 minutes leads to complete precipitation of insoluble 
gelatin fractions. But as displayed in Table 2, the majority of insoluble gelatin is 
already precipitated after 90 seconds. In addition to this sedimentation kinetics 
information, Table 2 also illustrates that the averaging percentage of gelatin within 
the hydrogel-like sediment remains constant with 23.6 ± 1.2% (w/w). Thus, while 
A B 
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we start with originally 1.25 g gelatin before the first desolvation step, the final 
particles are prepared with a fraction of 26 – 51% (w/w) of the original gelatin 
amount.  
Table 2: Relationship between sedimentation time, amount of resulting hydrous 
sediment and the actual protein content within this sediment. 
Prec. time (s) 
hydrogel-like 
sediment (g) 
Dried protein (g) Protein content (%) 
30 
40 
50 
60 
90 
120 
1200 
1.334 
1.851 
2.050 
2.168 
2.669 
3.132 
3.430 
0.330 
0.415 
0.462 
0.540 
0.642 
0.699 
0.834 
24.7 
22.5 
22.4 
24.9 
24.1 
22.3 
24.3 
 
Starting with different amounts of the hydrogel-like sediment, we redissolved the 
respective sediment in 25 mL highly purified water at a temperature of 50°C. 
Before the slow addition of acetone (3-5 mL/min), the pH was adjusted to 3.0.  
DLS resulted with average sizes of 125 – 300 nm for the various nanoparticle 
batches (Fig. 11).  
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Fig. 11: Correlation between the weight of the hydrogel-like sediment after the first 
desolvation step and the resulting nanoparticle quality. 
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The results demonstrate that the final protein concentration of the solution prior  
to the second desolvation step has crucial influence on the particle size. A higher 
protein density within the solution obviously facilitates inter-molecular interactions 
and finally the co-aggregation of gelatin during the second desolvation step. Thus, 
bigger nanoparticles are the result. It has to be mentioned that 125-140 nm 
represents a certain lower size limit for nanoparticles prepared under the applied 
conditions. Furthermore, for sediment weights below 1.25 g (~0.31 g dry protein) 
the standard addition of 50 mL acetone was unable to induce complete desolvation 
of the protein. Accessory amounts of acetone had to be added which continuously 
worsened the PIs of the nanoparticles. This is due to the fact that higher 
concentrations of the desolvation agent apparently enforce aggregation tendencies 
of the nanoparticles. Sediments above 3.0 g (~0.70 g dry protein) likewise led to 
worse PIs above 0.1. So, slower precipitating gelatin components with probably 
lower molecular weight seem to facilitate aggregation as well.  
3.3.3 pH value before the second desolvation step  
The net charge of low charge density polyelectrolytes such as gelatin in solution is 
strongly affected by the prevalent pH conditions. Hence, changing the pH led to 
strong alterations in final particle size (Fig. 12). The pH region we observed was 
between pH 2.0 and 4.5. Since gelatin type A has an IEP of pH 9.0, it had a 
positive net charge at all tested conditions. Under standardized conditions as 
previously described (see 2.2), it was possible to produce gelatin nanoparticles 
within a range of pH 2.3 – 4.0. Above pH 4.0 the produced gelatin nanoparticles 
tended strongly towards aggregation and precipitation. Obviously, this pH value is 
too close to the IEP of gelatin type A. Thus the remaining net charge of gelatin is 
too weak to prevent the freshly in-situ formed nanoparticles from instabilities. 
Within the favorable pH region, increasing acidic conditions correlated with the 
reduction of the particle’s mean sizes. The produced nanoparticles had sizes 
between 115.0 and 425.8 nm (Fig. 12). Highly homogenous nanoparticles with PIs 
below 0.1 could be produced between pH 2.3 and 3.8.  
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Fig. 12: Correlation between the adjusted pH value before the second desolvation 
step and the resulting nanoparticle quality. 
Performing the dropwise addition of 50 mL acetone to generate the nanoparticles it 
was noticed that a first turbidity, indicating phase separation, and the generation of 
nanoparticles appeared at a later point of acetone addition by shifting the pH 
towards lower values. Thus, at pH 2.3 additional 25 mL acetone were necessary to 
induce the phase separation. Below this pH even additional 50 mL of acetone could 
not induce any phase separation. The net charge of the gelatin molecules was 
apparently too intense, so that the intermolecular repulsion forces stabilizing the 
characteristic three-dimensional protein shape prevented it from collapse and 
aggregation induced by the desolvation agent.  
In the pH regions where nanoparticles can be produced, the same reasons seem to 
be responsible for the smaller particle sizes. Intermolecular electrostatic repulsion 
forces obviously hinder the inter-molecular co-aggregation.  
In Fig. 13, the ζ potentials of gelatin before the second desolvation step at various 
pH values are illustrated. Referring to these data, the averaging ζ potential of the 
polypeptide molecules has to be approximately between 9 and 16 mV (in 1 mM 
NaCl) to enable the production of nanoparticles. 
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Fig. 13: ζ potential values of redissolved gelatin sediments in correspondence to the 
pH (n=3) 
3.3.4 Acetone addition-rate during the second desolvation step 
In this study we wanted to determine the maximum applicable rate for the addition 
of acetone. As depicted in Fig. 14, the resulting nanoparticles were not negatively 
influenced up to a rate of 5 mL/min. 
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Fig. 14: Correlation between the speed of acetone addition during the second 
desolvation step and the resulting particle quality (n=3) 
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Beyond this limit, mean particle sizes along with their corresponding PIs increased 
exponentially, thus indicating either particle aggregation or appearance of 
inhomogeneous nanoparticles. Consequently, no higher rate seems advisable if no 
further changes of the standard conditions (e.g. enhanced stirring) are applied. 
Below 5 mL/min the process is very robust against variations in acetone addition 
rates. 
3.3.5 Amount of the applied crosslinking reagent  
Crosslinking has to be done to prevent the in situ formed nanoparticles from 
disintegration when the desolvation agent acetone is evaporated. It can be 
performed with non-zero length and zero length agents. Zero-length crosslinking 
agents (e.g. EDC) activate carboxylic acid residues to react directly with amine 
groups on adjacent protein chains. For gelatin nanoparticles glutaraldehyde (GTA) 
is the agent of choice, since it is a highly reactive and efficient crosslinking agent. 
GTA is a non-zero length crosslinker as it operates by intra-particulate bridging of 
residual amino groups. But, GTA is due to its high reactivity also the most 
hazardous reagent being utilized for gelatin nanoparticle preparation. The potential 
toxicological hazards of GTA in conjunction with proteinaceous materials have 
been discussed in literature (Lin et al. 1998; Ulubayram et al. 2002; Zeiger et al. 
2005). In the present study we prepared gelatin nanoparticles according to the 
standard conditions (see 2.2; sediment weight after the first desolvation: ~2.5 g; 
adjusted pH: 3.0) and varied the amount of applied GTA from 6.25-75 mg per 
sample. Each condition was prepared in triplicates.  
As depicted in Fig. 15, the particle size decreases steadily along with higher 
amounts of GTA applied. Even though, the further size reduction is decelerated 
from an amount of ~30 mg GTA on. But in total we can state in consensus with 
other authors (Cascone et al. 2002) that increasing amounts of crosslinks lead to 
denser and smaller nanoparticles.  
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Fig. 15: Correlation between the amount of GTA applied for crosslinking and the 
resulting particle quality (n=3) 
With regards to the measured PI values, 43.75 mg represent an optimum with the 
most homogeneous nanoparticles resulting. The slight increase of the PI values 
beyond this point might be addressed to stronger interparticulate aggregation 
tendencies which are facilitated by higher amounts of GTA.  
From a toxicological point of view, it would be advisable to keep the amount of 
GTA as low as possible. But there are further aspects that have to be taken in 
consideration. The number of crosslinks of gelatin nanoparticles is also responsible 
for a later degradation and the release kinetics of potentially incorporated drugs. 
Finally, the number of functionally available amino groups for covalent bonding of 
amino-reactive ligands is also affected by the number of crosslinks. 
The goal of the present experiments was to optimize the particle preparation and 
not to achieve specific release kinetics of incubated drugs. So, 43.75 mg GTA were 
chosen as advisable standard amount. At these conditions, the most homogeneous 
nanoparticles could be produced.  
3.3.6 Evaluation of the conditions for tailor-made nanoparticles  
Summarizing the results of all parameters evaluated, we finally defined conditions 
for the preparation of the three different nanoparticle sizes: 100 nm, 150nm, and 
300 nm (Table 3). To verify the reproducibility of the nanoparticles produced 
under these conditions, we repeated every experiment 6 times.  
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Table 3: Evaluation of optimized conditions for the reproducible preparation of 
distinctive nanoparticles  
 
300 nm 150 nm 100 nm 
Temp. before 1st desolvation (°C) 50 50 50 
Precipitation time (sec.) / weight of 
hydrous sediment (g) 
100 / 2.8 40 / 1.8 30 / 1.3 
Temp. before 2nd desolvation (°C) 50 50 50 
pH before 2nd desolvation 3.75 2.75 2.25 
speed of acetone addition  
(2nd desolvation) (mL/min) 
<5 <5 <5 
Amount of acetone  
(2nd desolvation) 
50 50 75 
Amount of GTA for crosslinking 
(mg) 
43.75 43.75 43.75 
Mean particle size (nm) (n=6) 293.4 ± 9.9 150.8 ± 2.1 108.77 ± 14.4 
PI (n=6) 0.066± 0.021 0.026± 0.015 0.106± 0.022 
 
It can be assumed, that all tested conditions yielded very close to their target sizes 
with a high reproducibility. The results for the 150 nm particles were definitely 
outstanding, as they exactly hit their mark and were very homogeneous. But also 
the results of the other two batches were satisfying. Although it can be concluded 
that 100nm and 300 nm approximately represent the respective limits for the 
production of predictable high quality gelatin nanoparticles by two-step 
desolvation. 
3.4 Gelatin nanoparticles by one-step desolvation 
Even though the preparation of gelatin nanoparticles by two-step desolvation is 
already a very elegant and robust technique, it would be a further advantage to 
prepare nanoparticles from specific gelatin after one desolvation step. By default, 
gelatin type A (Bloom 175) purchased from Sigma-Aldrich (Taufkirchen, Germany) 
is used for nanoparticle preparation. With regards to the analytical data solutions of 
bulk gelatin, the sediment, and the supernatant after the first desolvation step (see 
particle size conditions/ 
results 
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3.2), it was assumed that an increase of hmw components and/or a reduction of 
lmw components are beneficial for the production of stable and homogenous 
nanoparticles. This was also suggested by literature (Farrugia 1998). We contacted 
Gelita AG (Eberbach, Germany), one of the world’s largest gelatin producers and 
asked them to produce specific gelatin batches with modified molecular weight 
profiles. The respective batches were screened for their suitability to produce stable 
and homogeneous nanoparticles at various pH conditions and concentrations in 
one desolvation step.  
As an analytical support to this work, Jan Zillies contributed the AF4/MALS 
analyses to characterize the molecular weight profile of the particularly applied 
gelatin batches. Parts of these analytical data (Fig. 16 - Fig. 18) are cited in the 
present chapter but will be part of his thesis (Zillies 2007). 
Via a specific preparation procedure, Gelita was able to produce gelatin lots with 
reduced amounts of peptides <65 kDa. The analysis of Sigma bulk gelatin via 
AF4/light scattering revealed a content of >50% of these low molecular peptides 
(Fig. 16) compared to the total protein content. 
 
Fig. 16: AF4/SLS fractogram of Gelatin type A (Bloom175) from Sigma-Aldrich 
(Taufkirchen, Germany, Productnr.: G-2326/LOT: 155469654). (Zillies 2007) 
The first specific gelatin batch from Gelita we investigated (PN307779), featured a 
<65kDa peptide content reduced to <40% of total peptide. Yet, we were unable to 
produce stable gelatin nanoparticles using this batch. 
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The second batch (VP 433), again featured a <65 kDa peptide content of <40% of 
the total gelatin. But additionally, Gelita had introduced an extra high amount of 
high molecular weight components >107 kDa to this gelatin batch via specific 
crosslinking. But also this approach failed to produce nanoparticles. Finally, we 
could successfully produce gelatin nanoparticles during a single desolvation step 
with two qualities of gelatin that contained amounts of <20% of <65kDa peptides 
(VP306/VP413-2) without extra hmw fraction (Fig. 17). 
 
Fig. 17: AF4/light scattering fractogram of gelatin (VP 306) produced by Gelita which 
enables the production of stable and homogeneous gelatin nanoparticles by a single 
desolvation step. (Zillies 2007) 
In this new simplified preparation approach, it was no longer necessary to perform 
an initial desolvation step to discard the disturbing gelatin fraction. Thus, gelatin 
was dissolved at a certain concentration under constant heating and stirring (50°C; 
500rpm). Similar to the gelatin solution before the usually second desolvation step, 
the pH was now adjusted to acidic values before nanoparticles were generated by 
dropwise addition of acetone. Finally nanoparticle crosslinking with GTA and 
purification were performed identically to the original two-step desolvation 
method. 
In the present screening, protein concentration (2-6% [w/w]) and pH-range (pH 
2.25-3.0) were varied to determine a first range of conditions where stable 
nanoparticles can be prepared by this new method. It can be derived from Table 4 
that monomodal size distributed nanoparticles could be produced within a range 
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from 180-250 nm. Even though it has to be mentioned, that the applicable pH 
range is narrower than in two-step desolvation experiments.  
Table 4: Overview of the successful preparation conditions screening with gelatin 
batch VP 306 (n=3) 
 
2.25 2.5 2.75 3.0 
2.0 no desolvation* no desolvation* no desolvation* no desolvation* 
3.0 no desolvation* 
180.7±2.7 nm 
PI: 0.007±0.001 
221.5±13.5 nm 
PI: 0.057±0.014 
instable 
particles** 
4.0 no desolvation* 
199.7±5.7 nm 
PI: 0.025±0.011 
248.7±27.4 nm 
PI: 0.105±0.021 
instable 
particles** 
6.0 precipitation*** 
instable 
particles** 
instable 
particles** 
precipitation*** 
 *    Even excessive addition of acetone did not induce any desolvation of gelatin. 
 **  Desolvation with acetone led to nanoparticles which aggregated and precipitated within  
          a few hours. 
 ***  Addition of acetone led to the formation of an amorphous sediment. 
To further characterize these gelatin batches, we analyzed the mean molecular 
weight of this gelatin via light scattering software (ASTRA 4.73, Wyatt Technology) 
and compared them with sediment and supernatant of Sigma gelatin after the first 
desolvation step (Fig. 18). 
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Fig. 18: Mean molecular weight analysis via light scattering analysis of supernatant 
(blue), gelatin batch VP306 (red), gelatin batch VP413-2 (green), and sediment 
(pink). (Zillies 2007) 
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Supernatant and sediment fractions revealed mean molecular weights of ~ 150 kDa 
respectively ~2300 kDa. Both specific gelatin batches resulted between supernatant 
and sediment (VP306: ~380 kDa; VP413-2: ~440 kDa). So it can be derived from 
the present data, that gelatin does not necessarily have to contain an increased 
amount of hmw components for the production of stable and homogeneous 
colloidal spheres as stated by other authors (Farrugia & Groves 1999). In fact, the 
absence or strong reduction of very low molecular weight components (<65 kDa) 
seems to be essential for the stability and homogeneity of the nanoparticles.  
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4. CONCLUSION 
The repetitive standardized preparation of homogeneous batches is a clear must to 
bring gelatin nanoparticles closer to the clinical use as a drug delivery system. 
Along with better manufacturing processes, high precision analytics are also needed 
to characterize the base material and the resulting nanoparticles. The new 
established combination of AF4 and MALS has proven to be a promising tool to 
close the gaps left by current analytical methods. With this new tool we could 
moreover clarify the molecular weight distribution of the heterogeneous 
biopolymer gelatin. The generated data helped to further specify hmw fractions of 
gelatin as being beneficial. However, the absence or strong reduction of lmw 
peptides < 65 kDa and not a predominant presence of extra-hmw fractions could 
be determined as the essential factor for the preparation of stable and 
homogeneous nanoparticles. In our process optimization studies, we were able to 
define specific conditions for the preparation of homogeneous (PI <0.15) 
nanoparticles with a predictability of better than ±15 nm of the resulting diameter 
within the range of 100-300 nm. The two crucial factors to control the result are 
the protein amount and the pH value before the second desolvation step. But also 
the amount of crosslinking is of high importance, especially if later release of 
entrapped drugs and degradation kinetics are concerned.  
In summary, the preparation of specific homogeneous and stable gelatin 
nanoparticles is now very well predictable. Consequently, gelatin nanoparticles can 
be considered as a ready to upscale, promising colloidal drug delivery system. 
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Chapter II 
Cationic gelatin nanoparticles as non-viral gene 
delivery system 
1. INTRODUCTION 
It is the aim of gene therapy to heal genetic and acquired diseases on a 
biomolecular level following the concept that hereditary diseases can be cured by 
substitution with plasmids encoding for the correct genes. Gene therapeutic 
strategies for acquired diseases, such as cancer or AIDS, are either to activate the 
body’s own immune defense, or to introduce suppression genes.  
One way to introduce genes to their target tissues is to transfect cells with genes ex 
vivo and to (re-)implant them into the patients afterwards. The second is to 
administer the plasmids in vivo to the patients. Thereby, the easiest way is the direct 
injection of naked DNA into the target tissue or organ. But this approach is limited 
to only a few applications as for example injection into solid tumors (Vile & Hart 
1993) or muscle tissue (Wolff et al. 1990). For most applications direct injection is 
not efficient enough due to enzymatic degradation and electrostatic repulsion 
between both negatively charged cell membrane and DNA, consequently inhibiting 
efficient cellular uptake. 
Thus, a carrier system, either viral or non-viral, is necessary. Statistics covering all 
clinical trials worldwide that are currently dealing with gene delivery reveal that viral 
vectors are still the clear number one, being used in more than 70% of all protocols 
(www.wiley.co.uk/genmed/clinical/). This can be attributed to the fact that viral 
vectors deliver genes with the highest efficiency, as it is the intrinsic feature of 
viruses to shuttle their genome into cells. The most commonly used viral vectors 
are adenoviruses, retroviruses, adeno-associated viruses, and herpes viruses 
(Boulaiz et al. 2005; Ciftci & Gupte 2006). Lastly, lentiviruses are presently 
discussed as promising new vectors (Romano 2005). Nevertheless, having the 
advantage of the highest efficiency in delivery, viral vectors comprise also major 
drawbacks with respect to safety hazards.  
A first tragic incident concerning viral gene delivery was on September 17, 1999 as 
18-year-old Jesse Gelsinger, who participated as a volunteer in a gene therapeutic 
trial, died from an immune reaction against the adenoviral vector (Ferber 2001). 
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Recently, it has been reported from clinical trials of γc-mediated gene therapy for 
X-linked severe combined immunodeficiency (X-SCID) that 3 out of 17 patients 
have developed T cell leukaemia as a consequence of the retroviral treatment 
(Anson 2004; Couzin & Kaiser 2005). Aside from these safety issues, difficulties in 
the scale-up process and high production costs of viral vectors are further 
restrictive factors. 
These substantial reasons made the development of non-viral alternatives highly 
desirable. Alternative delivery methods are either physical methods to transfer 
genetic material directly into the target cell or even the nucleus, or chemical 
methods using non-viral vectors. Electroporation, gene gun, particle bombardment, 
ultrasound, jet injection and micro injection represent the most common physical 
gene delivery methods. (Boulaiz et al. 2005). Chemical nonviral vectors are either 
complexes of nucleic acids with cationic polymers, i.e. polyplexes (De Smedt et al. ; 
Felgner et al. 1997), or based on cationic lipids, i.e. lipoplexes (Felgner et al. 1997; 
Felgner 1997). Furthermore, plasmid DNA (pDNA) can be loaded on the surface 
of previously formed cationic nanoparticles due to electrostatic interactions. But 
although a variety of efforts have been made in the past, the ideal system has not 
been found yet.  
However, efficient gene delivery represents also a very complex issue. Before the 
final gene expression, a non-viral vector has to shuttle the pDNA across various 
barriers until it reaches its final destination. Consequently, an ideal delivery system 
has to fulfil various requirements: 
a) Complexation of pDNA into colloidal dimensions 
b) Protection against extracelluar inactivation 
c)  Selective and effective internalization into the target cell 
d)  Quick release from the endo/lysosomal compartment 
e)  pDNA transfer to the nucleus and activation of the transcription 
f) Degradation of the vector without toxic by-products 
The escape from the endosome is a crucial bottleneck for most existing non-viral 
gene delivery systems. Thus, e.g. poly(L-lysine) (PLL) polyplexes, need the 
additional administration of endosomolytic agents, such as chloroquine, to generate 
efficient transfection results (Wagner et al. 1992) The polycationic polymer 
polyethylenimine (PEI) which was originally introduced as polyplex agent by the 
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research group of Jean-Paul Behr (Boussif et al. 1995) represents the most 
significant polycation for polyplex compositions at the moment. Due to the 
presence of unprotonated nitrogens at neutral pH, PEI features a so called ‘proton 
sponge’ character (Kichler et al. 1999). It is assumed that the low pH within the 
endosome forces PEI to cause an osmotic imbalance facilitating the endosomal 
release. Regarding to this, especially linear PEI with an average molecular weight of 
22 kDa represents currently the ‘gold standard’ amongst the present non-viral gene 
delivery systems. However, a severe handicap of PEI is its high in vitro and in vivo 
toxicity (Chollet et al. 2002; Boeckle et al. 2004) and non-biodegradability. 
Nevertheless, a very promising new approach that utilizes degradable and less toxic 
polymers consisting of reversibly crosslinked low molecular oligoethylenimines 
with e.g. 1.6-hexanediol-diacrylate  was just recently described (Kloeckner 2006).   
The idea of the present study was to introduce a cationic net charge onto the 
surface of gelatin nanoparticles. This should enable the loading of nucleotides onto 
the particle’s surface due to electrostatic interactions. Comparable approaches for 
nanoparticles based on other matrix materials, such as solid-lipid nanoparticles 
(Olbrich et al. 2001), silica nanoparticles (Kneuer et al. 2000a), polylactide (PLA) 
nanoparticles (Munier et al. 2005), poly(D,L-lactide-co-glycolide) (PLGA) 
nanoparticles (Kumar et al. 2004), HSA nanoparticles (Wartlick 2004), chitosan 
nanoparticles, and chitosan-modified poly(ε-caprolactone) (PCL) nanoparticles 
(Haas et al. 2005) can be found in literature.  
Our research group focuses on gelatin as potential matrix material for colloidal 
carrier systems. Positive results of other groups that have already shown the 
potential of gelatin (Truong-Le et al. ; Leong et al. 1998; Truong-Le et al. 1999) and 
cationized gelatin (Hosseinkhani et al. 2002; Fukunaka et al. 2002; Kushibiki et al. 
2003) as complexing agent or hydrogel matrix for gene delivery encouraged our 
plans. The first aim of this study was to evaluate a variety of surface-modified 
gelatin nanoparticles as nucleic acid carriers in for their zeta potential (ζ potential) 
increase and loading efficiency. After finding ideal conditions, the next step was to 
test the most appropriate formulations in vitro.  
Besides the optimization of experimental conditions, a second focus of the study 
was to monitor the cell toxic effects of the system, to prove the thesis that gelatin 
nanoparticles are physiologically very well tolerated. To enable an assessment of the 
achieved transfection results we compared the cationized gelatin nanoparticles with 
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the ‘gold standard’ PEI polypexes. Cell toxicological experiments were performed 
in comparison to pDNA-loaded cationic liposomes and PEI polyplexes.  
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2. MATERIALS AND METHODS 
2.1 Reagents 
Reagent Description Supplier 
Acetone p.a. VWR International GmbH  
(Ismaning, Germany) 
cholaminechloride 
hydrochloride 
(2-aminoethyl)-trimethyl-
ammoniumchloride hydrochloride 
Sigma-Aldrich GmbH  
(Taufkirchen, Germany) 
DOPC 1,2-dioleoyl-sn-glycero-3-
phosphocholine 
Avanti Polar –Lipids Inc.  
(Alabaster, AL, USA) 
DOTAP 1,2-dioleoyl-3-trimethylammonium-
propane chloride 
Avanti Polar –Lipids Inc.  
(Alabaster, AL, USA) 
EDC 1-ethyl-3-(3-dimethyl-aminopropyl) 
carbodiimide hydrochloride 
Sigma-Aldrich GmbH  
(Taufkirchen, Germany) 
Gelatin type A  175 Bloom Sigma-Aldrich GmbH  
(Taufkirchen, Germany) 
Glutaraldehyde  25% Sigma-Aldrich GmbH  
(Taufkirchen, Germany) 
Spermine 98.5%, crystaline Sigma-Aldrich GmbH  
(Taufkirchen, Germany) 
TEPA  Tetraethylenpentamine, 98.5% Merck-Schuchardt OHG 
(Hohenbrunn, Germany). 
TETA Triethylentetramine; 97-99% Merck-Schuchardt OHG 
(Hohenbrunn, Germany). 
Exgen 500  Linear poly(ethylenimine) with 
average 22 kDa (PEI 22) 
Euromedex (Souffelweyerheim, 
France) 
 
The pDNA used in our studies was pCMVLuc (Photinus pyralis luciferase under 
the control of the CMV enhancer/promoter) as previously described (Plank et al. 
1992). The single-stranded DNA oligonucleotide (ODN) applied for loading 
studies had a random sequence (TCG-CTC-GAT-AGC-TCG-ATC) and was kindly 
donated by MWG Biotech (Ebersberg, Germany). 
2.2 Preparation of cationized gelatin nanoparticles 
Plain gelatin nanoparticles were produced in reference to previously established 
optimized conditions (see Chapter I). In order to bind DNA by electrostatic 
interactions onto the particle’s surface, various amines such as the quaternary amine 
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cholamine (Mw 175.10 Da), or the polyamines spermine (Mw 202.35 Da), TEPA 
(Mw 189.30 Da), and TETA (Mw 146.24 Da) were covalently coupled onto the 
surface and later evaluated for their nucleotide binding properties. The chemical 
structures of the particular molecules are depicted in Fig. 1. 
 
Fig. 1: Chemical structures of the applied cationization agents 
The used cationization procedure was a further modified and optimized version of 
a procedure previously described for cholamine (Coester 2003). In this new, 
optimized version, an aqueous dispersion of native nanoparticles has to be adjusted 
to pH 4.5 and a molar excess of the cationization agent (e.g. 50 mg per 500 mg 
nanoparticles) was added under constant stirring. After 5 minutes of incubation, a 
molar excess of EDC (50 mg) was added to activate free carboxyl groups on the 
particles to react with cholamine. During the cationization reaction the primary 
amino groups of the particular agents can react with two possible functional groups 
on the nanoparticle’s surface, as exemplified for cholamine in Fig. 2. The first 
interaction sites are residual aldehyde groups derived from only mono-functionally 
bound crosslinking reagent glutaraldehyde. Furthermore, the primary amino groups 
can react with activated carboxyl groups on the nanoparticles surface. The reaction 
is stopped after 1 h and the nanoparticles were purified by 3-fold centrifugation 
and redispersion, analogous to the purification of plain nanoparticles (see 
Chapter I. – 2.2)  
The final particles were characterized by size determination via dynamic light 
scattering and measurement of the ζ potential. The determinations of both 
parameters were conducted with a Zetamaster (Malvern Instruments, 
Worcestershire, UK). Each assigned size and corresponding polydispersity index 
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was the mean of 10 subruns. The ζ potential was determined by the same 
instrument and calculated as the mean of 10 individual measurements.   
 
Fig. 2: Schematic illustration of the surface cationization of gelatin nanoparticles with 
cholamine; step 1: activation of the carboxyl groups with EDC; step 2: covalent 
bonding of cholamine with residual aldehyde groups and activated carboxyl groups 
2.3 Cell culture 
Cell culture media, fetal calf serum (FCS) and antibiotics were purchased from 
Invitrogen GmbH (Karlsruhe, Germany). 
B16F10 cells were grown in Dulbeco’s Modified Eagle’s Medium (DMEM) (1.0 g 
glucose/L) supplemented with 10% FCS at 37°C in 5% CO2 humidified 
atmosphere. 
EDC 
Cholamine 
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2.4 Plasmid DNA (pDNA) and oligonucleotide (ODN) loading 
of gelatin nanoparticles 
Various batches of cationized nanoparticles were loaded with different amounts of 
pDNA or ODN (0.33 – 10% [w/w]) in varying conjugation media to find 
optimized conditions. The used conjugation media were highly purified water, 
phosphate buffered saline (PBS) 7.4, PBS 7.0/water (1:1 ratio), HEPES-buffered 
glucose (HBG, 5 % [w/w] glucose, 20 mM HEPES, pH 7.1), or HEPES-buffered 
saline (HBS, 20mM HEPES, 150mM NaCl, pH 7.1).  
2.4.1 Experiments to determine the maximum pDNA or ODN payload on 
surface-modified nanoparticles 
Various amounts of ODN or pDNA were co-incubated over 2-20 min. with 
nanoparticles at ambient temperature in one of the selected conjugation media. 
After this incubation period, the amount of unbound oligonucleotide was 
determined UV spectrophotometrically (260nm, UV1, Thermo Spectronic, 
Dreieich, Germany) in the supernatant of the reaction media after the separation of 
the nanoparticles by centrifugation at 14000g (neo lab 16/18, Hermle 
Labortechnik, Wehingen, Germany). 
2.4.2 pDNA loading of cholamine-modified nanoparticles for subsequent in 
vitro application 
In order to bind the pDNA onto the nanoparticles, a dispersion of nanoparticles 
was pipetted to a solution of pDNA (c=4 µg/mL) in buffer and mixed vigorously. 
After an incubation period of 2 min, 50 µL nanoparticle dispersion containing 
200 ng pDNA (luciferase pDNA) loaded in various pDNA to nanoparticle ratios 
was directly added to each well.  
2.5 Preparation and pDNA loading of cationic liposomes 
The applied cationic liposome batch (FG56) was kindly prepared by Dr. Friedrich 
Gruber. For detailed preparation conditions see his PhD thesis (Gruber 2004). 
Shortly summarized, they were prepared by a film method followed by extrusion 
through a 200 nm sterile filter at ambient temperature. The total lipid concentration 
was 5mM in 5% glucose solution. Thereby, DOTAP and DOPC were utilized in a 
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molar ratio of 1:1. The overall batch volume was 10 mL. Right after the extrusion, 
the samples were aliquoted in glass vials at 500 µL/vial and lyophilized. The 
reconstituted liposomes had a mean diameter of 188.7 nm and a PI of 0.122.  The ζ 
potential of the liposomes reconstituted in water was +45.6 mV. 
pDNA was identically loaded onto the liposomes as described for cationic gelatin 
nanoparticles (see 2.4). 
2.6 Preparation of PEI polyplexes 
For complex preparation, PEI was used at a 1 mg/mL working solution, 
neutralized to pH 7.0 with HCl. 
DNA complexes were prepared by first diluting PEI 22 in HBS pH 7.1. This PEI-
conjugate buffer solution was pipetted to pDNA diluted in HBS and mixed 
vigorously. Complexes were formed at a molar ratio of PEI nitrogen atoms to 
DNA phosphate (N/P) of 6. Complexes were allowed to stand for at least 20 min 
at room temperature before use. The final concentration of DNA (luciferase 
pDNA) in complexes was 20 µg/mL. Complexes containing 200 ng pCMVLuc 
were added directly to each well. 
2.7 Transfection 
5.0 x 103 cells per well were seeded out into 96-well plates (TPP, Trasadingen, 
Switzerland). After 16 h of incubation with the different formulations, the 
transfection medium was removed and replaced by fresh medium containing 10% 
FCS. After 24 h medium was again replaced. During transfection and for the 
following 24h 100 U/mL penicillin and 100 µg/mL streptomycin were present in 
the media. 
2.8 Luciferase assay 
For luciferase detection, cells were washed once with PBS, lysed in 50 µL of 
Promega cell lysis solution (Promega, Mannheim, Germany), and assayed as 
previously described (Carlisle et al. 2001). Luciferase activity was determined from 
20 µL samples of the lysate using the Luciferase Assay system (Promega); 
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measurements were performed in a luminometer (Lumat LB9507, Berthold, Bad 
Wildbad, Germany). 
Values are given as light units and represent the total luciferase activity per 5.0 x 103 
cells as mean ± s.d. of at least triplicates. 2 ng of recombinant luciferase (Promega) 
corresponded to 107 light units. 
2.9 Cell viability 
In comparison to PEI polyplexes, cell viability studies with loaded and unloaded 
nanoparticles were performed using a CellTiter-Glo™ Luminescent Cell Viability 
Assay (Promega, Mannheim, Germany) according to the manufacturer’s 
instructions. This assay is based on quantification of the ATP content of viable 
cells. 
2.10 Hemolysis assay 
Human erythrocytes were isolated from fresh citrate-treated blood and washed in 
PBS by 3 centrifugation cycles, each at 1000 g for 20 min at 4°C. The final cell 
suspension was adjusted to a concentration of 5% erythrocytes as stock suspension. 
Erythrocyte stocks were used within 24 h and the particular concentrations were 
determined using a specific Fuchs-Rosenthal counting chamber. Erythrocyte stocks 
were stored before usage at 4°C. 50 µl of the erythrocyte stock suspension were 
added to 950 µl of pDNA-loaded nanoparticle dispersions or unloaded 
nanoparticles. The particle dispersions had a concentration of 500 µg/mL 
nanoparticles loaded with 5 µg of pCMV-LUC. DOTAP/DOPC liposomes (1:1 
ratio) were loaded in the same ratio and tested in comparison.  
Each sample was co-incubated with the erythrocytes at 700 rpm on a Thermomixer 
comfort (Eppendorf AG, Hamburg, Germany) for 30 min (37°C). Afterwards, the 
samples were centrifuged at 1000 g to separate the erythrocytes. The supernatant 
was then centrifuged at 16000 g for another 20 min to separate the nanoparticles or 
liposomes. This final supernatant was then quantified UV-metrically at λ=576 nm 
to determine the haemoglobin release.   
For the calibration of the assay, PBS solution containing 1% Triton X-100 was 
added to achieve complete hemolysis. To obtain a calibration curve, dilutions of 
this 100% value were measured.  
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3. RESULTS AND DISCUSSION 
3.1 Characterization of the surface-modified nanoparticles 
Starting with one homogeneous plain gelatin nanoparticle batch, particular 
modifications were performed and the final modified nanoparticles were then 
monitored for changes regarding their mean particle size and homogeneity 
(Table 1).  
Table 1: Nanoparticle sizes measured with DLS 
 
mean particle 
size (nm) PI 
Gelatin 205.4 0.043 
Cholamine 212.7 0.075 
TETA 245.7 0.144 
TEPA  237.5 0.131 
Spermine 270.8 0.215 
 
Overall, gelatin nanoparticles remain more or less homogeneous and stable after 
modification. Increases in the particle mean size and PI can be attributed to the fact 
that after the activation of the carboxyl groups with EDC, the reactive intermediate 
can also interact with primary amino groups on the surface of other particles. Thus, 
inter-particulate covalent linking occurs. Whereas, PI values are rather abstract 
numbers, the worsening particle quality of higher PI values could be very well 
visualized by overlay-plots of the respective size distributions by volume (Fig. 3). 
Spermine-modified gelatin nanoparticles which resulted with the highest PI value 
had also the most inhomogeneous size distribution graph with initial signs of a 
dimeric or multimeric peak. 
The statistical chance for particle-particle interactions is rather low, since the 
cationization agent is added in molar excess and is more flexible to interact with 
activated carboxyl groups on the nanoparticles surface than sterically hindered 
nanoparticles. However, the polyamines (TETA, TEPA, and spermine) apparently 
tend more towards inter-particulate crosslinking as they contain reactive primary 
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amino groups at both ends of the molecule. Consequently, this might cause the 
increased mean sizes and PIs. Cholamine-modified particles remained almost 
unchanged in mean size and homogeneous according to the low PI.  
 
Fig. 3: DLS size-distribution by volume of plain gelatin nanoparticles and the 4 
differently surface-modified batches 
An elegant method to track a successful cationization of nanoparticles is to 
compare their particular ζ potentials. The two main factors having significant 
impact on the detectable potential are the prevailing pH and conductivity of the 
nanoparticle dispersion (Rawle 2004). The presence of ions attenuates the 
detectable net charge signal, so increasing ionic strength reduces the extent of the 
detectable potential values. In a first experiment, we measured the various prepared 
nanoparticles directly as dispersion in highly purified water (conductivity: 0.02-0.04 
mS/cm) without further pH adjustment (Table 2). The detected pH of the aqueous 
particle dispersions was always between 4.0 and 5.0. 
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Table 2: ζ potentials (mV) of plain gelatin nanoparticles and the various surface-
modified gelatin nanoparticles in highly purified water (aq. disp.) and 10 mM NaCl 
adjusted to pH 7.0 (10 mM NaCl pH 7.0); the particular conductivities are put in 
parentheses 
 aq. disp. 10 mM NaCl pH 7.0 
Gelatin 
26.23 ± 0.48 mV 
(0.03 mS/cm) 
-3.78 ± 0.08 mV 
(1.46 mS/cm) 
Cholamine 
46.93 ± 0.93 mV 
(0.03 mS/cm) 
11.70 ± 0.58 mV 
(1.52 mS/cm) 
TETA 
49.77 ± 0.83 mV 
(0.02 mS/cm) 
-3,51 ± 0.04 mV 
(1.50 mS/cm) 
TEPA  
39.31 ± 0.38 mV 
(0.03 mS/cm) 
-3.47 ± 0.07 mV 
(1.61 mS/cm) 
Spermine 
35.92 ± 1.12 mV 
(0.04 mS/cm) 
-3,14 ± 0.05 mV 
(1.59 mS/cm) 
 
ζ potential calculation performed at these conditions resulted for all nanoparticle 
types, even unmodified gelatin nanoparticles in positive values.  Furthermore, it 
could be noticed that all surface modifications led to an increase of the particles´ 
net charge in comparison to plain gelatin nanoparticles. However, these acidic 
conditions might be applied for nucleotide loading but do not represent the later 
physiological conditions the delivery system will encounter in vivo. Thus, we chose 
neutral pH 7.0 as second measurement point. In order to enable the adjustment of 
the pH with HCl/NaOH without causing too many alterations concerning the 
ionic background, we chose 10 mM NaCl as standard background (conductivity: 
1.46-1.61 mS/cm). As depicted in Table 2, only the cholamine-modified particles 
had a positive ζ potential of + 11.70 mV at pH 7.0. The amino groups of the 
polyamines are obviously not protonated at neutral conditions, whereas the 
quaternary amino group of cholamine induces a pH-independent positive net 
charge. 
To prove this thesis, we determined the ζ potentials of cholamine-modified gelatin 
nanoparticles compared to unmodified gelatin nanoparticles with an ionic 
background of 1mM NaCl (Fig. 4). 
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Fig. 4: ζ potential measured in correlation to the pH value (ionic background: 1 mM 
NaCl; conductivity: 0.16-0.19 mS/cm) 
Whereas plain gelatin nanoparticles resulted in an IEP of ~5.7, the nanoparticles 
modified with cholamine remained positively charged within the whole measured 
pH range. Consequently, the pH of the physiological environment should not have 
an effect on the DNA loading.  
3.2 Nucleotide loading efficiency of surface-modified 
nanoparticles 
The introduction of further nitrogen groups to the nanoparticle surface does not 
automatically mean, that this enables efficient loading of nucleotides at any 
conditions. The results of our nucleotide loading experiment using comparatively 
big double-stranded pDNA consisting of a few thousand base-pairs and small 
single-stranded 18-mer ODN were quite different.  
The small ODN could be completely loaded onto all surface-modified nanoparticle 
batches up to a concentration of 100 µg ODN per mg nanoparticles (10% [w/w]) 
(Fig. 5). The experiments were performed in PBS pH 7.4 and did not show any 
tendency towards aggregation during 2 hours. Without any surface modification, 
gelatin nanoparticles were only able to adsorb 38% of the offered ODN onto their 
surface. 
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Fig. 5: Random 18-mer ODN loading efficiency in PBS 7.4; applied ODN amount: 
10% (w/w); n=3 
As we performed similar experiments with larger, double-stranded pDNA, several 
nanoparticle batches modified with polyamines and the non-modified nanoparticle 
batch failed to adsorb significant amounts of pDNA in PBS 7.4 (Fig. 6). Solely the 
cholamine particles, which represent the only modification with positive ζ potential 
at neutral conditions (see 3.2) were able to bind the pDNA quantitatively. The 
maximum amount of complete pDNA loading that could be achieved with 
cholamine-modified gelatin nanoparticles was 50 µg/mg (5% [w/w]). But these 
formulations were very instable and agglomerated, respectively precipitated very 
quickly. This rapid process could only be stopped by reducing the amount of 
loaded pDNA to 20 µg/mg (2% [w/w]). 
If the pDNA was co-incubated with the various nanoparticle formulations under 
the acidic and ‘ion-free’ conditions in highly purified water, now all surface-
modified nanoparticle types were able to bind up to 50 µg/mg (5% [w/w]) pDNA 
completely. Non-modified gelatin nanoparticles were only able to adsorb 26% of 
the total pDNA amount. Again the same aggregation tendencies were visible as in 
PBS 7.4. Thus, the presence of disturbing ions is not the reason for the aggregation 
of the nanoparticles loaded with amounts higher than 20 µg/mg pDNA. In fact, 
the larger structure of pDNA in comparison to the small ODN seems to be 
responsible for these instabilities and facilitates the aggregation of the nanoparticle 
formulations. The present aggregation results correlate very nicely with findings 
concerning cationic silica nanoparticles (Kneuer et al. 2000b) where the authors 
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demonstrated at comparable loading ratios, that nanoparticles and pDNA tend to 
form complex structures, that can be described with a spaghetti-meatball model. 
They visualized via atomic force microscopy, that the DNA is wound around and 
sandwiched by multiple nanoparticles. Obviously, this aggregation tendency is 
hindered, when the relative amount of pDNA is reduced. Size determinations of 
cholamine-modified nanoparticles loaded with 2% (w/w) pDNA by DLS and 
AF4/MALS demonstrated, that the nanoparticles did not show any aggregation 
tendency at this loading ratio (Fraunhofer 2003; Fraunhofer et al. 2004).  
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Fig. 6: pDNA loading efficiency in PBS 7.4 (grey) and highly purified water (white); 
applied pDNA amount: 2% (w/w); n=3 
Summarizing the results of the various surface modifications, it can be concluded, 
that the ζ potential of the nanoparticles has significant impact on the pDNA 
binding abilities of the gelatin nanoparticles, in contrast to the nucleotide 
adsorption of short single-stranded ODNs.  
Experiments with other types of nucleotide-based drugs gave further indications 
that loading properties of various nucleotides onto cationic gelatin nanoparticles 
cannot be generalized. Preliminary experiments with single-stranded mRNA 
consisting of a few hundred nucleotides and cholamine-modified gelatin 
nanoparticles exhibited also certain aggregation tendencies comparable to pDNA, 
but in an alleviated manner. Jan Zillies demonstrated that short 22-mer double-
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stranded NF-κB decoys with phosphorothioated backbone can be loaded onto 
cholamine-modified gelatin nanoparticles comparable to short single-stranded 
ODNs. 21-mer double-stranded siRNA with phosphodiester backbone however, 
revealed only weak binding properties with cholamine-modified particles (Zillies & 
Coester 2004).  
As a consequence, we decided to choose cholamine surface-modified nanoparticles 
as favored type of cationized gelatin nanoparticles for the following in vitro 
transfection experiments. Furthermore the cationization procedure with cholamine 
preserved the original homogeneous particle quality and did not induce instabilities. 
Nevertheless the polyamines are worth to be kept in mind, as they might be 
beneficial for applications with pH-controlled release, or could be used in 
combination with cholamine to induce a quicker release of the delivery system 
from the endosome, according to the ‘proton sponge’ theory.  
3.3 Optimized pDNA transfection conditions with cholamine-
modified gelatin nanoparticles 
In the previous drug loading studies (see 3.2), we found that the maximum amount 
of pDNA that should be loaded onto cationized nanoparticles without causing 
rapid instabilities is 20 µg/mg (2% [w/w]). As we performed the previous 
experiments only in PBS and highly purified water, we wanted to test also other 
conjugation media, to investigate if the loading amount can be increased. Therefore 
we tested HEPES-buffered glucose (HBG, 5 % [w/w] glucose, 20 mM HEPES, 
pH 7.1), and HEPES-buffered saline (HBS, 20mM HEPES, 150mM NaCl, pH 7.1) 
as alternatives, as they have shown good potential as conjugation media for 
polyplexes (Kloeckner 2006). But as for PBS, incubating our formulations within 
these media led to same results in case of HBS and an even stronger tendency 
towards aggregation in case of HBG. So, PBS 7.4 and PBS 7.0 diluted with highly 
purified water (1:1 ratio) were chosen as standard conjugation media.  
Conducting first transfection experiments with formulations that were loaded with 
20 µg/mg (2% [w/w]), failed to induce any gene expression. Instead we found that 
only formulations loaded between 3.3 µg/mg and 10 µg/mg (0.33-1% [w/w]) 
showed significant transfection results. Searching for reasons, we investigated the ζ 
potentials of formulations containing different DNA to nanoparticle ratios (Fig. 7).  
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Fig. 7: ζ potential determination of formulations with various ratios of DNA to 
nanoparticles (w/w). 
The measurements were performed in physiological PBS 7.4. Formulations 
containing 3-5% (w/w) payload tended towards quick agglomeration and resulted 
in strong negative ζ potentials. Reducing the DNA content to 2% (w/w) prevented 
aggregations and correlated with a characteristic reduction of the formulations’ ζ 
potential to -9.5 mV. Finally, the formulations that were able to transfect the B16 
cells (0.33-1% [w/w]) had all either a neutral or slightly positive ζ potential, which 
appears to be crucial for successful gene delivery as it facilitates the passage 
through the negatively charged cell membrane. 
The two nanoparticle batches used in this study had a mean size of 288.3 nm 
(ZWgen288+) and 182.7 nm (ZWgen182+). Dynamic light scattering suggested a 
uni-modal size distribution for both batches, having low PIs of 0.067 
(ZWgen288+) and 0.101 (ZWgen182+). 
For nanoparticulate pDNA formulations loaded in PBS 7.4, none of the three 
different loading concentrations showed any significant gene expression after 24 h. 
However the PEI polyplexes showed their strongest gene expression (1.46 x 107 
RLU [relative light units]) at this point (Fig. 8).  
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Fig. 8: Transfection efficiency of cationized gelatin nanoparticles after 24 h; 
conjugation buffer: PBS 7.4; cells: untreated cells; PEI: standard polyplex; 1%, 0.5%, 
0.33%: relative amount of pDNA loaded onto gelatin nanoparticles (w/w) 
Performing the DNA loading of the particles in PBS 7.0/water (1:1 ratio) instead 
of PBS 7.4 led to first detectable gene expressions for the formulations loaded with 
0.5% pDNA (w/w) after 24 h (Fig. 9).  
 
Fig. 9: Transfection efficiency of cationized gelatin nanoparticles after 24 h; 
conjugation buffer: PBS 7.0/water (1:1 ratio); cells: untreated cells; PEI: standard 
polyplex; 1%, 0.5%, 0.33%: relative amount of pDNA loaded onto gelatin 
nanoparticles (w/w) 
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After 72 h, both the nanoparticles incubated in PBS 7.4 (Fig. 10) and in PBS 
7.0/water (1:1 ratio) (Fig. 11) resulted in distinct increases of gene expression.  
 
Fig. 10: Transfection efficiency of surface-modified gelatin nanoparticles after 72 h; 
conjugation buffer: PBS 7.4; cells: untreated cells; PEI: standard polyplex; 1%, 0.5%, 
0.33%: relative amount of pDNA loaded onto gelatin nanoparticles (w/w) and in PBS 
7.0/water (1:1 ratio) (Figure 6) resulted in distinct increases of gene expression.  
 
Fig. 11: Transfection efficiency of surface-modified gelatin nanoparticles after 72 h; 
conjugation buffer: PBS 7.0/water (1:1 ratio); cells: untreated cells; PEI: standard 
polyplex; 1%, 0.5%, 0.33%: relative amount of pDNA loaded onto gelatin 
nanoparticles (w/w) 
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Formulations prepared in PBS 7.4 showed already noticeable outcomes with 2.98 x 
104 RLU for the larger nanoparticles (ZWgen288+) containing 0.33% pDNA 
loading (w/w) and 4.94 x 104 RLU for ZWgen182+ (0.5% [w/w] pDNA). The best 
gene expressions could be achieved in PBS 7.0/water (1:1 ratio) with 1.12 x 105 
RLU for ZWgen288+ and 2.63 x 105 RLU for ZWgen182 (both 0.5% [w/w] 
pDNA).  
Overall, there is a tendency favoring the use of 182.7 nm large particles as carrier 
(ZWgen182+) with a relative amount of 0.5% pDNA (w/w) loaded onto the 
particles. As for the conjugation buffer, further studies have to be performed to 
find ideal media. Compared to PEI, the peak gene expression occurs with a certain 
delay and a one order of magnitude lower efficiency. One reason could be a 
prolonged intracellular processing due to slow endosomal escape or a different 
cellular uptake mechanism.  
3.4 Cytotoxicity of cationized gelatin nanoparticles  
Since cytotoxicity of our formulations was the second focus of our experiments, we 
monitored the viability of the transfected B16 F10 cells simultaneously (Fig. 12). 
 
Fig. 12: Cell viability of B16 F10 cells after 72 h of incubation; PEI: standard 
polyplex; 1%, 0.5%, 0.33%: relative amount of pDNA loaded onto gelatin 
nanoparticles (w/w) 
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 After a total time of 72 h, only averaging 10.9% of the B16 F10 cells transfected 
with PEI polyplexes remained viable, whereas the viability of all cells that have 
been transfected with gelatin nanoparticle formulations was between 83.3 and 
100%. For transfection, PEI formulations are typically incubated with cells for 4 h 
instead of 16 h as in this study. This might explain the low cell viability of cells 
transfected with PEI polyplexes but also demonstrates the good physiological 
tolerance of gelatin nanoparticle formulations. A trend was observed, that 
formulations loaded with less relative pDNA amount are more toxic. The reason 
for this might be that the higher remaining positive net charge of the formulations 
induces lower cell viability. Furthermore, a marginal tendency towards formulations 
conjugated in PBS 7.4 showing less cell viability can be seen but in general, the cell 
toxicological effects of our formulations are minimal compared to PEI polyplexes.  
In addition to this cytotoxicity data we characterized also the hemolytical activity of 
our formulations on human erythrocytes. Since erythrocytes are one of the first cell 
species, nanoparticles will face when administered intravenously, this experiment 
provides valuable information concerning in vivo practicability. To rate the achieved 
results we compared cationized gelatin nanoparticles with plain gelatin 
nanoparticles and DOTAP/DOPC liposomes (1:1 ratio). These liposomes 
represent another well recognized effective non-viral gene delivery system (Fig. 13).   
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Fig. 13: Relative hemolysis of unloaded (grey) and 20 µg/mg pDNA-loaded (white) 
cholamine-modified nanoparticles vs. DOTAP/DOPC liposomes 
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Plain gelatin nanoparticles hardly induced any erythrocyte lysis (0,94% ± 0,62). The 
activity of loaded and unloaded plain gelatin nanoparticles was as expected similar, 
because no pDNA loading was expected, so the pDNA remained in solution. 
pDNA-loaded cationized nanoparticles also did not induce any significant release 
of hemoglobin(1.58% ± 0.59). Even unloaded cationized gelatin nanoparticles were 
only slightly haemolytic (2.98% ± 0.30). If these results are compared with 
DOTAP/DOPC liposomes, unloaded cationized gelatin nanoparticles are still far 
below the hemolytic activity of the loaded liposomes (17.60% ± 1.02). Some might 
argue that this occurred possibly due to a higher remaining ζ potential of the loaded 
liposomes, since unloaded liposomes had a higher potential in highly purified water 
(+45.6 mV). But this was not the case as pDNA-loaded liposomes had an 
ζ potential of +6.9 mV in PBS 7.4, whereas less toxic unloaded cationized gelatin 
nanoparticles had a ζ potential of +11.4 mV and can be referred as almost ideal 
physiologically tolerated according to these present in vitro results. 
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4. CONCLUSION 
According to the results of this study, it is possible to bind ODNs and pDNA to 
surface-modified gelatin nanoparticles. In case of ODNs this is pH-independently 
possible with all modification-types tested in this study.  
The pH-independent binding of pDNAs is limited to the cholamine-modification. 
Amino groups of the polyamine-modifications need to be protonated to adsorb 
pDNAs. This fact offers the chance for pH-dependent controlled release. 
Aside from the tested approaches it is as well possible to combine the binding of 
cholamine or other quaternary amino groups with the binding of polyamines. The 
quaternary amino group ensures pH-independent drug loading whereas the 
polyamines with their amino groups as protonable tools could potentially accelerate 
the endosomal escape after cellular uptake.  
In the second part of this study we were able to demonstrate in vitro that 
cholamine-modified gelatin nanoparticles are a promising new non-viral carrier 
system for gene therapy. A major benefit is not only the very low cytotoxocity, but 
also their simple and reproducible production, which would facilitate future 
upscaling. Low costs of the base material gelatin make this approach commercially 
attractive. Gene transfer efficiency of our formulations are only approximately one 
order of magnitude lower than the efficiency of the ‘gold standard’ cationic PEI 
polyplexes; these in vitro transfection rates are significant and quite remarkable 
considering that we are still at an early stage of formulation optimization. Of course 
other approaches are already further on their way towards the ideal non-viral 
delivery system, the so-called ‘artificial virus’ (Wagner 2004), as they are highly 
sophisticated intelligent systems. Nevertheless, the already achieved results with this 
simple system are very promising.  
One advantage offered by the amino acid side-chains of the gelatin matrix molecule 
is the option of multiple further modifications. This could be used for coupling of 
ligands to improve targeting diseased tissues, to enhance specific cellular uptake or 
affect intracellular distribution.  
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Chapter III 
In vitro delivery of immunogenic CpG oligonucleotides 
1. INTRODUCTION 
1.1 The immune system and the role of toll-like receptors 
The human immune system represents a collective of cells, tissues, and organs that 
defends the human body against foreign pathogenic invaders such as viruses, 
bacteria, parasites, and fungi. It can be divided into innate and adaptive or acquired 
components. The innate immune system is the first quick line of defense. But 
neither are pathogens specifically recognized, nor mechanisms of safety against 
repetitive future infections initiated. Important elements of the innate immune 
system are the humoral component i.e. the complement system and the cellular 
components i.e. phagocytotic cells such as macrophages, granulocytes, and natural 
killer (NK) cells. Even though the innate immune system is very quick, it mostly 
fails to abolish the pathogen completely due to its lack of specificity. But, it triggers 
the acquired immune system which consists of antibodies as humoral components 
and lymphocytes as cellular components. Characteristic for the acquired immune 
system are its high specificity against pathogens and its memory function. Via 
clonal selection lymphocytes specific for one pathogenic antigen are produced. 
Some of these lymphocytes are differentiated to memory cells. The lymphocytes 
can be subdivided in B cells and T cells. B cells produce antibodies, whereas T cells 
act either as T helper cells (TH cells), supporting other immune cells or cytotoxic T 
lymphocytes (CTL) that are able to induce the death of infected cells. TH cells are 
positive for the antigen CD4 (cluster of differentiation antigen 4), whereas CTLs 
are positive for CD8. Naïve CD4+ T-cells (TH0 cells) are activated via antigens that 
are presented by antigen presenting cells (APCs) such as macrophages and 
dendritic cells (DCs). According to the co-administered cytokines, the naïve TH0 
cells are further differentiated to either TH1 or TH2 cells. TH1 cells support cellular 
immune responses, while TH2 cells support the activation of B cells to produce 
antibodies, thus inducing a humoral immune response. Within the immune system, 
APCs and especially DCs play a major role because they connect innate and 
acquired immune response.  
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Activation of the innate immune system occurs by the exposure to pathogen-
associated molecular patterns (PAMPs) that are expressed by diverse infectious 
microorganisms (Medzhitov & Janeway 1997b). These PAMPs are recognized by 
specific pattern recognition receptors (PRRs) that are mainly present in APCs. 
Although PAMPs represent a very heterogeneous group, all PAMPs have in 
common their specificity for microbial pathogens that cannot be found in the host 
organism. Furthermore, PAMPs are part of the respective pathogenicity and are 
indispensable for the pathogen’s survival (Medzhitov & Janeway 1997a). The PRRs 
that exist in vertebrates are lectin receptors (Stahl et al. 1998), scavenger receptors 
(Peiser et al. 2002), and toll-like receptors (TLRs). 
Presently, there are 10 human TLRs described in literature, although some of their 
natural ligands have not been identified so far. Most of these ligands are of 
microbial origin. But, there are also supposed to be endogenous ligands that are 
released during inflammation reactions due to cellular stress or damage (Matzinger 
2002). An overview of the known TLRs and their corresponding ligands is given in 
Table 1 (Kaisho & Akira 2002). 
Table 1: TLRs and ligands 
TLR PAMP Origin of ligand Reference 
TLR1 cooperates with TLR2   
TLR2 Lipoproteins Gram-positive 
bacteria 
(Yoshimura et al. 1999; Underhill 
et al. 1999) 
 Zymosan Yeast (Underhill et al. 1999) 
 Lipoarabinomannan Mycoplasma (Means et al. 1999a; Means et 
al. 1999b) 
 MALP-2 Mycobacteria (Takeuchi et al. 2000; Takeuchi 
et al. 2001) 
TLR3 Double-stranded RNA Virus  (Alexopoulou et al. 2001) 
TLR4 LPS Gram-negative 
bacteria 
(Qureshi et al. 1999; Hoshino et 
al. 1999) 
 F protein Respiratory 
syncytial virus 
(Kurt-Jones et al. 2000) 
 HSP60 Host (Ohashi et al. 2000; Vabulas et 
al. 2001) 
 Fibronectin EDA domain Host (Okamura et al. 2001) 
TLR5 Flagellin Bacteria with flagella (Hayashi et al. 2001) 
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TLR6 Cooperates with TLR2  (Takeuchi et al. 1999) 
TLR7 Guanosine analogs, 
single-stranded RNA 
 (Hornung et al. 2004) 
TLR8 Guanosine analogs  (Jurk et al. 2002) 
TLR9 CpG motifs Bacteria, viruses (Hemmi et al. 2000) 
TLR10 unknown   
 
TLR1, 2, 4, 5, and 6 are specialized on the recognition of ligands that are unique in 
bacteria and cannot be produced by the infected host itself. TLR3, 7, 8, and 9 are 
responsible for the detection of viral pathogens and the recognition of nucleic acids 
that do not only exist in microbial organisms. In these cases, the differentiation 
between own and foreign DNA does not only rely on the type of ligand but also on 
the accessibility of the particular TLRs. Thus, these TLRs are located in subcellular 
compartments.  
1.2 History and mechanism of action of CpG ODNs 
As described in Table 1, bacterial or viral DNA is recognized by TLR9 via non-
methylated cytosine-phosphate-guanosine dinucleotides in particular sequence 
contexts (CpG motifs) that are sensed as the key danger signals (Krieg et al. 1995). 
Concerning the immunogenicity of viral or bacterial DNA, first findings were 
already made more than 100 years ago. Back in 1890, William Coley introduced the 
deliberate use of bacterial extracts for the treatment of cancer (Wiemann & Starnes 
1994). Even though temporary tumor-restitution and a surprising complete 
remission rate of 10% (Coley 1991) were achieved, this approach was not further 
established since it lacked reproducibility and was ruled out by other methods such 
as radiotherapy. It took until the 1970ies before a second approach was conducted 
using attenuated mycobacteria Bacillus Calmette Guerin (BCG) for tumor therapy 
which was finally established as standard therapy for human bladder cancer 
(Morales 1978). Other research groups explored later that the anti-tumoral effect of 
the vaccination with BCG was related to a stimulation of the immune system 
(Tokunaga et al. 1984). More precisely,  the bacterial DNA was responsible for the 
induction of natural killer cell (NK cell) activity and the production of type 1 and 
type 2 interferons (Yamamoto et al. 1992). After further investigations, the 
researchers concluded that self-complementary palindromes in the nucleotide 
sequence containing at least one cytosine-phosphate-guanosine (CpG) dinucleotide 
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(Kuramoto et al. 1992) were responsible for this stimulation of the immune system. 
Another research group independently reported that purified bacterial DNA as well 
as poly-(dG,dC) nucleotides in contrast to vertebrate DNA, induced the 
proliferation of murine B cells and immunoglobulin secretion (Messina et al. 1991). 
Furthermore this group explored that the mitogenicity of poly-(dC,dG)-nucleotides 
was abolished by methylation of cytosine (Pisetsky & Reich, III 1998). So they 
suggested that methylation interferes the formation of unique higher order 
structures, which are responsible for the immunogenic effect.  
During experiments with antisense ODNs in 1995, Arthur M. Krieg coincidentially 
observed immune stimulatory effects such as strong B cell proliferation and 
immunoglobulin secretion of certain ODNs. After further analysis of the ODNs, 
Krieg found out that CpG dinucleotides in particular sequence contexts (XCGY 
whereas X can be random but C and Y can be random but G) are decisive to 
induce a stimulation of the immune system. Inversion of the base sequence (GpC) 
as well as methylation of cytosine abolished the immune stimulation. 
Concomitantly, it could be disproved that the formation of higher order structures 
related to a palindrome sequence is necessary for action (Krieg et al. 1995).  
Summarizing all these insights, it can be explained how TLR9 succeeds to 
differentiate between own and foreign DNA (Bird et al. 1987): 
a) CpG dinucleotides are statistically underrepresented in vertebrate DNA 
(1:60), whereas nucleotide utilization in bacterial DNA is random (1:16). 
b) The majority of cytosines (70%) in CpG dinucleotides are methylated in 
vertebrate, but not in microbial DNA.  
With this knowledge various synthetic ODNs were developed which were highly 
effective concerning their immune stimulation in murine in vitro and in vivo 
experiments. But it was noticed that optimized sequences and settings of the 
murine experiments could not be transferred to nonhuman primates and humans, 
as there are significant evolutionary based differences in the recognition of CpG 
motifs. Whereas GACGTT was determined as the optimized CpG motif to activate 
the immune system of mice (Rankin et al. 2001) it is GTCGTT for nonhuman 
primates and humans (Hartmann & Krieg 2000) (Table 2). Moreover, the cell-types 
that contain TLR9 differ remarkably. In mice, TLR9 is also present in cells of the 
myeloid lineage such as myeloid dendritic cells (MDCs; CD11c+ DCs). In humans 
the receptor is exclusively present in plasmacytoid dendritic cells (PDCs; CD11c- 
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DCs) and B cells (Rothenfusser et al. 2002). Murine MDCs are often utilized in in 
vitro models, since these cells are conveniently derivable from bone marrow 
precursors being treated with GM-CSF. But TLR9 is not present in human MDCs, 
so the significance of the data produced with this in vitro model is limited. Caution 
seems advisable when extrapolating murine CpG ODN data to primates and 
humans. 
1.3 Synthetic CpG ODN classes for humans and their effects on 
the immune system 
With respect  to the induced immunological effects, there are two major classes of 
CpG ODNs described for humans which are called CpG-A (also known as ODN 
type D (Klinman 2004)) and CpG-B (also known as ODN type K (Klinman 2004)).  
Table 2: Nucleotide sequences of CpG ODN 1826 (prototype murine CpG ODN), 
CpG ODN 2216 (prototype CpG-A class), and CpG ODN 2006 (prototype CpG-B 
class). 
CpG ODN type Description Sequence (5’-3’) 
1826 murine CpG ODN TCCATGACGTTCCTGACGTT* 
2216 CpG-A ODN GGgggacgatcgtcgGGGGg* 
2006 CpG-B ODN TCGTCGTTTTGTCGTTTTGTCGTT* 
*capital letters: nucleotides with phosphorothioated backbones;  
 others: phosphodiester backbones  
 
CpG-A with its prototype ODN 2216 (Krug et al. 2001) (Table 2) is known to 
stimulate the production of high amounts of IFN-α/β (type I interferons). The 
ODNs of this class possess characteristic structural features (Krug et al. 2001):  
a) chimeric backbone with phosphorothioate-modified 5’ and 3’ ends 
and a phosphodiester center portion  
b) poly-G sequences at both ends 
c)  central palindrome sequence 
d)  CpG dinucleotide within the palindrome 
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However, the B cell activation of CpG-A ODNs is only weak. On the other hand, 
CpG-B ODNs selectively activate PDCs and induce their maturation, but are 
unable to initiate the secretion of IFN-α/β. Moreover, CpG-B ODNs are able to 
activate B cells. The sequence prototype ODN 2006 (Hartmann & Krieg 2000) 
(Table 2) is currently tested in various clinical trials as ODN 7909 (ProMune™, 
Coley Pharmaceutical Group, Wellesley, MA, USA). A more detailed overview of 
the effects of CpG ODNs on the two cell types that are directly activated in the 
human immune system is given  in Fig. 1 (Rothenfusser et al. 2002):  
 
Fig. 1: Effects of CpG ODN on the human immune system (Rothenfusser et al. 2002)  
Whereas PDCs and B cells are directly activated by CpG ODNs, other immune cell 
subsets such as monocytes, MDCs, T cells and NK cells are only indirectly 
activated.  
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Effects mediated via CpG-A class ODNs are: 
a) partial activation of CD8  cytotoxic T lymphocytes (CTL) (Hornung et al. 
2002)  
b) strong activation of NK cells (→ production of IFN-γ and lytic activity) 
(Rothenfusser et al. 2001) 
c)  promotion of proliferation, IFN-γ production, and lytic activity of γδ T cells 
(Rothenfusser et al. 2001) 
Effects mediated via CpG-B class ODNs are: 
a) direct activation of B cells (Hartmann & Krieg 2000) 
b) synergistic stimulation of IL-12 with CD40 L in PDCs leading to priming of 
naïve CD4 T cells and the development of TH1 cells (Rothenfusser et al. 
2002) 
Both CpG ODN classes upregulate co-stimulatory molecules in monocytes and 
MDCs.  
Recently, with the CpG-C class, a new class of CpG ODNs was introduced. These 
CpG ODNs activate both, the secretion of IFN-α in PDCs and the proliferation of 
B cells (Hartmann et al. 2003; Poeck et al. 2004; Vollmer et al. 2004).  
1.4 Fields of applications for synthetic CpG ODNs 
Potential fields of application for synthetic CpG ODNs are illustrated in Fig. 2 
(Klinman 2004). They can be applied as immunoprotective stand-alone agent, 
inhibitor of TH2-cell-mediated allergic reactions, adjuvant for vaccine applications, 
and for the immunotherapy of cancer. 
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Fig. 2: Potential therapeutic uses of CpG ODNs (Klinman 2004) 
Immunoprotective activity of CpG ODNs 
Various research groups have proven in vivo that the prophylactic administration of 
CpG ODNs and bacterial DNA induces protection against various viruses, bacteria 
and extracellular parasites. So, pretreated mice were e.g. resistant versus bacteria 
inducing listeria and tularaemia (Krieg et al. 1998; Klinman et al. 1999; Elkins et al. 
1999). Similar results could be achieved for the protection from viral pathogens 
such as the herpes simplex virus and the cytomegalovirus (Pyles et al. 2002; Ashkar 
et al. 2003) as well as from parasites inducing leishmaniasis and malaria 
(Zimmermann et al. 1998; Gramzinski et al. 2001). Thereby, the immunoprotective 
activity reached its maximum after several days and lasted for several weeks. In first 
experiments with primates (macaques), the malignance of infections was strongly 
reduced when the monkeys were pretreated with CpG-A ODN (Verthelyi et al. 
2003). Finally, it was also demonstrated in this study that the CpG-induced 
immunoprotection is mainly PDC-related, since PDC-deficient mice treated with 
CpG ODNs did not show any protection against infections.  
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Prevention and treatment of allergies 
Allergic asthma, an inflammatory disease of the respiratory tract, is associated with 
TH2-biased activation mainly via the cytokines IL-4 and IL-5 (Robinson et al. 1992). 
Furthermore it is known that cytokines that induce a TH1-type immune response, 
such as INF-γ and IL-12, strongly reduce the symptoms by inhibiting the TH2-
pathway (Sur et al. 1996). Research groups demonstrated in mouse models that 
allergic asthma could be attenuated or even cured when CpG ODNs were co-
administered with allergens (Kline et al. 1998; Sur et al. 1999). Intratracheally 
administered CpG ODN shifted the balance between INF-γ- and IL-4-secreting 
cells towards INF-γ, reduced the number of allergen specific IgE-producing cells 
and diminished the allergen-induced eosinophil recruitment (Sur et al. 1999).  
Immunotherapy of cancer 
CpG ODNs have shown great potential in murine tumor models. Effective anti-
tumor immunity can be achieved with CpG ODNs in both, monotherapy and in 
combination with chemo- or radiotherapy (Ballas et al. 2001; Heckelsmiller et al. 
2002; Weigel et al. 2003; Milas et al. 2004; Meng et al. 2005; Bourquin et al. 2006). 
These anti-tumoral effects appear, because the immune cascade that is elicited by 
CpG ODNs results in the activation of NK cells and cytotoxic T lymphocytes 
(CTLs). Even complete tumor remission in mice could be achieved and due to the 
presence of memory immune cells, no recidivisms occurred (Heckelsmiller et al. 
2002). However, the published results indicate that the type of tumor, as well as the 
type of administered CpG ODN is crucial for the success of a prophylactic or 
therapeutic application. 
Adjuvant for vaccine applications 
CpG ODNs induce the production of cytokines and chemokines that create an 
supportive environment for antigen-specific immune response. In addition, CpG 
ODNs activate professional APCs and induce their maturation. Consequently, 
CpG ODNs are discussed as potent vaccine adjuvants, as they strongly enhance the 
immunogenicity of co-administered antigens. In agreement with the production of 
TH1-type cytokines, CpG ODNs activate the production of INF-γ that promotes 
the production of IgG2a antibodies and facilitates the development of antigen 
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specific CTLs (Moldoveanu et al. 1998; Eastcott et al. 2001). These issues are 
further investigated in Chapter IV of this thesis. 
1.5 Clinical trials with CpG ODNs 
Due to the promising in vivo data derived from animal studies, CpG ODNs have 
made their way straight forward towards clinical trials. Until 2004, CpG ODNs 
have been administered in more than 12 clinical trials (Klinman 2004). Most of 
these studies are in Phase I or Phase II. Applications tested are either CpG ODNs 
alone, or in combination with allergens, vaccines, or antibodies. So, CpG ODNs 
are evaluated for the treatment of various allergies, asthma, cancer, and as vaccine 
adjuvant.  
So far, the results of two clinical trials have been described in literature. In these 
experiments, CpG ODN 7909 (= CpG-B ODN 2006 sequence) has been used as 
vaccine adjuvant. In a first randomized double-blind study, CpG ODN 7909 was 
co-administered by intramuscular injection with Engerix-B® (GlaxoSmithKline) a 
commercial hepatitis B vaccine. This co-administration led to 13 - 45-fold higher 
antibody titers than with Engerix-B® alone (Halperin et al. 2003; Cooper et al. 
2004a). In a second double-blind study where CpG ODNs were co-administered 
with the influenza virus vaccine Fluarix® (GlaxoSmithKline), humoral responses 
were not significantly enhanced by the addition of CpG 7909, except in individuals 
with pre-existing immunity (Cooper et al. 2004b). However, co-administered CpG 
ODN induced significantly higher INF-γ secretion from peripheral blood 
mononuclear cells (PBMCs). Thus, CpG ODN 7909 may allow the use of reduced 
Fluarix® doses without reducing the immunogenicity. 
1.6 CpG ODN transport by delivery systems and aim of the study 
Professional antigen presenting cells naturally phagocytose bacteria, viruses, and 
other microorganisms and process their proteins for antigen presentation to T cells 
for the induction of antigen specific immune responses. Colloidal particulate 
formulations fall within the same size range as microorganisms and thus are 
preferentially phagocytosed by MDCs. Hence, particulate vaccine delivery systems 
have proven to be advantageous for subunit vaccines based on proteins, peptides 
and DNA (Raychaudhuri & Rock 1998; Singh & O'Hagan 2002).  
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Following this concept, enhanced TH1-biased immune responses have been 
observed in mice subsequent the delivery of CpG ODNs via liposomes (Joseph et 
al. 2002; Suzuki et al. 2004) and micro- or nanoparticulate delivery systems (Singh et 
al. 2001; Diwan et al. 2002; Fearon et al. 2003; Diwan et al. 2004). Our cooperation 
partners at the University of Alberta already demonstrated the advantage of CpG 
ODNs after incorporation in biodegradable poly(D,L-lactic-co-glycolide acid) 
(PLGA) nanoparticles (Diwan et al. 2002; Diwan et al. 2004). Another research 
group (Singh et al. 2001) achieved very promising results using CpG ODNs 
adsorbed onto cationized Polylactide-co-glycolide (PLG) microparticles due to 
electrostatic interactions. The advantage of this system is the direct presentation of 
CpG ODNs on the carrier’s surface. This might result in a quicker activation 
compared to carrier-incorporated CpG ODNs since no diffusion or particle 
degradation is necessary before ODNs can interact with the receptor.  
It was the aim of the present study to evaluate CpG ODN-loaded cationized 
gelatin nanoparticles (CpG-GNPs). Thereby the same cholamine-modified 
cationized gelatin nanoparticles were applied as already introduced as non-viral 
gene delivery system (Chapter II). 
At first in vitro uptake of plain gelatin nanoparticles into murine myeloid dendritic 
cells (MDCs) was studied in competition with other established nanoparticulate 
carrier system. At the same time we started to evaluate the loading behavior of 
CpG ODNs onto cationized gelatin nanoparticles. Optimized CpG-GNPs were 
then investigated in this previously established murine in vitro model. However, due 
to differences in the distribution of TLR9 and the ideal CpG ODN sequences 
comparing murine and human organisms, these data allow only to draw limited 
conclusions. Hence, primary human blood cells were utilized in the third part of 
this study, where immunological effects of all three CpG ODN classes that exist 
for humans and non-human primates were evaluated. 
 Chapter III. In vitro delivery of immunogenic CpG oligonucleotides 
- 84 - 
published by Verlag Dr. Hut, Munich, www.dr.hut-verlag.de, ISBN: 3-89963-451-9 
2. MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Reagents 
Reagent Description Supplier 
Acetone p.a. VWR International GmbH  
(Ismaning, Germany) 
Chloroform HPLC grade Fisher (Nepean, ON, Canada) 
Cholaminechloride 
hydrochloride 
(2-aminoethyl)-trimethyl-
ammoniumchloride hydrochloride 
Sigma-Aldrich GmbH  
(Taufkirchen, Germany) 
DABCO 1,4-Diaza[2.2.2]bicyclooctane; 
98% 
Sigma-Aldrich GmbH  
(Taufkirchen, Germany) 
DMSO Dimethyl Sulfoxide; ≥99.9% Sigma-Aldrich GmbH  
(Taufkirchen, Germany) 
EDC 1-ethyl-3-(3-dimethyl-aminopropyl) 
carbodiimide hydrochloride 
Sigma-Aldrich GmbH  
(Taufkirchen, Germany) 
Gelatin type A  175 Bloom Sigma-Aldrich GmbH  
(Taufkirchen, Germany) 
Glutaraldehyde  25% Sigma-Aldrich GmbH  
(Taufkirchen, Germany) 
Glycerol For molecular biology Sigma-Aldrich GmbH  
(Taufkirchen, Germany) 
HCl 1 N VWR International GmbH  
(Ismaning, Germany) 
HSA Human serum albumin 
(lyophilized; ≥99.9%) 
Sigma-Aldrich GmbH  
(Taufkirchen, Germany) 
Mowiol™ 4-88  Calbiochem (La Jolla, CA, USA) 
NaCl p. a. VWR International GmbH  
(Ismaning, Germany) 
NaOH 1 N VWR International GmbH  
(Ismaning, Germany) 
PLGA poly(D,L-lactic-co-glycolic acid) 
polymer (ratio 50:50) 
BPI (Birmingham, AL, USA) 
Polyvinyl alcohol 87-89% hydrolyzed; Mw. 31,000-
50,000  
Aldrich (Milwaukee, WI, USA) 
Paraformaldehyde Solution (4%) Sigma-Aldrich GmbH  
(Taufkirchen, Germany) 
Water for injection  Wyeth Pharma (Muenster, Germany) 
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2.1.2 Fluorescent dyes and monoclonal antibodies 
Reagent Description Supplier 
Alexa™ Fluor 488 
Concanavalin A 
 Molecular Probes  
(Leiden, Netherlands) 
Alexa™ Fluor 596 
Concanavalin A 
 Molecular Probes (Eugene, OR,USA) 
Alexa™ Fluor 488 
succinimidyl ester 
Mixed isomers Invitrogen (Karlsruhe, Germany) 
CD11c antibody + FITC-conjugated secondary 
antibody 
BD Pharmingen (Mississauga, 
Canada)/(Heidelberg, Germany) 
CD86 antibody + FITC-conjugated secondary 
antibody 
BD Pharmingen (Mississauga, 
Canada) 
MHC II antibody + FITC-conjugated secondary 
antibody 
BD Pharmingen (Mississauga, 
Canada) 
Texas Red-X™ 
succinimidyl ester 
Mixed isomers Molecular Probes (Leiden, 
Netherlands) 
2.1.3 Applied ODNs 
Name Description Supplier 
ODN 1826 Mouse specific CpG ODN 
5’ TCCATGACGTTCCTGACGTT 3’* 
Operon Technologies Inc. 
(Alameda, USA). 
ODN 1911 Control ODN 
5’ TCCAGGACTTTCCTCAGGT 3’* 
Operon Technologies Inc. 
(Alameda, USA). 
ODN 2006 Prototype CpG-B ODN 
5’ TCGTCGTTTTGTCGTTTTGTCGTT 3’* 
Coley Pharmaceutical Group 
 (Wellesley, MA, USA) 
ODN 2216 Prototype CpG-A ODN  
5’ GggggacgatcgtcGGGGGg 3’* 
Coley Pharmaceutical Group 
 (Wellesley, MA, USA) 
ODN M362 Prototype CpG-C ODN  
5’ TCGTCGTCGTTCGAACGACGTTGAT 3’* 
Coley Pharmaceutical Group 
 (Wellesley, MA, USA) 
ODN M383 GC pendant to ODN M362  
5’ TGCTGCTGCTTGCAAGCAGCTTGAT 3’* 
Coley Pharmaceutical Group 
 (Wellesley, MA, USA) 
*capital letters: nucleotides with phosphorothioated backbones;  
 others: phosphodiester backbones  
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2.1.4 Cell culture reagents 
Reagent Description Supplier 
FCS Fetal calf serum GibcoBRL (Paisley, UK) 
Human 
AB-serum 
 BioWhittaker Inc. 
(Wakersville, MD, USA) 
HSA  Human serum albumin;  ≥97% Pharmacia & Upjohn 
(Erlangen, Germany) 
L-glutamine  PAA (Linz, Ausrtria) 
Penicilline  PAA (Linz, Ausrtria) 
RPMI-1640  medium Biochrom AG  
(Berlin, Germany) 
Streptomycine  PAA (Linz, Austria) 
 
2.2 Preparation of cationized gelatin nanoparticles 
Cationized gelatin nanoparticles were prepared according to the procedure 
described in Chapter II. – 2.2. Cholamine was chosen as cationization agent for the 
nanoparticle surface. In order to prevent contaminations, which might influence 
the immune response, all preparation steps were performed under aseptic 
conditions.  
2.3 Preparation of fluorescent gelatin nanoparticles 
To enable the detection of the gelatin nanoparticles in CLSM and FACS 
experiments, they were labeled with fluorescent dyes. The labeling was conducted 
during the particle preparation process.  
2.3.1 Covalent linkage of aminoreactive fluorescent dyes 
For fluorescence labeling, 2 mg of the aminoreactive dye, e.g. Texas Red-X™ 
succinimidylester, were added to the redissolved gelatin solution after the first 
desolvation step. This mixture was constantly stirred over 2 hours. After this, we 
proceeded with the standard preparation method.  
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2.3.2 Incorporation of dextran-linked fluorescent dyes 
2 mg TMR dextran (Mw. 40,000) was added to the redissolved gelatin solution after 
the first desolvation step and encapsulated into the nanoparticle matrix during the 
second desolvation step.  
2.4 Preparation of fluorescent HSA nanoparticles 
HSA nanoparticles were prepared using a previously described desolvation 
technique (Marty et al. 1978; Weber et al. 2000). 200 mg HSA was dissolved in 
2.0 mL highly purified water. To incorporate a fluorescent dye, 1 mg TMR dextran 
was added to this solution. Desolvation of this protein solution was initiated by 
dropwise addition of 6.0 mL ethanol. 80 μL of 25% aqueous glutaraldehyde 
solution were added to stabilize the in-situ formed particles by crosslinking. After 
stirring over 24 h, the resulting nanoparticles were purified by 3-fold centrifugation 
and redispersion with injectable water. 
2.5 Preparation of fluorescent PLGA nanoparticles 
TMR dextran containing PLGA nanoparticles were kindly prepared by our 
cooperation partner Praveen Elamanchili (University of Alberta) with a double 
emulsion solvent evaporation technique as described earlier (Elamanchili et al. 
2004).  
2.6 Characterization of the nanoparticles 
The size of the prepared nanoparticles and CpG-A ODN 2216 was measured by 
dynamic light scattering using a Zetasizer 3000 HSA or a Nanosizer ZS (Malvern, 
Worcestershire, UK). The resulting mean size was calculated on the basis of 10 
individual subruns. Zeta potential (ζ potential) measurements were conducted in 
1 mM NaCl at pH 7.0 (Zetasizer 3000 HSA, Malvern, Worcestershire, UK) if not 
stated otherwise. 
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2.7 ODN loading of cationized gelatin nanoparticles 
600 µg nanoparticles were incubated with 30 µg of ODN in 400 µL of physiological 
PBS 7.4 for 30 min under gentle shaking at room temperature. In analogy to 
pDNA experiments (see Chapter II), the nanoparticle dispersion was centrifuged 
and the supernatant was analyzed UV-spectrophotometrically at 260 nm 
wavelength for unbound ODN.  
2.8 Experiments with murine myeloid dendritic cells (MDCs) 
2.8.1 Culture of MDCs 
MDCs were generated from murine bone marrow precursors following the method 
previously described (Lutz et al. 1999). Briefly, 2 × 106 bone marrow cells obtained 
from the femurs of C57BL/6 mice were plated in bacteriological grade petri dishes 
in 10 mL of RPMI-1640 medium containing 20 ng/mL of GM-CSF (complete 
media) and incubated at 37°C and 5% CO2. On day 3, the cells were supplemented 
with 10 mL of complete media and on day 6, half of the media was removed and 
replaced with fresh complete media. The purity of the semi-adherent and non-
adherent DC populations on day 7 was found to be greater than 80% (based on the 
expression of CD11c).  
2.8.2 FACS analysis of nanoparticle uptake by MDCs 
Seven days old DCs were incubated for 12 hours with CpG ODN-loaded 
formulations (ZWCaTMR) or unloaded nanoparticles. After 12 hours, the cells 
were harvested and washed thoroughly in cold staining buffer (PBS containing 10% 
FBS and 0.05% sodium azide) and transferred into FACS tubes. For phenotypic 
analysis of cells that have taken up the nanoparticles, surface staining was 
performed after 12 h of incubation with fluorescence-labeled nanoparticles using 
monoclonal antibodies specific for CD11c, CD86, and MHC-II molecules (along 
with their respective isotype controls) and appropriate FITC-conjugated secondary 
antibodies. The samples were then transferred into FACS tubes and analyzed using 
a FACsort. All events were collected by gating on the total live cell populations 
without further specific gating of particular subpopulations. A minimum of 10,000 
events was collected. 
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2.8.3 Visualization of nanoparticle uptake by MDCs via CLSM 
Day 7 DC primary cultures were transferred into Lab-Tek II eight well chamber 
slides (Nalge Nunc International, Rochester, USA) at 4 x 105 cells in 300 µL of 
medium. The cells were incubated with 8 µg of CpG ODN-loaded Texas Red-X-
labeled nanoparticles (ZWCaTEX; containing 400 ng of CpG ODN) in a final 
volume of 500 µL. Control wells were treated with the phagocytosis inhibitor 
Cytochalasin B (5 µg/mL) 30 min prior addition of nanoparticles and throughout 
the whole incubation. After incubation for 8 hours, the supernatant in the chamber 
slide cultures was carefully removed. The cells were washed thrice with PBS and 
stained with a CD11c specific primary antibody followed by a FITC-labeled 
secondary antibody. After the final washing step, cells were fixed with 4% 
paraformaldehyde. Chamber slides were finally prepared with a solution of 2.5% 
DABCO and PBS/glycerol (1:1) and visualized under a Zeiss 510 LSM NLO 
confocal laser scanning microscope (Carl Zeiss Microscope Systems, Jena, 
Germany). 
2.8.4 Quantification of cytokine secretion  
1 x 106 cells of 7 days old MDCs were transferred into 50 mm petri dishes in 5 mL 
of complete RPMI-1640. The MDCs were incubated with 200 µg of two differently 
sized cationized gelatin nanoparticle batches (ZWCa01 and ZWCa02) containing a 
payload of 10 µg (5% [w/w]) CpG ODN each. In addition, some MDC groups 
were incubated with 10 µg of soluble CpG ODN or nanoparticles that contained 
10 µg of non-stimulatory control ODN or 200 µg of unloaded cationized gelatin 
nanoparticles. After 24 hours, the supernatant of each group was collected and 
frozen for later cytokine analysis. Quantitative cytokine analysis for IL-6, IL-12p70, 
and TNF-α was performed using specific ELISA Ready-SET-Go kits (eBioscience 
Inc., San Diego, USA) according to the manufacturer’s instructions.  
2.8.5  Special conditions for kinetic experiments 
Different from the experiments we performed on our own, our cooperation 
partners Dr. Dr. Carole Bourquin and Philip von der Borch at LMU’s Division of 
Clinical Pharmacology purified CD11c+ MDCs from other cells by magnetic-
activated cell sorting (MACS) (Miltenyi Biotech, Bergisch Gladbach, Germany). All 
experiments were performed in 96-well plates (BD Biosciences, Heidelberg, 
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Germany) containing 5x104 MDCs in 200 µL RPMI-1640 medium. Standard CpG-
GNP concentration per well was 60 µg/mL. Thus, 600 ng CpG ODN loaded onto 
12 µg cationized gelatin nanoparticles were administered per 5x104 cells. CpG-
GNP uptake into MDCs was examined by flow cytometry (FACSCalibur, BD 
Biosciences). Data were analyzed using CellQuest software (BD Biosciences) 
Cytokine concentrations were determined by ELISA for IL-6 (BioSource, Solingen, 
Germany) and IL-12p70 (BD Biosciences) according to the manufacturer’s 
protocol. 
2.9 Experiments with primary human blood cells  
The present in vitro experiments testing CpG-GNPs on primary human PBMCs, 
PDCs, and B-cells, were performed in cooperation with Julia Battiany and PD Dr. 
Gunther Hartmann from the Division of Clinical Pharmacology at the Department 
of Internal Medicine at LMU Munich, Germany. 
2.9.1 Isolation of PBMCs 
Human PBMCs (monocytes and lymphocytes) were isolated from buffy coats 
(leucocytes obtained by centrifugation from the whole blood) provided by the 
blood bank of the University of Greifswald, Germany. Blood donors were between 
18 to 65 years old healthy women and men, which were tested to be negative for 
HIV, HBV, and HCV. Further exclusion criteria were manifest infections during 
the last 4 weeks, fever, symptomatic allergies, abnormal blood cell counts, increased 
liver enzymes or medication of any kind except vitamins and oral contraceptives. 
PBMCs were prepared from buffy coats by Ficoll-Hypaque density gradient 
centrifugation (Biochrom, Berlin, Germany). Thereby, PBMCs are separated from 
other formed elements in the blood. The sample is layered onto a Ficoll-sodium 
metrizoate gradient of specific density; following centrifugation, lymphocytes are 
collected from the plasma-Ficoll interface.  
2.9.2 Isolation of PDCs 
PDCs were positively isolated using an anti-BDCA-4 antibody according to the 
manufacturer’s protocol (BDCA-4 Cell-Isolation-Kit, Miltenyi Biotec, Bergisch-
Gladbach, Germany). The purity of the isolated PDC cultures was 96-98% as 
assessed by flow cytometric analysis.  
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2.9.3 Isolation of B cells 
Purified B cells were obtained by using the CD19 B cell isolation kit from Miltenyi 
Biotec. Briefly, B cells were labeled with anti-CD19 antibody coupled to colloidal 
paramagnetic microbeads and passed through a magnetic separation column (LS, 
Miltenyi Biotec). The purity of isolated B cells was >95% as assessed by flow 
cytometric analysis with no PDCs detectable (<0.005%).  
2.9.4 Cell cultures 
The various isolated cells were resuspended in RPMI 1640 medium  supplemented 
with 8% human AB-serum, 1.5 mM L-glutamine, 100 U/mL penicillin, and 
100 µg/mL streptomycin. Cells were cultured in 96-well round-bottom plates 
(200 µL medium/well; final concentration PBMCs: 2×106/mL, PDCs: 
2.5×105/mL, B cells: 2×105/mL). All compounds were purchased endotoxin-
tested. Viability of isolated cells was determined by trypan-blue exclusion.  
2.9.5 Cytokine quantification by ELISA 
IFN-α was quantified with the IFN-α module set from Bender MedSystems 
(Vienna, Austria; detection range 8-500 pg/mL). This ELISA detects most of the 
IFN-α isoforms, except IFN-α B and IFN-α F. IL-6 was measured by using the 
human IL-6 OptEIA ELISA (Bender Med Systems; detection range 4.7-
300 pg/mL). 
2.9.6 CLSM experiments 
Uptake experiments into PDCs were performed with CpG ODNs that were 
previously labeled (3’terminal) with fluoresceine (Coley Pharmaceutical Group). 
5x104 isolated PDCs in 200 µL of medium were transferred into Lab-Tek II eight 
well chamber slides (Nalge Nunc International). The medium additionally 
contained 2 ng IL-3. The cells were incubated with 12 µg of fluorescence-labeled 
(3’terminal) CpG-A ODN 2006-loaded cationized gelatin nanoparticles (containing 
600 ng of CpG ODN). After incubation for 8 hours, the supernatant in the 
chamber slide cultures was carefully removed. The cells were washed thrice with 
PBS and stained with 100 µL of a 0.0005% Alexa Fluor™ 594 Concanavalin A 
solution in PBS for 1 min (unspecific cell membrane stainer). After the final 
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washing step, cells were fixed with 4% paraformaldehyde. Chamber slides were 
finally prepared with a solution of 2.5% DABCO and PBS/glycerol (1:1) and 
visualized under a Zeiss 510 LSM NLO confocal laser scanning microscope (Carl 
Zeiss Microscope systems, Jena, Germany). 
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3. RESULTS AND DISCUSSION 
3.1 Comparative uptake study of various biodegradable colloidal 
carrier systems into murine myeloid dendritic cells (MDCs) 
Our cooperation partners have already shown in the past that nanoparticles based 
on poly(D,L-lactic-co-glycolic acid) (PLGA) are potent vehicles for various drugs, 
such as peptides and plasmid DNA to generate immune response in vivo (Diwan et 
al. 2002). Besides PLGA particles, further biodegradable and physiologically very 
well tolerated colloidal carriers exist, such as nanoparticles based on gelatin and 
human serum albumin (HSA). Both of them are discussed as interesting alternative 
delivery systems due to their protein structure, which offers a multitude of selective 
linking opportunities. Hence, we compared in this initial study the potential of 
these 3 different nanoparticle types as drug vehicles into MDCs. 
3.1.1 Nanoparticle characterization via DLS  
All prepared particles had sizes within the colloidal range. Concerning particle 
homogeneity, DLS suggested unimodal size distributions for all batches as 
displayed by low polydispersity indices (Table 3). 
Table 3: DLS data of the applied nanoparticle batches  
particle type mean size (nm) polydisp. index 
HSA 277.9 0.0756 
PLGA 387.6 0.1083 
Gelatin 216.2 0.0782 
3.1.2 FACS analysis of the cellular uptake 
The purity of the MDCs being cultured according to the previously described 
method was assessed via FACS analysis of CD11c positive cells to be 75%. One 
million of 7 days old MDCs were incubated with 200 µg of different fluorescence-
labeled nanoparticulate formulations each. After the incubation period of 24 hours, 
all nanoparticulate formulations were basically taken up by MDCs. However, 
distinct differences could be detected. Whereas 68% of the cells incubated with 
gelatin nanoparticles and 52% of those incubated with HSA nanoparticles were 
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positive for nanoparticles, only 41% were positive for PLGA nanoparticles (Fig. 3). 
Due to the higher averaging fluorescence detected within the cells that were 
incubated with gelatin or HSA nanoparticles, a higher number of those 
nanoparticles was obviously taken up. Moreover, analyzing the FACS dot-plots 
(data not shown), the highest shift towards MDCs with increased size and 
granularity compared to untreated MDCs could be seen with gelatin nanoparticles. 
Indeed, the prepared PLGA nanoparticles were larger in size, but this issue should 
not have such a crucial impact on the cellular uptake, since we haven’t seen those 
differences in preliminary studies where we used differently sized gelatin 
nanoparticles (data not shown). 
 
A B
C D
Fig. 3: Uptake of various nanoparticulate formulations into MDCs. FACS histogram 
plots (FL2-height) of untreated MDCs (A), MDCs incubated with gelatin nanoparticles 
(B), MDCs incubated with PLGA nanoparticles (C), MDCs incubated with HSA
nanoparticles (D). 
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3.1.3 Visualization of the cellular uptake by CLSM 
FACS data indicated that all of the tested nanoparticles are taken up by MDCs. But 
FACS is unable to differentiate between surface adsorbed and internalized 
nanoparticles. So, CLSM studies were employed to pin point the localization of 
these nanoparticles. Surprisingly, only gelatin and PLGA nanoparticles could be 
localized within the cells. The majority of HSA nanoparticles in contrast, was 
adsorbed onto the cell membrane (Fig. 4).  
 
Fig. 4: CLSM pictures of MDCs incubated with various formulations: gelatin 
nanoparticles (A); HSA nanoparticles (B); PLGA nanoparticles (C). 
3.1.4 Discussion and Summary 
Summarizing the data generated in this study, we found significant differences 
between three types of biodegradable nanoparticles in terms of delivery into 
MDCs. In fact, only PLGA and gelatin nanoparticles were effectively internalized 
into MDCs, whereas HSA nanoparticles remained mainly sticking to the cell 
membrane. Since e.g. antigen delivery with the objective of subsequent 
presentation requires the uptake into the MDCs, HSA nanoparticles appear 
relatively unsuitable for this purpose. Moreover most of the other potential 
applications with DCs as target, such as the delivery of various PAMPS to their 
target TLRs require intracellular uptake. Thus, only a few potential applications 
remain where it might be advantageous to achieve only cell-membrane delivery. 
One example might be the adjuvant monophosphoryl lipid A (MPLA) that has its 
target receptor, TLR4, located on the cell membrane of APCs. 
Quantitative FACS analysis revealed that gelatin nanoparticles were most efficiently 
taken up by the MDCs. Hence, gelatin nanoparticles seem well armed for 
competing PLGA nanoparticles as potential delivery system into DCs. 
CA B 
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3.2 Delivery of CpG ODN-loaded cationized gelatin 
nanoparticles (CpG-GNPs) into murine MDCs 
Based on the promising data with cholamine-modified cationized gelatin 
nanoparticles during gene therapeutic experiments (see Chapter II) we decided to 
evaluate the applicability of this nucleotide delivery system with immunogenic short 
single-stranded CpG oligonucleotides. In 3.1, uptake data of gelatin nanoparticles 
into MDCs had been shown.  
3.2.1 Characterization of the nanoparticles 
Most of the nanoparticles used in our experiments ranged from 230 to 260 nm 
(Table 4). We chose smaller, 133.8 nm sized nanoparticles (batch ZWCa01) as an 
additional sample to investigate a possible impact of the particle size. Dynamic light 
scattering (DLS) characterized all nanoparticle batches as very homogeneous. The 
respective size distributions were very narrow as displayed by polydispersity indices 
below 0.1.  
 Table 4: Sizing data obtained by DLS of unloaded vs. CpG ODN-loaded gelatin 
nanoparticles batches (5% [w/w] payload).  
 unloaded loaded 
 Mean particle size (nm) PI* Mean particle size (nm) PI* 
ZWCa01 133.8 0.0763 135.3 0.0891 
ZWCa02 244.3 0.0625 245.0 0.0759 
ZWCaTEX 232.7 0.0342 233.2 0.0411 
ZWCaTMR 255.4 0.0881 259.2 0.0911 
*PI = polydispersity index 
Cationization of the nanoparticles was monitored by measuring the ζ potential of 
the formulations. The linking of cholamine introduces a pH independent cationic 
net charge onto the nanoparticles due to the quaternary amino group. 
Consequently, the ζ potentials of all batches were positive independent of the 
persisting pH conditions. In contrast, plain gelatin nanoparticles are negatively 
charged at neutral pH due to their isoelectric point at pH 5.7 (see Chapter II - 3.1).  
After CpG ODN loading of the nanoparticles in PBS 7.4, no significant changes, 
neither in mean size nor in size distribution, were detectable (Table 4).  
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To find the optimal CpG ODN payload of the nanoparticles we tried to load 
increasing amounts of ODN onto the nanoparticles. After an incubation of 30 min 
the formulations were analyzed via UV spectroscopy for complete ODN loading 
(see 2.7). Furthermore, we visually monitored aggregation tendencies and measured 
the respective ζ potentials of the formulations. Results indicated that up to 100 µg 
CpG ODN 1826 could be completely loaded onto 600 µg (16.7% [w/w]) 
nanoparticles in 400 µL PBS 7.4. However, these nanoparticles were not stable in 
physiological PBS and tended to aggregate, most probably due to their neutral net 
charge (Table 5) that facilitates aggregation since inter-particulate electrostatic 
repulsion forces are absent (Müller 1996). This aggregation tendency could be 
circumvented by reducing the amount of payload to 60 µg per 600 µg nanoparticles 
(10% [w/w]). In our gene therapeutic experiments (see Chapter II) we have 
demonstrated that the highest transfection efficiency can be achieved with 
nanoparticle formulations bearing a final ζ potential of ~ +3 mV in PBS 7.4. Based 
on this knowledge we chose 30 µg CpG ODN per 600 µg nanoparticles (5% 
[w/w]) as payload of choice for all later in vitro experiments with murine MDCs, 
since the respective averaging ζ potentials of the formulations was around the 
favored value, e.g. +3.90±0.87 mV for ZWCa02 (Table 5). 
Table 5: ζ potential values and visible aggregation tendencies of cationized gelatin 
nanoparticles (batch ZWCa02) loaded with various amounts of CpG ODN 1826 after 
30 min of incubation; measurements were performed in PBS 7.4; respective 
conductivity values are put in parentheses 
Payload (w/w) 
ζ potential 
(Conductivity) Aggregation 
unloaded 
+7.39 ± 0.35 mV 
(17,03 mS/cm) 
no 
5.0% 
+3.90 ± 0.87 mV 
(16.34 mS/cm) 
no 
10.0% 
+1.33 ± 0.25 mV 
(16.08 mS/cm) 
no 
16.7% 
-0.63 ± 0.17 mV 
(17.33 mS/cm) 
yes 
 
Comparing the amounts of loaded CpG ODN 1826 with the maximum payloads 
of pDNA, the achieved maximum of stable payload of CpG ODNs is one order of 
magnitude higher (see Chapter II). Apparently 10-30mer single-stranded ODNs 
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can be better adsorbed onto the nanoparticle surface than comparatively huge 
pDNA consisting of some thousand base-pairs. The huge double-stranded ring 
structure of pDNA complicates the complexation on only one single nanoparticle 
and facilitates possible interactions with other nanoparticles resulting in aggregates. 
Performing experiments with various other single- and double-stranded RNA and 
DNA oligonucleotides has shown that it is difficult to declare universally valid 
principles for the loading of nucleotides onto cationized gelatin nanoparticles 
(Zillies & Coester 2004; unpublished data). Summarizing all our nucleotide loading 
experiments, we can state as rules of thumb that short single-stranded DNA is 
easier to be adsorbed on cationized gelatin nanoparticles without causing aggregates 
than large double-stranded DNA. In addition DNA seems to be more convenient 
than RNA.  
3.2.2 FACS analysis of CpG-GNP uptake by MDCs 
As we had shown in 3.1, plain gelatin nanoparticles are efficiently taken up by 
MDCs. So, our first focus was to compare the uptake of CpG ODN-loaded 
cationized gelatin nanoparticles (ZWCaTMR) by MDCs with that of plain gelatin 
nanoparticles. MDCs incubated with nanoparticulate formulations displayed an 
increased forward and side scatter, indicating an increase in size and granularity of 
the cells as a result of the particle uptake (Fig. 5).  
 
Fig. 5: FACS dotplots of untreated MDCs (A), MDCs incubated with plain non-
cationized gelatin nanoparticles (B) and MDCs incubated with CpG-GNPs (C). 
Furthermore, these results showed that MDCs had an immature phenotype at the 
time of nanoparticle pulsing and thus efficiently internalized the nanoparticle 
formulations. To determine the number of cells that had taken up the 
nanoparticles, the rhodamine fluorescence signal (FL-2) emitted from the MDCs 
was analyzed. As depicted in Fig. 6, 33% of the cells were TMR-dextran positive 
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when incubated with plain non-cationized gelatin nanoparticles whereas 68% were 
positive when the cells were incubated with CpG-GNPs.  
 
Fig. 6: FACS histogram plots (FL-2 Height) of untreated MDCs (A), MDCs incubated 
with plain non-cationized gelatin nanoparticles (B) and MDCs incubated with CpG-
GNPs (C). 
3.2.3 Visualization of CpG-GNP uptake by CLSM  
Although the current FACS data indicated that CpG-GNPs are efficiently taken up 
by MDCs, we performed CLSM experiments to exactly localize these formulations. 
This time, MDCs in the chamber slides were identified by CD11c antibody-
staining. Scanning various planar sections, CpG ODN-loaded and Texas Red-X-
labeled nanoparticles (ZWCaTEX) could be observed as distinct dots within the 
cells (Fig. 7A). Furthermore, inhibition of nanoparticle uptake by MDCs following 
treatment with phagocytosis inhibitor Cytochalasin B revealed that phagocytosis 
was the main mechanism involved in the nanoparticle uptake process (Fig. 7B).  
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Fig. 7: CLSM images of MDCs incubated with fluorescent CpG-GNPs (A) and MDCs 
treated with Cytochalasin B before and during incubation with CpG-GNPs (B) 
3.2.4 Phenotypic maturation of MDCs following treatment with CpG-GNPs 
Subsequent to the recognition of a danger signal, immature MDCs upregulate their 
surface expression of MHC and co-stimulatory molecules and transform into 
mature MDCs. In the current study, the efficiency of CpG-GNPs to activate 
MDCs was investigated based on the augmentation in expression of MHC class II 
and CD86 molecules. As shown in Fig. 8, MDCs treated with CpG-GNPs 
upregulated their expression of MHC-II and CD86 molecules. These results thus 
indicated that delivery of CpG ODN loaded onto cationized gelatin nanoparticles 
could efficiently activate MDCs and cause their maturation.  
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Fig. 8: FACS histogram plots (FL-1 Height); A: MHC II antibody staining; untreated 
MDCs (grey) vs. CpG-GNP treated MDCs (black); B: CD 86 antibody staining; 
untreated MDCs (grey) vs. CpG-GNP treated MDCs (black) 
3.2.5 Cytokine secretion following treatment of MDCs with CpG-GNPs  
The transformation of phenotypically immature MDCs to mature following 
treatment with CpG-GNPs prompted the assessment of the functionality of these 
MDCs with regard to their cytokine secretion profile. To qualitatively determine 
the type of cytokines and chemokines being secreted, the supernatants of the MDC 
cultures treated with the different CpG ODN formulations were initially screened 
with cytokine microarray membranes (TranSignalTM Mouse Cytokine Antibody 
Arrays, Panomics, Redwood City, USA) (Fig. 9).  
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Fig. 9: Qualitative microarray membrane analysis of the secreted cytokines and 
chemokines when treated with plain cationized GNP (A), soluble CpG ODN (B), and 
CpG-GNPs (C). 
No detectable cytokine secretion could be observed following treatment with plain 
nanoparticles (Fig. 9A) whereas soluble CpG ODN treatment induced the 
secretion of IL-6, IL-12p40/70, TNF-α, and chemokines like RANTES (regulated 
upon activation, normal T cell expressed and secreted) and macrophage 
inflammatory protein 1α (MIP-1α) (Fig. 9B). MDCs treated with CpG-GNPs 
qualitatively had the same cytokine and chemokine secretion profile as soluble CpG 
ODN. Overall, the cytokine and chemokine secretion patterns correlated with 
previously described induction patterns polarizing the stimulation towards TH1-
type immune response (Jakob et al. 1999; Krieg 2002) (Fig. 9C). TH2-polarizing 
cytokines such as IL-4, IL-5, or IL-10 could not be detected in any of the cell 
supernatants. 
Based on these data we decided to perform quantitative ELISAs of IL-12, IL-6 and 
TNF-α to receive detailed information on the particular cytokine amounts secreted 
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after 24 hours. In all of these experiments, no measurable amounts of the cytokines 
could be detected in the supernatants of the untreated control cells and cells treated 
with plain gelatin nanoparticles or gelatin nanoparticles loaded with non-stimulating 
ODN (Fig. 10A-C).  
IL-12 is the key cytokine directing immune response towards TH1. Two subtypes of 
IL-12 do exist, IL-12p40 and its bioreactive heterodimer IL-12p70. To get more 
precise information about the actual TH1 polarization potential, it was decided to 
quantify only the rare bioreactive IL-12p70 (Fig. 10A). 
Collecting cell supernatants of the samples after 24 hours, 266 ± 53 pg/mL IL-
12p70 was secreted by MDCs following stimulation with 10 µg (2 µg/mL) soluble 
CpG ODN whereas the two batches of CpG-GNPs were able to induce the 
secretion of averaging 595 ± 107 pg/mL (ZWCa01) and 690 ± 56 pg/mL 
(ZWCa02). So we achieved 2-3 fold cytokine induction by loading CpG ODN onto 
244.8 nm sized gelatin nanoparticles (ZWCa02).TNF-α which is a key inflammatory 
cytokine that induces MDC maturation (Arrighi et al. 2001; Iijima et al. 2003) was 
minimally secreted following soluble CpG ODN treatment whereas CpG ODN 
loading onto nanoparticles increased its secretion 7-9 times (Fig. 10B). Again, the 
larger sized nanoparticles (ZWCa02) resulted with a slightly higher signal. Lastly, no 
significant difference in the secretion of IL-6 by MDCs was observed following 
delivery of CpG ODN in nanoparticulate or soluble form 
 (Fig. 10C). 
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Fig. 10: Levels of IL-12p70 (A), TNF-α (B), and IL-6 (C) per mL cell supernatant after 
24 hours incubation: untreated MDCs (untr. DCs); unloaded gelatin nanoparticles 
ZWCa02 (ZWCa02); soluble CpG ODN (soluble CpG ODN); non-stimulating control 
ODN-loaded gelatin nanoparticles ZWCa02 (ZWCa02 + CpG); CpG ODN-loaded 
gelatin nanoparticles ZWCa01 (ZWCa01 + CpG); CpG ODN-loaded gelatin 
nanoparticles ZWCa02 (ZWCa02 + CpG) 
A 
B 
C 
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3.2.6  Assessment of CpG-GNP uptake and immune-stimulation kinetics 
In cooperation with our partners Dr. Dr. Carole Bourquin and Philip von der 
Borch (Department of Internal Medicine, Division of Clinical Pharmacology, LMU 
Munich) we wanted to take a closer look on the respective kinetics of CpG-GNP 
uptake into MDCs and the related activation of the immune system.  
Conducting a critical retrospective of the data we generated so far (see 3.2.1-3.2.5), 
a certain weakness was the purity of the MDC cell population. Following the 
described procedure (Lutz et al. 1999) generating MDCs from murine bone marrow 
precursors, implicates a maximum purity of CD11c+ MDCs of ~ 80%. Thus, data 
derived from the whole cell population always contains a certain imprecision. 
Together with our cooperation partners we were able to isolate highly purified 
MDC populations via magnetic -activated cell sorting (MACS). The so derived 
averaging purity of MDCs was between 96-98%.  
The first issue we investigated with Alexa Fluor™488-labeled CpG-GNPs were the 
cellular uptake kinetics of the formulations. The chosen fluorescence dye is excited 
at comparable wavelengths as fluorescein-isothiocyanate (FITC) but with higher 
stability against bleaching.  
In previous experiments, we had already shown, that plain gelatin nanoparticles 
(see 3.1) and CpG-GNPs (see 3.2.2) are preferentially taken up by MDCs after 24 
h. Now, we wanted to determine the velocity and saturation tendencies of the 
internalization process.  
Incubation of 5x104 MDCs with 12 µg CpG-GNPs (containing 600 ng CpG ODN) 
in 200µL medium/well (→ administered CpG ODN concentration: 3 µg/mL) led 
to an immediate uptake as depicted in Fig. 11.  
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 Fig 11: FACS analysis of Alexa Fluor™488-labeled CpG-GNP internalization into 
MDCs (5x104 cells) at various points of time; administered amount of CpG-GNPs per 
well: 12 µg (containing 600 ng CpG ODN). FL-1: green FITC-fluorescence (x-axis); 
FL-2: red PE-fluorescence (y-axis); Lower left quadrant: cells gated as MDCs without 
nanoparticles; lower right quadrant: cells gated as nanoparticle containing MDCs; 
upper quadrants: cells that were not considered for calculation. 
To give more detailed information on the impact of MDC autofluorescence, it was 
decided to present the data in a two-dimensional quadrant plot, with additional 
acquired red PE (Phycoerithrin) FL-2 signal instead of an Fl-1 histogram plot view 
only. Already after 1 min, significant uptake or at least adherence of Alexa 
Fluor™488-labeled CpG-GNPs could be detected by FACS (Fig. 11A). A state of 
certain saturation was achieved after 20 min (Fig. 11D). From this point, no further 
cells could be detected positive for CpG-GNPs (data not shown). The respective 
fluorescence intensities, indicating the uptake of more nanoparticles in cells that 
have already internalized CpG-GNPs, were also not further increased. The 
maximum amount of MDCs that were CpG-GNP positive after the administration 
of 12 µg CpG-GNPs per 5 x 104 MDCs, remained constant at ~63% from 20 
minutes until the last reading point of the study at 4 h. 
In the next experiments the impact of various administered CpG-GNP 
concentrations on the cellular uptake was screened. It was our aim to determine the 
maximum in vitro administrable amount of CpG-GNPs without causing distinct 
FL-1: PE -signal 
FL-2: FITC-signal 
A: no particles  
B: 1min 
C: 4 min 
D: 8 min 
E: 20 min 
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cytotoxicity. Starting with a very low concentration of 3 µg CpG-GNPs per 5x104 
cells in 200 µL medium (Fig. 12B), the administered amount was elevated up to 
100 µg CpG-GNPs (Fig. 12E).  
 
Fig. 12: FACS analysis of Alexa Fluor™488-labeled CpG-GNP internalization into 
MDCs (5x104 cells) at various CpG-GNP amounts administered per well; incubation 
time: 4 h; FL-1: green FITC-fluorescence (x-axis); FL-2: red PE-fluorescence (y-axis); 
lower left quadrant: cells gated as MDCs without nanoparticles; lower right quadrant: 
cells gated as nanoparticle containing MDCs; upper quadrants: cells that were not 
considered for calculation. 
Even at this high amount of CpG-GNPs, no significant cytotoxicity was visually 
detected under the microscope by trypan-blue exclusion. However in contrast to 
lower administered CpG-GNP amounts, cells treated with 100 µg CpG-GNPs very 
strongly aggregated and formed cell clusters (Fig. 13), which are undesirable in vivo 
since embolisms might be induced. 
FL-1: PE-signal 
FL-2: FITC-signal 
A: no particles  
B: 3 µg CpG-GNP 
C: 10 µg CpG-GNP  
D: 30 µg CpG-GNP 
E: 100 µg CpG-GNP 
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Fig. 13: Micrographs of MDCs (5x104 cells) being incubated with various amounts of 
CpG-GNP after 4 hours of incubation; A: 12 µg CpG-GNPs (containing 600 ng CpG 
ODN) in 200µL medium/well; B: 100 µg CpG-GNPs (containing 5 µg CpG ODN) in 
200µL medium/well 
Finally, the kinetics of the immune system’s activation were investigated. Therefore 
we analyzed the respective secreted amounts of IL-12p70 (Fig. 14A) and IL-6 
(Fig. 14B) at distinct time-points after the addition of CpG-GNPs. After a certain 
lag time, the secreted amounts of both cytokines increased after 2.5 hours past 
administration. IL-12 reached a maximum plateau phase after 8 h and was not 
further elevated until 40 h after administration. For IL-6 this plateau was reached 
after 12 h.  
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Fig. 14: Cytokine secretion kinetics of CpG-GNPs over 40 h after administration on 
5x104 MDCs; administered amount: 12 µg CpG-GNPs (containing 600 ng CpG ODN) 
in 200µL medium /well (n=3); A: Induction of IL-12p70; B: Induction of IL-6 
Comparing the cytokine kinetics data of CpG-GNPs with those from soluble CpG 
ODN (unpublished data Philip von der Borch), no delay was visible, neither 
concerning the initial point of cytokine secretion nor the achievement of a plateau-
phase. Thus only a higher amount of cytokines was secreted within the same period 
of time. 
Since no delayed signal recognition occurred in case of CpG-GNPs in comparison 
to soluble CpG ODN, neither release of CpG from the particle surface nor particle 
degradation seem necessary to allow interaction between CpG ODN and its 
endosomal receptor TLR9. Apparently, CpG ODNs fixed onto the surface of 
nanoparticles are able to directly activate TLR9, but in an amplified manner. One 
explanation for this might be an enhanced phagocytotic uptake of CpG ODN 
when loaded onto the nanoparticle surface. Another could be that a highly 
concentrated presentation of CpG motifs on nanoparticles enforces these increased 
immune reactions. 
3.2.7 Discussion and summary 
The use of delivery systems for CpG ODNs to enhance the ODNs activity is 
currently one of the immunological topics that are discussed e.g. to be utilized as 
adjuvant formulation or as all-in-one vaccine formulation with a co-delivered 
antigen. In this context, our partners at University of Alberta and others have 
shown that the immunogenicity can be increased by its delivery in biodegradable 
B 
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micro- or nanoparticles (Singh et al. 2001; Diwan et al. 2002; Diwan et al. 2004). In 
this study we used for the first time cationized gelatin nanoparticles as carrier for 
CpG ODNs. Gelatin offers several advantages as a biomaterial for preparation of 
colloidal drug carriers. In the current study, we set out to demonstrate that CpG 
ODN could be efficiently loaded onto cationized gelatin nanoparticles and that 
these formulations could effectively be internalized by MDCs. A loading ratio 
between 10:1 and 20:1 (w/w) of nanoparticles to CpG ODN was found to be 
favorable since the formulations remained stable within physiological media and 
had a slightly positive net charge. These positively charged nanoparticles have been 
reported to be better phagocytosed by MDCs and macrophages than neutral or 
negatively charged particulate formulations (Roser & Kissel 1993; Thiele et al. 2001; 
Foged et al. 2005). In agreement with this, MDCs internalized the positively 
charged CpG ODN nanoparticles more efficiently than the non-cationized gelatin 
nanoparticles, which have a partially negative ζ potential (see Chapter II - 3.1). 
CLSM studies showed that the uptake of nanoparticles was inhibited by treatment 
of MDC cultures with Cytochalasin B, an inhibitor of intracellular actin-myosin 
polymerization, an essential step in phagocytosis (Davis et al. 1971). Thus, the 
observed uptake of the cationized gelatin particles by MDCs could be assumed to 
be driven by active phagocytosis, and neither due to mere adherence of the 
particles to cell surfaces, nor due to pinocytosis. Upregulation of MHC and co-
stimulatory molecules on the MDC surface improves the ability of MDCs to 
activate and prime T cells. The results of our study indicated that CpG ODN 
loaded onto the gelatin nanoparticles superiorly upregulates MHC-II and CD86 
molecules. These data also indicated that MDCs were in their immature state at the 
time of phagocytosis and CpG that ODN loaded onto the cationized nanoparticles 
efficiently induced MDC maturation. Similar to soluble CpG ODN which 
promotes the secretion of TH1 polarizing cytokines and cytotoxic immune response 
by MDCs (Chu et al. 1997; Krieg et al. 2000), CpG-GNPs induced the secretion of 
IL-12p70, IL-6, and TNF-α. However, the extent of secretion of IL-12p70 and 
TNF-α was amplified in comparison to soluble CpG ODN treatment. No 
significant difference in the extent of cytokine secretion was observed for the 
secretion of IL-6. Since IL-6 is discussed to have adverse effects on the TH1 
differentiation (Diehl & Rincon 2002), this circumstance would favor a bias 
towards TH1 immune response even more. Regarding particle size, overall CpG 
ODN loaded on the batch with larger particle size, ZWCa02 (245.0 nm), induced 
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slightly higher immune stimulation than loaded on ZWCa01, having a mean size of 
135.3 nm. This finding is in agreement with Foged et al. (Foged et al. 2005), who 
tested the phagocytosis activity of various polystyrene particles in a diameter range 
between 0.04-15 µm and found that particle diameters around 0.5 µm and slightly 
below were optimal for uptake into MDCs. Consequently, our system might be 
advantageous compared to already established microparticulate carrier systems. 
The absence of cytokine secretion following the treatment of MDC cultures with 
plain nanoparticles, or control nonstimulatory ODN, indicated a basic 
biocompatibility of the nanoparticles and the preparation process, as any endotoxin 
contamination would have triggered cytokine secretion by MDCs. 
Investigating the reaction kinetics of CpG-GNP uptake into MDCs, it was noticed 
that the formulations were quickly internalized within 20 min. The amount of the 
internalized CpG-GNPs can be influenced by the administered concentration. 
Congruent to the cell toxicological data we generated for cationized gelatin 
nanoparticles in gene therapeutic experiments, even huge amounts of CpG-GNPs 
(100 µg per 2 x 104 MDCs) did not cause significant cell death. However, cell 
clustering occurred at this high amount of administered CpG-GNPs. So it seems to 
be advisable to reduce the amount of CpG-GNPs below this value.  
Cytokine secretion can be detected within 3-12 h after CpG-GNP administration. 
In comparison to soluble CpG ODN, no retarded or sustained cell activation could 
be observed. Thus, CpG ODNs seem to be still attached onto the nanoparticles 
when interacting with TLR9. This apparently induces enhanced but not prolonged 
activation of the immune system. 
Interestingly, polymers known for their good properties in non-viral gene delivery 
due to quick endosomal release (e.g. PEI) lead to less activation when administered 
as polyplex with CpG ODNs than soluble CpG ODN alone (Ilardia et al. 2006; 
unpublished data Dr. Dr. Bourquin). But since TLR9 is located within the 
endosome, quick endosomal release is undesirable in this case. In pDNA 
transfection experiments with cationized gelatin nanoparticles, the gene expression 
occurred with certain delay (see Chapter II). Due to the present CpG ODN data it 
appears obvious that this delay was caused by sustained endosomal release in 
comparison to PEI polyplexes. Summarizing, it seems that these properties of 
cholamine-modified cationized gelatin nanoparticles that are rather unfavorable for 
gene transfection, are ideal for CpG ODN delivery.  
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CpG ODNs are reported to be less toxic than other investigated adjuvants 
(Weeratna et al. 2000). However, other studies have reported dose-dependent 
systemic adverse effects for CpG ODN (Klinman et al. 1996; Lipford et al. 2000; 
Heikenwalder et al. 2004). Significant dose reduction would be expected to 
minimize the risk of side effects of this new class of immune adjuvants. 
Nanoparticulate CpG ODN delivery decreases the effective dose needed to 
generate or increase an immune response in the present in vitro data.  
The present data is a promising first step towards the application of cationized 
gelatin nanoparticles in the field of immuno therapeutics. Even though, correlation 
of the murine in vitro data with humans or non human primates seems, due to the 
previously mentioned different cellular distribution of TLR9, doubtful. So, further 
experiments with primary human B cells and plasmacytoid dendritic cells (PDCs) 
were indispensable in addition to the present data. 
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3.3 Transfer from murine setup to primary human cells 
DCs are the sentinels of the immune system (Banchereau & Steinman 1998). 
Within the human body two different phenotypic subtypes of DCs are known in 
the peripheral blood: myeloid CD11c+ DCs (MDCs) and plasmacytoid CD11c- 
DCs (PDCs). Both of them are containing TLRs. Performing immunological 
experiments, it is cheap in early stages to gain primary cell cultures for first in vitro 
experiments from murine origin. When transferring in vitro experiments to in vivo, 
the species that are chosen for first experiments are mice. Surveying CpG, there is 
unfortunately a significant discrepancy between humans and rodents concerning 
the TLR9 expression pattern. TLR9 in humans is in contrast to mice only 
expressed in PDCs instead of MDCs being utilized in previous experiments (see 
3.2). To get an exact correlation of the data it was necessary to substantiate this 
murine model data with in vitro data from human PDCs.  
As already mentioned in the introduction, three classes of CpG ODNs have been 
assessed by scientists. CpG-A ODNs activate the secretion of large amounts of 
IFN-α in PDCs. CpG-B ODNs are known for the activation of B cells, but are 
rather poor in inducing the secretion of IFN-α. Finally, CpG-C ODNs can activate 
both with intermediate strength. Thus, we decided to scrutinize how the activation 
pattern of the immune response is influenced when the prototypes of each class 
CpG ODN 2216 (CpG-A), CpG ODN 2006 (CpG-B), and CpG ODN M362 
(CpG C) are loaded onto cationized gelatin nanoparticles. 
3.3.1  Activation of CpG ODN sensitive human cell-lines after CpG-GNP 
treatment 
Analogous to the in vitro experiments with murine MDCs, we compared again two 
differently sized nanoparticle batches: GNP-H1 (mean size: 160 nm; PI: 0.099) and 
GNP-H2 (mean size: 293 nm; PI: 0.039). The nanoparticles were loaded with CpG 
ODN at a ratio of 50 µg ODN per mg nanoparticles, i.e. 5% (w/w).  
In a first experiment, we refrained from further cell purification and measured the 
secretion of IFN-α of the whole population of primary human peripheral blood 
mononuclear cells (PBMCs). In analogy to our experiments with murine MDCs, 
the total amount of CpG ODN administered per well either in soluble form or 
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bound onto nanoparticles was 600 ng CpG-ODN in 200 µL media (3µg/mL). 
Each well contained 4x105 PBMCs (Fig. 15). 
 
Fig. 15: Induction of IFN- α in human PBMCs (4x105 PBMCs/well) after 48h; CpG 
ODNs were administered in soluble form (white columns) or loaded onto cationized 
gelatin nanoparticles: CpG-GNP-H1 (black columns¸160 nm) and CpG-GNP-H2 
(grey columns; 293 nm). The CpG ODNs tested were CpG-B (ODN 2006), CpG-C 
(ODN M362), CpG-A (ODN 2216) and the corresponding GpC control ODN (ODN 
383) to CpG-C. Results are based on the mean values ± s.d. of 8 individual 
experiments each. 
Within PBMCs, adsorption of the CpG ODNs 2006 (CpG-B) and M362 (CpG-C) 
onto nanoparticles led to enhanced stimulation of IFN-α. Soluble CpG-B and 
CpG-C only led to weak or almost no secretion. More precisely, the IFN-α 
inducing effect of CpG-C was doubled by particulate administration and in soluble 
form non-inducing CpG-B was able to induce IFN-α secretion when attached onto 
nanoparticles. The detected IFN-α amounts were remarkable and reached 
depending on the applied nanoparticle batch almost the values of soluble CpG-A 
ODN (ODN 2216), the ‘gold-standard’ CpG ODN for the induction of IFN-α. 
However, the ability of CpG-A to induce IFN-α was strongly reduced by binding it 
onto the surface of cationic gelatin nanoparticles.  
It could be proven that the presence of CpG motifs is still mandatory for the 
stimulation of the immune system, since nanoparticles loaded with the 
corresponding GpC-control ODN (M383) did not induce any stimulation. So, 
gelatin nanoparticles alone are no stimulus for the IFN-α production in PDCs. 
Noticeable were the significant differences between the detected amounts of IFN-α 
when using the two different sized nanoparticle batches CpG ODN loaded  
soluble CpG ODN 
CpG-GNP-H1 (160 nm) 
CpG-GNP-H2 (293 nm) 
 Chapter III. In vitro delivery of immunogenic CpG oligonucleotides 
- 115 - 
published by Verlag Dr. Hut, Munich, www.dr.hut-verlag.de, ISBN: 3-89963-451-9 
GNP-H2 (293 nm) was far more effective than GNP-H1 (160 nm). These data 
correlate very well with murine MDC experiments (see 3.2). 
To confirm the hypothesis that nanoparticulate bound CpG ODNs behave similar 
to soluble CpG ODNs and directly stimulate the secretion of IFN-α, the 
experiments were repeated in purified PDCs. In these experiments, the same 
amount of CpG ODN was administered (600 ng/200µL media) on 5x104 purified 
PDCs per well.  
The IFN-α signal augmentation by nanoparticulate formulations of CpG-B ODN 
and CpG-C ODN could be proven (Fig. 16A). In addition, also the IFN-α pattern 
of CpG-A ODN and control ODN M383 as determined in PBMC experiments 
could be reproduced. Depending on the utilized nanoparticle batch, we were able 
to exceed the IFN-α levels of the ‘gold-standard’, soluble CpG-A ODN 2216.  
 
Fig. 16: CpG-GNP induced immunostimulatory activity on PDCs and B cells. Both 
cell populations were incubated for 48 hours with CpG-GNP formulations. The size of 
the applied nanoparticle batches was 160 nm and 300 nm; IFN-α was quantified in 
the supernatants of PDC cultures (A), whereas B cells were analyzed for IL-6 (B). 
The depicted data represent average values ± s.d. of 5 individual experiments 
respectively.  
soluble CpG ODN 
CpG-GNP-H1 (160 nm) 
CpG-GNP-H2 (293 nm) 
B 
A 
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In another experiment we used purified B cells to measure their activation by the 
formulations, since they are the second cell type that contains TLR9 in humans. In 
these experiments also 600 ng CpG ODN were administered in 200 µL medium on 
2x105 purified B cells per well (Fig. 16B).  
CpG-B ODNs and CpG-C ODNs are known to directly activate B cells. 
Subsequently, B cells start to proliferate and secrete IL-6 as first cytokine after 
activation with CpG ODNs. The results of the experiments were quite surprising, 
since no enhanced B cell stimulation was induced with any of the CpG-GNP 
formulations in comparison to soluble CpG ODN. Moreover the effects of CpG 
ODNs were attenuated for CpG-GNP-H1 (160 nm) and CpG-GNP-H2 (293 nm) 
did almost diminish any activation.  
Evidently, particulate presentation of CPG-B and CpG-C promotes the activation 
of TLR9 in PDCs, but simultaneously it also interferes the activation of B cells. An 
explanation might be that particulate bound CpG ODNs are not taken up into B 
cells. But, preliminary FACS data indicated that both particulate bound CpG-B 
ODN and CpG-C ODN in contrast to CpG-A were internalized into B cells in 
similar quantities as their respective soluble form (data not shown).  
3.3.2 Morphological investigations of CpG-A ODN 2216 
According to our data, particulate presentation of CpG ODNs is beneficial for the 
induction of IFN-α in PDCs. Similar findings were just recently published for 
polystyrene nanoparticles (Kerkmann et al. 2005). Concerning the ODN sequences, 
CpG-A ODN 2216 is the prototype being applied to achieve IFN-α induction in 
PDCs. This ODN possesses both, a central palindrome sequence and terminal 
poly(G) motifs at the 5’ and 3’ end, which are known to enforce the formation of 
inter- and intra-molecular bonds (Krug et al. 2001). Thus, CpG-A spontaneously 
forms stable nanoparticulate structures under physiological conditions consisting of 
up to 30 ODN strands (Marshall et al. 2003) with an average mean size of 20-100 
nm (Costa et al. 2004). To verify these statements we performed own DLS and 
SEM experiments with soluble CpG-A ODN 2216. Measuring the ODN 2216 in 
sterile filtered PBS resulted in an average mean size of 99.4 nm (PI:0.352). This 
indicated the presence of quite heterogeneous particulate ODN aggregates. 
However, the absoluteness of the suggested mean size should not be over-
estimated because DLS accuracy is limited for such heterogeneous samples. 
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Surveying vacuum-dried samples of ODN 2216 also revealed particulate ODN 
aggregates which are apparently the key for the activation of IFN-α secretion in 
PDCs (Fig. 17).  
Fig. 17: SEM image of ODN 2216 revealing its particle-like aggregated structure 
Overall, the generated DLS and SEM data of CpG-A ODN 2216, were in sound 
agreement with just recently published data (Costa et al. 2004; Kerkmann et al. 
2005). Moreover, the resolutions achieved in SEM images exceeded those of 
published AFM images; thus gave new detailed insights on the aggregated 
morphology of CpG-A ODN 2216. 
 
3.3.3 Effects of CpG ODN-loading on particle mean size and homogeneity 
According to our experiments with mouse specific CpG ODN 1826, we simply 
adopted the established settings for the loading of the human specific CpG ODNs. 
But since CpG-A ODN 2216 is known for its aggregation tendencies, it was 
mandatory to monitor if any changes in nanoparticle size occur, when any of the 
three CpG ODN classes is loaded onto cationized gelatin nanoparticles. As 
depicted in Table 6, the averaging mean sizes of the nanoparticles did not change, 
when loading increasing amounts of CpG-B ODN 2006 and CpG-C ODN M362 
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onto the nanoparticles. The results were analogous to the ones derived from mouse 
specific CpG ODN 1826. Hence, no aggregation tendencies could be detected up 
to a payload of 10% (w/w). In contrast to that, enforced aggregation could be 
monitored with increasing CpG-A ODN amounts already after 30 min of 
incubation. The occurrence of these huge aggregates is  evidently responsible for 
the hindrance of the immunogenic activation with nanoparticulate bound CpG-A 
ODN 2216.   
Table 6: DLS size determination of cationized gelatin nanoparticles that were loaded 
with each CpG ODN class in various payloads; incubation time: 30 min in PBS (n=1)  
 CpG-A 
(ODN 2216) 
CpG-B 
(ODN 2006) 
CpG-C 
(ODN M362) 
unloaded 209.2 nm 209.2 nm 209.2 nm 
2.5% 422.7 nm 208.1 nm 204.2 nm 
5% 1203.4 nm 202.1 nm 212.1 nm 
7.5% 4100.6 nm 201.2 nm 205.3 nm 
10% 6475.8 nm 201.1 nm 199.9 nm 
 
Another aspect we wanted to investigate further was the previously assessed 
optimum payload of 5% (w/w). For murine MDC experiments, this number was 
only determined by comparing the measured ζ potential data with the experiences 
from the in vitro gene transfection experiments (Chapter II). Now, the optimum 
was determined via measuring the ability of various loading ratios to induce IFN-α 
on PDCs. Performing these experiments with CpG-B ODN and CpG-C ODN, 
our theoretically predicted optimum payloads were substantiated, since the highest 
IFN-α amounts were achieved between 5-10% (w/w) (Fig. 18). 
Payload 
(w/w) 
ODN- 
type 
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Fig. 18: CpG-GNP induced immunostimulatory activity on PDCs of various applied 
payloads (1-10%); PDCs were incubated for 48 hours with CpG-GNP formulations or 
soluble CpG ODNs (n=3).  
3.3.4 Is enhanced cellular uptake the key for the enhanced activation of the 
immune system? 
Searching for an answer, we performed CLSM and FACS experiments with 
fluorescence-labeled CpG ODNs.  FACS experiments (data not shown) did not 
show any remarkable differences comparing uptake of ODN 2216, ODN 2006 and 
nanoparticulate bound ODN 2006. The data even suggested that the uptake of 
particulate ODN 2006 was slightly lower than that of soluble CpG 2006, which 
does not induce the release of significant amounts of IFN-α.  
CLSM images of soluble CpG-A ODN 2216, particulate bound CpG-B ODN 
2006, and soluble CpG-B ODN 2006, proved that all three were internalized into 
PDCs. Furthermore, no significant differences could be seen concerning the 
respective amount of ODN that was taken up. Solely, soluble ODN 2006 appears 
rather diffuse on the images, whereas particulate CpG-B 2006 and soluble ODN 
2216 could be identified as distinct dots within PDCs (Fig. 19).  
However, some research groups suggest that the enhanced immunogenic activity of 
CpG ODNs bound onto a particulate or liposomal delivery system is based on an 
enhanced cellular uptake (Gursel et al. 2001; Fearon et al. 2003). Whereas other 
research groups have assessed contrary statements (Marshall et al. 2004; Kerkmann 
et al. 2005) in agreement with the data we have generated.  
For ODNs containing poly-G-motifs, such as CpG-A ODNs it has been 
postulated that they are preferentially internalized into APCs thus being more 
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Fig. 19: CLSM images of 
fluoresceine-labeled CpG ODN 
uptake into PDCs (2.5x105 PDCs 
/mL) after 4 h; administered CpG 
ODN concentration: 3µg/mL; 
soluble CpG ODN 2216 (A); CpG 
ODN 2006 loaded cationized 
gelatin nanoparticles (B); soluble 
CPG ODN 2006 (C)  
efficient (Dalpke et al. 2002; Gursel et al. 2002). It has been described that this 
enhanced uptake occurs due to the recognition of the  polyguanosine-motifs by 
scavenger receptors (Dalpke et al. 2002). But this statement was only proven for 
macrophages, monocytes, and murine CD11+ MDCs (Lee et al. 2000; Gursel et al. 
2002). Recent results revealed that scavenger receptors are not expressed in PDCs 
(Dr. Simon Rothenfusser, unpublished data). 
.   
   
 
Surveying B cells, preliminary FACS data with soluble CpG ODN and CpG GNP 
demonstrated that both were internalized into B cells (data not shown). But 
contrary to PDCs the particulate delivery of CpG ODNs did not induce enhanced 
secretion of IL-6 the key cytokine of B cell activation (see 3.3 – Fig. 18). Instead, a 
reduction of the immunogenic effect occurred that was even stronger for larger 
nanoparticles (~300 nm). Thus, the immune stimulation of B cells is induced by 
conditions converse to those of PDCs. 
C
A B
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3.3.5 Discussion and summary 
 In the present study we demonstrated that CpG-GNPs are internalized into 
human PDCs and B cells, the respective cells being sensitive for CpG motifs in 
humans. Based on the results with the various established classes of CpG ODNs 
for humans, we were able to show that the structural prerequisites for the 
successful presentation of CpG ODNs to B cells and PDCs differ remarkably. 
Comparable INF-α levels with CpG-B and CpG-C being adsorbed onto the surface 
of our cationized nanoparticles indicated that the activation of PDCs is driven by 
the nanoparticulate structure instead of a specific sequence. These findings are in 
sound agreement with the results of other research groups using cationic PLGA 
microparticles (Fearon et al. 2003) or microparticles based on the polycationic 
antibiotic polymyxin B (Marshall et al. 2004). Adsorption of CPG-A ODN 2216 on 
nanoparticles, which possesses already a particulate structure, led to huge 
aggregates, which are obviously unable to be internalized into PDCs and/or to act 
as signal transducer. Aside from this structural component, a stimulating sequence 
with CpG motifs is still necessary to activate PDCs, as proven with the control-
ODN M383, which represents the corresponding GpC pendant to ODN M362 
(CpG-C) but does not induce any activation of the immune system when being 
adsorbed onto gelatin nanoparticles. 
IFN-α could already be measured after 3 hours when ODN release is not yet 
expected. Furthermore, CpG ODN could be identified as distinct particles in the 
CLSM pictures. Thus it can be stated that the interaction with TLR9 apparently 
occurs while CpG ODN is still attached onto the nanoparticles. This hypothesis 
was furthermore substantiated by the kinetics data we had previously generated in 
our murine model (see 3.2.6). Scanning literature, there are further hints that dense 
and close assembly of CpG motifs on the particles’ surface induces clustering of 
TLR9. Interaction of only one receptor with one ligand represents just a simplified 
reflection of the actual incidents. Investigations of the interaction between DC and 
T-cell have demonstrated that the whole scenery is far more complex than what is 
described in textbooks (Monks et al. 1998). A multitude of receptors accumulates in 
most cases at defined areas of the cell membrane which are called lipid rafts (Pralle 
et al. 2000). This receptor clustering enables enhanced and efficient signal 
transduction. Other groups have described that multimeric presentation induces 
crosslinking of TLR9 in PDCs, thus leading to the enhanced secretion of IFN-α. 
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Consequently, soluble monomeric CpG-B ODN fails to induce significant IFN-α 
secretion (Fearon et al. 2003; Marshall et al. 2004; Wu et al. 2004). Presumably, the 
presentation of CpG ODN in particulate matter allows various receptor-ligand 
interactions and amplifies the transcription of IFN-α. 
Thus, an optimized primary sequence for immune stimulation of PDCs such as the 
one of ODN2216 (palindrome, chimeric backbone, poly-G ends) is not mandatory. 
CpG-B ODN 2006 attached onto gelatin nanoparticles revealed identical 
immunogenic activation patterns. The specific ODN sequence is just necessary to 
form a particulate structure of the CpG ODN by self-assembly. The recognition by 
TLR9 occurs by the CpG motif alone. Intermediate activation of IFN-α secretion 
by soluble CpG-C ODNs can be explained with findings that these ODNs tend to 
form dimers in physiological media due to a central palindrome structure in their 
ODN sequence (Battiany 2006).  
In contrast, the activation of B cells seems mainly to be driven by the sequence of 
the CpG ODN, whereas particulate delivery seems rather disadvantageous. 
However, particulate bound CPG-B ODN 2006 and particulate bound CpG-C 
ODN M362 are still able to activate B cells as well. Apparently, the respective 
degree of B cell activation depends on the size of the utilized nanoparticles. 
Nevertheless, the present data demonstrate that optimized activation of B cells and 
PDCs requires completely different delivery and presentation of CpG ODNs. 
Possible explanations for these differences might be: 
a) Polymorphic types of TLR9 do exist in PDCs and B cells, which require 
different structural prerequisites of their particular ligands.  
b) A non-identified CpG co-receptor exists in one of the two cell populations. 
c) TLR9 is located in different compartments of the endosome with different 
accessibility and/or activation requirements.  
Summarizing, CpG-GNP formulations of CpG-B ODN 2006 and CpG-C ODN 
M362, represent a promising alternative tool to CpG-A ODN 2216 for the 
endogenous secretion of IFN-α. Even though the induced in vitro secretion of these 
new formulations is only slightly higher than that of CpG-A ODN 2216, CpG-
GNPs comprise another aspect which makes this approach so auspicious. The 
highly defined and reproducible formulation procedure of CpG-GNPs offers exact 
formulation optimization and will consequently facilitate a future approval by the 
authorities.  
 Chapter III. In vitro delivery of immunogenic CpG oligonucleotides 
- 123 - 
published by Verlag Dr. Hut, Munich, www.dr.hut-verlag.de, ISBN: 3-89963-451-9 
CpG-A ODN 2216 represents an undefined mixture of various secondary and 
tertiary structures, that consist of different numbers of molecules (Kerkmann et al. 
2005). Moreover, CpG ODN-A 2216 is also very unstable to external parameters 
such as freeze-thaw-cycles. These arguments make the development of a future 
formulation that will fulfil the requests for approval rather difficult. 
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4. CONCLUSION 
We were able to demonstrate that gelatin nanoparticles are efficiently taken up into 
various APCs. Thus, they possess immense potential as carrier for immunogenic 
drugs that have their target receptors within these cells. CpG ODNs adsorbed onto 
the surface of cationized gelatin nanoparticles were a first drug delivery approach 
we extensively evaluated. Initial murine MDC data demonstrated in detail that this 
newly established way of CpG ODN delivery leads to strongly enhanced cytokine 
secretions. The cytokine pattern is still TH1 and CTL specific such as the one of 
plain CpG ODNs. Moreover, it could be shown that maturation of the MDCs is 
intensively induced, thus supporting the overall immune response even more. 
Since the recognition of CpG ODNs differs remarkably between humans and 
rodents, it was essential to proceed from the murine model to primary human cells. 
Experiments were performed with nanoparticles that were loaded with the three 
different classes of CpG ODNs that exist for humans. The applied cell-types were 
primary human B cells and PDCs, the only cells within humans that can recognize 
CpG ODNs. The data derived from these experiments provided additional 
precious information on the activation principles of CpG ODNs in humans.  
It can be concluded that the respective ODN sequence is responsible for the 
intensity of B cell activation. Particulate delivery rather attenuates the strength of 
activation. Consequently, soluble CpG-B and CpG-C ODN are the most 
appropriate. PDCs, the other cell type being sensitive to CpG ODNs by inducing 
the production of IFN-α and indirectly TH1/CTL-supportive cytokine milieu, 
behaves completely converse to B cells. For this cell line particulate presentation of 
CpG ODN could be demonstrated to be favorable in congruency with previous 
murine MDC data. Thereby, the importance of a specific ODN sequence could be 
disproved. Solely the presence of CpG-motifs is essential. The sequence of CpG-A 
ODN, which was originally stated as optimum PDC activator is not essential for 
ideal receptor activation. Instead, this specific sequence facilitates only the 
formation of colloidal particles via self-assembly in physiological media. The key 
for efficient TLR9 stimulation in PDCs is the presentation of CpG motifs in 
particulate form. Presentation of the other two CpG ODN classes in particulate 
form by attaching them onto cationized gelatin nanoparticles, led to comparable or 
even better activation of IFN-α secretion. Present in vitro data suggest cationized 
gelatin nanoparticles with an averaging diameter of ~ 300 nm and a payload of 5-
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10% (w/w) are most promising. Summarizing, CpG-B/CpG-C ODNs adsorbed 
onto cationized gelatin nanoparticles bear great potential as new immunogenic 
formulations. Consequently, the very positive and comprehensive in vitro results 
recommended the straight forward proceeding to investigate this new established 
approach in vivo (see Chapter IV). 
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Chapter IV  
In vivo characterization of CpG ODN-loaded gelatin 
nanoparticles – Application as efficient and safe 
vaccine adjuvant 
1. INTRODUCTION 
1.1 Novel vaccine adjuvants 
In the early 20th century, the introduction of vaccines led to an enormous 
improvement of the average live expectancy by almost completely abolishing 
various deadly infectious diseases. Thus, currently available vaccines prevent up to 
3 million deaths and >750,000 children are kept from serious disability (O'Hagan & 
Rappuoli 2004). Vaccination is typically performed with live attenuated pathogens, 
inactivated bacterial toxins, or inactivated organisms. Even though those traditional 
approaches have been highly successful for a number of diseases, a lot of unsolved 
and new challenges still exist. Of course, attenuated or related but less virulent live 
pathogens are mostly very efficient, but bear always the danger of reversion into 
the full virulent form. Whole-killed antigens however, lack often cell-mediated 
immunity and are sometimes difficult to be grown in cell culture. 
Recent novel approaches that use recombinant protein subunit vaccines, synthetic 
peptides, protein-polysaccharide conjugates, and DNA plasmids are free of 
infectious hazards, but are very often poorly immunogenic and have high 
production costs (McCluskie & Weeratna 2001). Consequently, further efforts such 
as the co-administration of adjuvants are required.  
Adjuvants are substances that are used in combination with a specific antigen and 
support the antigen to give a more robust immune response. This can be achieved 
by various modes of action that e.g. include:  
a) an increased antigen uptake and presentation,  
b) an enhancement of the biological or immunological half-life of the co-
administered antigen,  
c) an induction of a specific immune response supporting cytokine milieu. 
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Already back in 1926, aluminum compounds were the first adjuvants to be reported 
in literature, since they were demonstrated to enhance the immunogenic effect of 
diphtheria toxoids (Glenny et al. 1926). Even 80 years later, aluminum-based 
compounds, which are also called alum, still represent the only adjuvants that are 
currently approved by the FDA. But even though alum possesses well documented 
safety properties, it features also various significant drawbacks. Thus, aluminum 
salts are only weak potentiators of recombinant vaccines, rather polarizing towards 
TH2 instead of TH1 or CTL-mediated immune responses (Gupta 1998). Moreover, 
the appearance of allergic reactions has been reported for some patients due to the 
induction of IgE antibodies. Finally, alum cannot be utilized as adjuvant for 
mucosal immunization, since it is unable to induce IgA antibody immune response 
(Relyveld et al. 1998; Gupta 1998). Actually, a lot of scientific work is currently 
concentrated on the development of promising new adjuvants.  
In principle, the two major alternative strategies to alum are the use of antigen 
delivery systems, such as liposomal or particulate systems, virosomes, and virus-like 
particles, or the use of substances bearing an immunomodulatory influence on the 
in vivo cytokine milieu. The most relevant of the immunomodulatory adjuvants are:  
a) Synthetic ODNs containing CpG motifs  
b) Monophosphoryl lipid A (MPLA) and derivatives  
c) Saponin derivatives (Quil A) 
d) Muramyl dipeptide  (MDP) and derivatives 
e) Double-stranded RNA (dsRNA) 
f) Small molecule immune potentiators  
g) Cytokines 
Already in the previous chapter, co-administration as adjuvant in conjunction with 
an antigen has been described as a potential field of application for CpG ODNs 
(see Chapter III).  
MPLA is derived from lipopolysaccharide (LPS), which is constituent of the 
cellular membrane in gram-negative bacteria. LPS itself is too toxic to be utilized in 
clinical trials, since it induces excessive amounts of inflammatory cytokines. 
However, MPLA is investigated in various clinical trials as it interacts with TLR4 
on APCs and induces TH1/CTL immune response supporting cytokine milieu. 
Thus, MPLA was already proven as an effective adjuvant for vaccines against 
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infectious diseases, cancer, and allergies (Evans et al. 2003). Additionally, our 
cooperation partners at University of Alberta have demonstrated that the 
immunogenic efficiency of MPLA can be enhanced when incorporating it into 
PLGA nanoparticles (Diwan et al. 2003; Chong et al. 2005).  
Immunostimulatory saponin derivatives, also known as Quil A, are typically 
obtained from the bark of the Quillaja saponaria tree and are already a common 
constituent of various veterinary vaccines (e.g. CattleMaster GOLD FP 5; Pfizer). 
The mechanism of action of Quil A is supposed as intercalation with the 
cholesterol in cell membranes, thereby forming holes or pores that may facilitate 
the antigen uptake into APCs (Singh & O'Hagan 2002).  Especially QS21, a highly 
purified fraction of Quil A, has shown the highest potential in clinical trials (Kensil 
& Kammer 1998). But it was reported that QS21 induces only enhanced T cell 
proliferation but no CTL-mediated cytotoxic immune response (Evans et al. 2001). 
N-acetylmuramyl-L-alanyl-D-isoglutamine, also called muramyl dipeptide (MDP), is 
the active component of Freund’s complete adjuvant (FCA), a mycobacterial 
extract in oil emulsion. FCA is a commonly used adjuvant in laboratory settings, 
but its toxic properties prohibit clinical use (McCluskie & Weeratna 2001). MDP 
itself is pyrogenic, thus a number of synthetic derivatives have been synthesized 
and revealed immunostimulatory activity by inducing high amounts of 
proinflammatory and chemotactic cytokines. Consequently, those derivatives have 
shown great potential as adjuvants (Azuma 1992).  
Double-stranded RNA (dsRNA) is recognized by TLR3 on APCs. Poly [I]:poly [C] 
is the prototype synthetic dsRNA and was shown to induce TH1-biased cytokines. 
But, it has also been found to be clinically toxic, causing renal failure, 
coagulopathies and hypersensitivity reactions (Robinson et al. 1976). However, an 
analogue of poly [I]:poly [C], poly [I]:poly [C12U] (Ampligen®), has been 
demonstrated to have minimal toxicity in clinical studies (Thompson et al. 1996). 
Our cooperation partners at LMU’s Department of Pharmaceutical Biotechnology 
just recently utilized the high anti-tumoral potential of poly [I]:poly [C] dsRNA. 
They showed that specific delivery of poly [I]:poly [C] dsRNA, complexed with a 
non-viral vector targeting for the epidermal growth factor (EGF) receptor, could 
eliminate glioblastoma, breast cancer, and adenocarcinoma in mice (Shir et al. 2006). 
Thereby, a polyethelenimine, polyethyleneglycol, and EGF conjugate was 
complexed with poly [I]:poly [C] dsRNA.  
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 Among small molecular immune potentiators, imidazoquinolines such as 
resquimod have to be mentioned. This class of a small nucleoside-like molecules 
are promising substances that induce TH1 immune responses (Wu et al. 2004).  
Finally, also cytokines can be used directly to modify and/or redirect an immune 
response. IL-1, IL-2, IL-12, IFN-γ, and GM-CSF represent  the most extensively 
investigated cytokines (Singh & O'Hagan 2002).   
1.2 Aim of the study and potential safety hazards 
In the previous chapter, cationized gelatin nanoparticles loaded with CpG ODN 
(CpG-GNPs) have been presented as highly effective immunogenic formulation in 
vitro. In the present chapter, the results of subsequent in vivo experiments are 
described. A first goal was to investigate the immunological effects of CpG-GNPs 
depending on the administration route. In addition to this, CpG-GNPs were tested 
as adjuvant in conjunction with the model protein antigen ovalbumin (OVA) in 
soluble or particulate bound form. 
Basically it is also always mandatory to have an eye on possible safety issues when 
using immunmodulatory substances. This is especially the case when new delivery 
systems are evaluated that potentially increase the immunogenicity of the 
substance. Fig. 1 summarizes the various deleterious effects that might be caused 
by CpG ODNs (Klinman 2004).  
One aspect is that enhanced immune response against pathogen antigens might 
also promote autoimmune diseases. A certain predisposal towards systemic 
autoimmune reactions might occur due to the conjunction of polyclonal B-cell 
activation, increased production of autoantibodies, and attenuated apoptosis of 
lymphocytes. A predisposing factor for organ-specific autoimmunity is the over-
induction of TH1-biased cytokines in conjunction with the presence self-antigens. 
Finally, the production of TNF and IFN-γ might cause septic shocks in patients. 
These hypotheses were further substantiated by studies, where bacterial DNA was 
administered in high doses to healthy mice and caused the production of 
autoantibodies against double-stranded DNA (Gilkeson et al. 1995). 
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Fig. 1: Potential safety issues concerning the use of CpG ODNs (Klinman 2004) 
To further investigate these issues, various experiments were performed in mice. 
Subsequent to continuous administration of CpG DNA, indeed DNA-specific 
IgGs were detectable in the blood serum of some mice, but the IgG amount was 
not sufficient to initiate an autoimmune response or pronounce an existing one 
(Katsumi et al. 1994). The potential hazards of septic shocks was investigated with 
BALB/c mice that were weekly treated with CpG ODN doses that were usually 
administered to patients in ongoing clinical vaccination trials (Elkins et al. 1999). All 
animals remained healthy and neither macro- nor microscopic indications for 
inflammations could be observed. Clinical studies as well did not show any 
evidence of toxicity so far.  
Another theoretical source of safety hazards might also be the delivery system 
itself, gelatin nanoparticles. Even though, gelatin possesses a very well safety 
record, there were certain epidemiological observations made among the Japanese 
population, which indicated the rare presence of allergies against gelatin in some 
individuals (Kelso 1999; Saito et al. 2005). This local concentration of gelatin 
hypersensitivity reports is mainly attributed to historical evolutionary reasons. 
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Traditionally, the Japanese population derived in the past, in contrast to other 
populations, their nutrient protein predominantly from grain and soy beans. 
However, Japanese people shifted their dietary habits and started increased eating 
of animal protein such as beef and pork and gelatin containing food. Consequently, 
these dramatic nutrition changes within only a short period of time are discussed as 
cause of this local phenomenon. Nevertheless, this antigencity issue has to be kept 
in mind when investigating gelatin nanoparticles in vivo. This is even more the case 
when gelatin nanoparticles are used as drug delivery system for an 
immunomodulatory adjuvant, e.g. CpG ODNs and/or vaccines. Consequently, this 
issue was another focus in the present study.  
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2. MATERIALS AND METHODS 
2.1 Reagents 
Reagent Description Supplier 
BD Pharm Lyse TM 
Lysing Buffer 
ammonium chloride buffer BD Biosciences (Heidelberg, 
Germany) 
BSA Bovine serum albumin; fraction V; 
endotoxine-free 
Carl Roth (Karlsruhe, 
Germany) 
H2SO4 Sulfuric acid; 1 M, p.a. Sigma Aldrich (Taufkirchen, 
Germany) 
OVA Chicken egg ovalbumin; 99% 
endotoxine free 
Sigma Aldrich (Taufkirchen, 
Germany) 
o-phenylenediamine 
dihydrochloride 
crystaline Sigma Aldrich (Taufkirchen, 
Germany) 
PBS Phosphate buffered saline pH 7.4; 
endotoxine free 
Sigma Aldrich (Taufkirchen, 
Germany) 
Tween 20 Polysorbate 20 Carl Roth (Karlsruhe, 
Germany) 
 
CpG ODN 1826 (5’-TCCATGACGTTCCTGACGTT-3’) was obtained from 
Coley Pharmaceutical Group (Langenfeld, Germany). For flow cytometry analysis, 
cells were stained with anti-mouse B220-PE, CD4-PE, CD8-PerCP, CD11c-APC, 
CD69-FITC, and isotype controls (BD Biosciences, Heidelberg, Germany). 
2.2 Preparation of gelatin nanoparticles 
2.2.1 Cationized gelatin nanoparticles 
Cationized gelatin nanoparticles and Alexa-Fluor 488-labeled nanoparticles were 
prepared according to the procedures being described in Chapter II and III.  
2.2.2 Gelatin nanoparticles with encapsulated OVA  
OVA was added to the gelatin solution before the second desolvation step in a 1:10 
ratio (m/m). The further particle preparation was performed according to the 
standard procedure for gelatin nanoparticles. The amount of incorporated OVA 
was semi-quantitatively determined via SDS-PAGE electrophoresis (NuPAGE 
  Chapter IV. In vivo characterization of CpG ODN-loaded gelatin nanoparticles 
- 142 - 
published by Verlag Dr. Hut, Munich, www.dr.hut-verlag.de, ISBN: 3-89963-451-9 
Novex, Invitrogen, Karlsruhe Germany). Therefore, staining was performed via 
Coomasie-Blue and quantitative analysis was done with ScanPack 3.0 Software 
(Biometra, Goettingen, Germany). 
2.3 CpG ODN or OVA loading of cationized gelatin 
nanoparticles 
Nanoparticle loading was performed according to the standard protocol that was 
described in the previous chapters for ODNs and pDNA.  
2.4 Mice 
Female Balb/c and C57BL/6 mice were purchased from Harlan-Winkelmann 
(Borchen, Germany). Mice were 5-12 weeks of age at the onset of experiments. 
Animal studies were approved by the local regulatory agency (Regierung von 
Oberbayern, Munich, Germany). 
2.5 Immunostimulation in vivo and immunization 
All immunological in vivo experiments were performed in cooperation with our 
partners at the Division of Clinical Pharmacology at LMU Munich’s Department of 
Internal Medicine. 
 For in vivo immunostimulation, 500 µg cationized gelatin nanoparticles were 
incubated with 50 µg of oligonucleotides and 100 µL PBS for 20 min and injected 
i.v. into the retroorbital plexus or s.c.. Single cell suspensions were prepared from 
spleen and draining lymph nodes 18 h after injection and treated with ammonium 
chloride buffer to lyse erythrocytes. For analysis of activation markers, cells were 
stained with fluorochrome-coupled mAbs and analyzed by flow cytometry. Data 
were acquired on a FACSCalibur (BD Biosciences) and analyzed using CellQuest 
software (BD Biosciences). Blood was obtained by retroorbital puncture at the 
indicated time points. Serum was prepared by centrifugation and stored at –20°C.  
For OVA immunization, formulations were injected s.c. on day 0 and day 14. 
Soluble OVA and both OVA formulations were administered in doses of 50 µg 
OVA each. Those groups that were additionally treated with CpG-GNPs or soluble 
CpG ODN became also doses containing 50 µg CpG ODN s.c. injected close to 
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the injection site of the OVA formulation. All formulations were administered in a 
volume of 100 µL. Spleens and serum were collected on day 21.  
2.6 Quantification of cytokines in serum 
Cytokine concentrations were determined by ELISA for IL-6 (BioSource, Solingen, 
Germany) and IL-12p70 (BD Biosciences) according to the manufacturers’ 
protocol. IFN-α was measured according to the following protocol: rat monoclonal 
antibody to mouse IFN-α (clone RMMA-1) was used as the capture antibody, 
rabbit polyclonal antibody to mouse IFN-α for detection (both from PBL 
Biomedical Laboratories, Piscataway, NJ, USA) together with HRP-conjugated 
donkey antibody to rabbit IgG as the secondary reagent (Jackson 
Immunolaboratories, West Grove, PA, USA). Recombinant mouse IFN- α (PBL 
Biomedical Laboratories) was used as standard (IFN-α concentration in IU/mL). 
2.7 OVA-specific immune response 
Serum antibodies to OVA were determined by ELISA: 96-well plates were coated 
overnight with 10 µg/mL OVA in PBS and blocked 1 h with 1% BSA in PBS. 
After incubation of serum samples for 1 h at a dilution of 1/200, plates were 
washed with PBS/1% Tween 20 and goat anti-mouse IgG, IgG1 or IgG2a 
conjugated to horseradish peroxidase (Southern Biotech, Birmingham, AL, USA) 
was added at 1 µg/mL for 1 h. Plates were again washed and ELISA was developed 
by o-phenylenediamine. Reaction was stopped by 1 M H2SO4 and optical density 
(OD) was read by photometer at 450 nm. For the detection of OVA-specific CD8+ 
T cells, freshly isolated splenocytes were lysed by ammonium chloride buffer and 
stained with H-2kb-OVA257-264-PE pentamers (Proimmune, Oxford, UK) and 
anti-CD8. Cells were stained with anti-CD8, then fixed with 2% paraformaldehyde 
and treated with permeabilizing solution (0.5% bovine serum albumin, 0.5% 
saponin, 0.02% sodium azide in PBS). The fixed cells were stained with FITC-
conjugated anti-IFN-γ antibody (BD Biosciences) for 25 min. The percentage of 
CD8+ T cells expressing IFN-γ was determined by flow cytometry.  
  Chapter IV. In vivo characterization of CpG ODN-loaded gelatin nanoparticles 
- 144 - 
published by Verlag Dr. Hut, Munich, www.dr.hut-verlag.de, ISBN: 3-89963-451-9 
2.8 Biodistribution studies via CLSM 
500 µg fluorescence-labeled GNPs loaded with 50 µg CpG ODN were injected i.v. 
into the retroorbital plexus or s.c. into the footpads of Balb/c mice. After 4h, the 
mice were sacrificed and liver, spleen, kidneys, and the draining lymph nodes were 
resected. The distribution into the different organs was determined by David Anz 
(Clinical Pharmacology, LMU Munich) via confocal laser scanning microscopy 
(CLSM).  
2.9 FACS analysis of lymph node tissue 
500 µg cationized gelatin nanoparticles were incubated with 50 µg of 
oligonucleotides and 100 µL PBS for 20 min and injected s.c.. Single cell 
suspensions were prepared from draining lymph nodes 18 h after injection. Cells 
were stained with fluorochrome-coupled mAbs and analyzed by flow cytometry. 
Data were acquired on a FACSCalibur (BD Biosciences) and analyzed using 
CellQuest software (BD Biosciences). 
2.10 Gelatin-specific immune response 
Serum antibodies to gelatin were determined by ELISA: 96-well plates were coated 
overnight with 10 µg/mL gelatin in PBS and blocked 1 h with 1% BSA in PBS. 
After incubation of serum samples for 1 h at a dilution of 1/200, plates were 
washed with PBS/1% Tween 20 and goat anti-mouse IgG1 or IgG2a conjugated to 
horseradish peroxidase (Southern Biotech) was added at 1 µg/mL for 1 h. Plates 
were again washed and ELISA was developed by o-phenylenediamine. Reaction 
was stopped by 1 M H2SO4 and optical density (OD) was read by photometer at 
450 nm. Further details are given in the Results and Discussion part of this chapter 
(see 3.3). 
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3. RESULTS AND DISCUSSION 
3.1 Systemic immunogenic activity of CpG-GNPs in vivo  
The previously obtained in vitro results indicated that CpG-GNPs stimulate an 
enhanced TH1/CTL-type immune response. Due to this it was the first focus to 
analyze if these well-plate-derived data correlate with in vivo activation patterns in 
mice. In these first in vivo experiments, we wanted to characterize the systemic 
immunogenic activity of CpG-GNPs. The two investigated routes of 
administration were intravenous and subcutaneous injection. Aside from the 
immunogenic activity, the biodistribution of CpG-GNPs following both injection 
pathways was the second factor to be studied. 
3.1.1 Intravenous injection 
Intravenous injection into the retroorbital plexus of the mice was the first route of 
administration to be examined. In analogy to in vitro experiments, again two 
differently sized nanoparticle batches were utilized: ZW IV1 (average size: 
289.4 nm; PI: 0.047) & ZW IV2 (average size: 150.7 nm; PI: 0.068). Fig. 2 displays 
the induced IL-12p70 (Fig. 2A) and IL-6 (Fig. 2B) levels that were detected 6 h past 
injection.  
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Fig. 2: IL-12p70 (A) & IL-6 (B) levels per mL blood serum at 6 hours past injection 
(n=3). CpG: 50µg soluble CpG ODN; CpG-GNPIV1: 500 µg GNPs (batch ZW IV1: 
289 nm) loaded with 50 µg CpG ODN; CpG-GNPIV2: 500 µg GNPs (batch ZW IV2: 
150 nm) loaded with 50 µg CpG ODN; GNPIV1/GNPIV2: 500µg unloaded GNPs 
controls; control: untreated control mice. 
Both CpG ODN formulations being tested in this setup resulted in successful 
cytokine secretion, whereas the controls did not show any activity. Moreover, in 
A B 
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vitro results indicating that larger sized nanoparticles are more efficient than smaller 
ones were confirmed. However, the respective differences between ~150 nm and 
~300 nm sized particles concerning the amount of induction were bigger than in 
in vitro experiments (see Chapter III). 300 nm sized nanoparticles ZW IV1, led to 
more than threefold higher IL-12p70 concentrations than soluble CpG ODN and 
slightly enhanced IL-6 values. The 150.7 nm large nanoparticle batch reached 
comparable IL-12p70 levels to soluble CpG ODN, but only reduced secretion of 
IL-6.  
As already discussed in Chapter III, the lack of strong enhancement of IL-6 levels 
in comparison to soluble CpG ODN is not necessarily unfavorable, since only IL-
12p70 is the key cytokine to trigger TH1 immune responses and IL-6 is discussed to 
show even adverse effects on a TH1 differentiation (Diehl & Rincon 2002). 
While observing the treated animals during the experiments, none of them showed 
signs of toxicity. However as we applied a third nanoparticle batch with even larger 
nanoparticles (500.8 nm) to determine if these particles are even more efficient, 
some of the animals died. As a consequence, maximum particle size of 
intravenously administered CpG-GNPs should not exceed 300 nm.  
Another method to monitor the activity of immunogenic CpG-GNPs is to detect 
the percentage of activated immune cells. Therefore, activation markers on various 
previously purified cell types were analyzed by FACS. Thus, both types of DCs 
showed enhanced maturation as detected via CD86, in comparison to control mice 
and mice treated with gelatin nanoparticles alone. However, the percentage of 
matured cells of both DC types was slightly below soluble CpG ODN (Fig. 3). 
CpG-GNP’s activation enhancement of B cells and CD8+ cells that was detected 
via the early activation marker CD69, was comparable or even slightly higher than 
soluble CpG ODN. Hence, CpG-GNPs are also in vivo able to activate the cells 
that are important for a successful immune response. 
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Fig. 3: Percentage of immunologically activated MDCs, PDCs, B cells, and CD8+ 
cells 2 h after intravenous administration; white columns: untreated control mice; light 
grey columns: mice treated with cationized gelatin nanoparticles alone; dark grey 
columns: mice treated with CpG-GNPs; black columns: mice treated with soluble 
CpG ODN.  
3.1.2 Subcutaneous injection 
Aside from intravenous injection, the subcutaneous route was the second examined 
type of administration. Again, systemic IL-12p70 and IL-6 levels were quantified to 
measure the systemic stimulation of the immune system. As depicted in Fig. 4, 
50 µg soluble CpG ODN was able to induce systemic activation of the immune 
system also after s.c. administration.  
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Fig. 4: Serum cytokine levels induced by s.c. administered soluble CpG ODNs and 
CpG-GNPs. A: IL-12p70 in blood serum after 2, 6, 22 & 48 h; B: IL-6 in blood serum 
after 2, 6, & 21h 
IL-12p70 reached its highest level after 6 hours whereas IL-6 achieved its peak 
concentration already at the first detection point after 2 h. In contrast to i.v. results, 
A B 
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none of the CpG-GNP batches was able to increase cytokine levels. In fact, all 
tested CpG-GNP batches were unable to induce any significant cytokine amounts, 
as exemplary displayed by the results of 289.4 nm sized CpG-GNP IV1. Even 
though it was already known from in vitro kinetic studies that particulate delivery of 
CpG ODNs does not induce any sustained or delayed activation of the immune 
system in comparison to soluble CpG ODNs, this possible aspect was surveyed 
once more. But even after very late detection points (IL-12p70: 21 h; IL-6: 22 & 
48 h), no cytokine secretions could be observed. Summarizing, subcutaneous 
administration does not induce systemic activation of the immune system.  
Nevertheless, this absence of systemic activity was not automatically judged 
negatively. For feasible applications of CpG ODNs, such as e.g. the co-
administration as vaccine adjuvant, an unspecific systemic cytokine secretion is 
rather a undesirable side effect bearing the potential risk of immunological over-
reactions (Klinman 2004). To give a final statement on this issue, further 
investigations of e.g. the biodistribution properties of s.c. administered 
formulations had to be performed. 
3.1.3 In vivo localization of fluorescence-labeled CpG-GNPs 
To track the in vivo fate of CpG-GNPs, mice were injected with fluorescence-
labeled CpG-GNPs. After 4 hours, the mice were sacrificed and their major organs 
were resected. Surveying selected tissue samples that were obtained from animals 
receiving intravenously administered CpG-GNPs under a confocal laser scanning 
microscope, it was possible to localize fluorescence-labeled CpG-GNPs in addition 
to blood cells also in liver, spleen and kidney (Fig. 5A). These data correlated nicely 
with other biodistribution data that were obtained with gelatin nanoparticles (Kaul 
& Amiji 2004; Zillies et al. 2005). Subcutaneously administered CpG-GNPs could 
not be detected in those tissues (Fig. 5B), thus the particles were obviously not 
further processed by the systemic bloodstream, at least not above the visually 
detectable limits.  
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Fig. 5: CLSM images of various tissues. Blue: cell nuclei; Green: fluorescence-
labeled CpG-GNPs. A: intravenous injection; B: subcutaneous injection 
Consequently, CpG-GNPs were only systemically distributed via the blood stream 
following intravenous injection instead of subcutaneous. These findings agree with 
those previously described for other colloidal drug delivery systems, such as solid 
lipid nanoparticles (Reddy et al. 2005) and liposomes (Oussoren et al. 1997). Those 
references describe that s.c. administered colloidal carriers frequently remain at the 
injection site and are partially transferred via the lymphatic system to the draining 
lymph nodes. In detail, the carriers are taken up at the site of injection by local 
phagocytotic cells such as immature DCs. Following this uptake the cells transform 
into their mature state and are transferred to the lymph nodes where they start to 
induce a local immune response, such as e.g. the TH1/CTL-type response that is 
activated by CpG ODNs.  
Due to this theoretical background, it was decided to further investigate tissue 
samples of the site of injection and the draining lymph nodes. Since the 
subcutaneous injections were conducted into the footpads, the next draining lymph 
nodes were located in the popliteal fossa and the inguinal region. However, 
confocal laser scanning microscopic analysis 4 h past injection revealed only a 
massive amount of nanoparticles at the site of injection. No nanoparticles could be 
identified in the draining lymph nodes (Fig. 6).  
A 
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Fig. 6: CLSM images of tissue samples at 4 h past subcutaneous injection; A: tissue 
at the site of injection; B: tissue of the popliteal lymph node  
Even though the nanoparticles could not be visually detected under the microscope 
after 4 h, it was decided to analyze the tissue of the popliteal and inguinal lymph 
nodes by more sensitive FACS analysis at various time points. In Fig. 7, a typical 
quadrant analysis of the cells derived from popliteal (Fig. 7A) and inguinal (Fig. 7B) 
lymph nodes is shown.  
         
Fig. 7: 2-color FACS analysis of cells that were derived from the draining lymph 
nodes being closest to the site of CpG-GNP injection. Sacrificed: 18 h post injection; 
y-axis: FL-1 fluorescence (Alexa FluorTM 488 labeled CpG-GNPs); x-axis: FL-2 
fluorescence: Allophycocyanin (APC) anti-mouse F4/80 antigen; A: popliteal lymph 
node; B: inguinal lymph node 
In the displayed two-color analysis macrophages have been additionally stained 
with F4/80 APC. They can be identified in the upper and lower right quadrants. 
Cells that have taken up nanoparticles are located in the upper quadrants. The 
results show that nanoparticles could be located within the cells of lymph nodes. In 
total, more nanoparticles could be located after 18 h in the popliteal lymph nodes 
that are located closest to the site of administration (Fig. 7A), whereas only a few 
cells indicated the presence of nanoparticles in the inguinal lymph nodes (Fig. 7B). 
Moreover, since cells can be found in both upper quadrants, the particles are 
A B 
A B 
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apparently taken up by various distinct cell-types, such as macrophages and other 
phagocytotic cells (DCs, etc.).  
Based on these histological results, the conclusion can be drawn that s.c. 
administered CpG-GNPs do not cause a systemic immune activation since they 
are, in contrast to soluble CpG ODN, not removed via the blood stream from the 
site of injection. But, as a certain movement towards the draining lymph nodes 
could be observed, it was potentially possible that an activation of the immune 
system by CpG-GNPs occurs. However this would only happen within a regionally 
restricted area encompassing the injection site.  
3.1.4 Summary 
The results of these first experiments to characterize the systemic immunogenic 
activity of CpG-GNPs revealed significant differences to soluble CpG ODN. 
Whereas soluble CpG ODN induces a systemic secretion of TH1/CTL-polarizing 
cytokines subsequent to both types of administration, CpG-GNPs did only cause a 
systemic immune response after intravenous injection. 
 Analyzing the systemic cytokine levels that were induced with i.v. administered 
CpG-GNPs, in vitro results indicating the size of the applied gelatin nanoparticles as 
significant factor on the immunogenic activity of CpG-GNPs were confirmed. The 
ideal nanoparticle size to excite the secretion of enhanced levels of IL-12p70, the 
key cytokine to promote TH1 differentiation, is apparently ~300nm. Observing the 
maturation or activation levels of myeloid DCs (MDCs), plasmacytoid DCs 
(PDCs), B cells, and CD8+ cells as second important benchmark aside from 
cytokine secretion revealed that CpG-GNPs led to comparable enhanced numbers 
of activated cells as soluble CpG ODN.  
Searching for possible explanations, why subcutaneous administration did not 
result in any detectable systemic cytokine levels, CLSM analysis gave valuable 
insights. S.c. administered CpG-GNPs are in contrast to i.v. injected CpG-GNPs 
not biodistributed via the bloodstream, thus remaining basically at the site of 
injection. Nevertheless, FACS analysis revealed that some nanoparticles are also 
transported to the closest draining lymph nodes.  
Consequently, it might be possible that CpG-GNPs are still able to induce an 
immune response. But due to the lack of systemic distribution, no systemic 
cytokine secretion occurs. If this potential local immune reaction would be 
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sufficient to e.g. boost the immune response against a co-administered antigen in 
comparable manner to soluble CpG ODNs, but without systemic side-effects, this 
would be a highly auspicious application. 
3.2 CpG-GNPs as immunization adjuvant for chicken egg 
ovalbumin (OVA) as model protein vaccine 
Summarizing the first results of s.c. administered CpG-GNPs it was hypothesized 
that they might possibly cause a locally restricted immune reaction in the area 
comprising the site of injection. As a consequence, the potential local 
immunological activity of s.c. injected CpG-GNPs should now be evaluated as 
adjuvant for a co-administered antigen protein. The chosen antigen was chicken 
egg ovalbumin (OVA), a commonly used model protein antigen. Other groups had 
recently demonstrated with different types of nanoparticulate delivery systems for 
CpG ODNs in combination with OVA, that strong immune induction can be 
observed in vitro, which might indicate also enhanced OVA specific immunization 
efficiency in vivo (Kwon et al. 2005; Jain et al. 2005).  
3.2.1 Orientation study to evaluate the applicability of CpG-GNPs as 
adjuvant for OVA 
In this orientation study with 3 mice per group, 2 groups were immunized with 
25 µg OVA by s.c. injection, whereas one group received additionally 100 µL of a 
CpG-GNP dispersion (containing 500 µg nanoparticles loaded with 50µg CpG 
ODN) s.c. injected (Fig. 8). Analyzing the blood sera that were collected on day 21 
past the initial injection, it could be revealed that CpG-GNPs led to increased anti-
OVA IgG titers in serum. Thus, the previously claimed hypothesis that CpG-
GNPs are able to induce immune responses when subcutaneously injected, but 
only in regionally limited manner and without unwanted systemic secretion of 
unspecific cytokines was confirmed.  
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Fig. 8: OVA-specific IgG titers in serum after s.c. immunization (n=3). OVA+CpG-
GNP: 25 µg soluble OVA + 500µg gelatin nanoparticles loaded with 50 µg CpG ODN; 
OVA: 25 µg soluble OVA; control: untreated control mice. 
3.2.2 Rational design of an applicable OVA delivery by gelatin 
nanoparticles  
A second project of this study was to evaluate if OVA can either be encapsulated 
into the matrix of gelatin nanoparticles or be adsorbed onto the surface of 
cationized gelatin nanoparticles, since OVA has a ζ potential of -7.3 mV in 
physiological PBS pH 7.4. To analyze the amount of OVA that was loaded onto 
the nanoparticles, UV-metrical detection of OVA in the particle supernatant, in 
analogy to the quantification method for free unbound nucleotides (see Chapter II), 
failed since the signal was to low for exact detection. So it was decided to use SDS-
Page electrophoresis to quantify the OVA loading. Staining was performed via 
Coomasie-Blue to enable the semi-quantitative analysis.  
The cationized gelatin nanoparticles that were used in these experiments belonged 
to the same batch (ZW IV1; average size: 289.4 nm; PI: 0.047) that was previously 
evaluated as optimum carrier for intravenously injected CpG ODNs. When trying 
to attach various amounts of OVA onto the surface of the cationized gelatin 
nanoparticles, 1.5 µg OVA were completely loaded onto 30 µg nanoparticles (~5% 
[w/w]), as it can be visually derived from Fig. 9A. Furthermore, the reduction of 
the band intensities of the other, higher OVA amounts could be quantified as 
averaging 1.47 ± 0.17 µg OVA and were in good agreement with the maximum 
  Chapter IV. In vivo characterization of CpG ODN-loaded gelatin nanoparticles 
- 154 - 
published by Verlag Dr. Hut, Munich, www.dr.hut-verlag.de, ISBN: 3-89963-451-9 
amount of completely loaded OVA. Repetitive experiments with the same and 
different nanoparticle batches, led to the comparable results (data not shown). 
     
Fig. 9: A: semi-quantitative analysis of OVA loading properties onto the surface of 
cationized gelatin nanoparticles; OVA standards (A-D): A=12µg B=6µg; C=3µg; 
D=1.5µg OVA; Nanoparticle samples (E-I) incubated with 30 µg nanoparticles each: 
E=12 µg; F=6 µg; G=3 µg; H=2 µg; I= 1.5 µg OVA administered; J= control markers 
B: semi-quantitative analysis of OVA encapsulation properties of gelatin 
nanoparticles; OVA Standards (B-F): B=18µg, C=9µg, D=4.5µg, E=2.25, F=1.125 µg 
OVA; Nanoparticle dispersion aliquots (G-J) containing nanoparticles prepared in 
1:10 (OVA:gelatin) ratio: G =76.4 µg, H =38.2 µg, I= 19.1 µg J=9.6 µg OVA 
administered; A= control markers 
In the other formulation approach, the efficiency of the OVA incorporation into 
the nanoparticle matrix was also analyzed via gel electrophoresis (Fig. 9B). This 
analysis was performed with freshly prepared nanoparticles. All samples resulted 
with a rather broad and smearing background signal. The reason was remaining 
soluble non-desolvated gelatin that was still present in these samples, since no 
purification could be performed before the gel electrophoresis, because the 
unbound OVA, the factor that should be determined, would thereby get discarded 
as well. Assuming that the signal in the typical region of OVA is only an OVA 
signal, then our yield of incorporated OVA would be ~97%, regarding to ScanPack 
calculation. Interestingly, the addition of OVA in 1:10 ratio to the gelatin solution 
before the second desolvation step had also significant impact on the size of the 
later nanoparticles. All three batches that were produced using standard conditions 
to achieve an averaging mean size of 250 nm resulted between 113 and 139 nm. 
The obtained PIs (0.09 – 0.13) were slightly worse than those typically known for 
pure gelatin nanoparticles, but still acceptable concerning their homogeneity. 
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Readily prepared nanoparticles were purified from non-desolvated gelatin and non-
incubated OVA by three-fold centrifugation and redispersion. 
Finally, both novel OVA formulations were applied for immunization in 
comparison to soluble OVA (Fig. 10). In these experiments, the previous results of 
the orientation study were substantiated, which indicated that additional 
administration of CpG-GNPs leads to a strong immunization boost.  
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Fig. 10: OVA-specific IgG titers in serum after s.c. immunization (n=3). Additionally 
administered CpG-GNPs: white columns → no; black columns → yes; no antigen: no 
OVA administered to mice; soluble OVA: soluble OVA administered to mice; surface 
OVA-GNP: OVA adsorbed onto cationized GNPs administered to mice; incorporated 
OVA-GNP: OVA entrapped into the gelatin nanoparticle matrix administered to mice 
Both of the new OVA formulations were able to induce comparable OVA-specific 
IgG titers to soluble OVA. Thus, it was demonstrated that no inactivation of the 
antigen’s immunogenicity occurred. Otherwise, also no additional increase of the 
immunization via particulate antigen delivery could be observed, although nano- or 
microparticulate delivery are referred as further adjuvant approach in literature 
(Singh et al. 2001; McCluskie & Weeratna 2001).  
Nevertheless, the performed new approaches are giving an outlook for potential 
future antigen formulations, where particulate delivery might be advisable. 
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3.2.3 Comparison of the adjuvant potential of CpG-GNPs vs. soluble CpG 
ODN 
In this study we wanted to determine the actual adjuvantive strength of s.c. 
administered CpG-GNPs in comparison to soluble CpG ODN. To keep the 
number of necessary groups of mice limited it was decided to perform the 
experiments with OVA being adsorbed onto the surface of cationized gelatin 
nanoparticles as only antigen formulation. Due to the results of the previous 
experiment soluble OVA or OVA incorporated into the particle matrix should 
expectedly result similar. 
As shown in Fig. 11, previous experiments indicating that additional administration 
of CpG-GNPs led to strongly enhanced production of OVA-specific IgG, were 
again substantiated. Thus, the IgG titer of mice that were immunized with OVA-
loaded nanoparticles and CpG-GNPs being co-administered was more than 3-fold 
higher than the one of OVA-loaded gelatin nanoparticles alone. But, comparing the 
induced IgG titers, CpG-GNPs resulted also slightly better as co-administered 
adjuvant than soluble CpG ODN (Fig. 11A). 
Aside from the actual IgG titer, an important benchmark of successful TH1/CTL-
biased immunization is the percentage of antigen specific CD8+ cells. While co-
administered soluble CpG ODN led only to a slight increase of OVA-specific 
CD8+ cells in blood serum in comparison to OVA-loaded gelatin nanoparticles 
alone, a 4-fold amount of specific CD8+ cells was obtained with CpG-GNPs that 
were co-admnistered with OVA-loaded nanoparticles (Fig. 11B). Hence, CpG-
GNPs are an ideal new adjuvant to selectively promote the immunization via a 
TH1/CTL-mediated pathway. 
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Fig. 11: OVA-specific IgG titer (A) and amount of OVA-specific CD8+ cells (B) in 
serum after s.c. immunization (n=5). OVA-GNP: Mice treated with OVA adsorbed 
onto gelatin nanoparticles; OVA-GNP + CpG-GNP; Mice treated with OVA adsorbed 
onto gelatin nanoparticles and co-administered CpG-GNPs; OVA-GNP + ODN 1826: 
Mice treated with OVA adsorbed onto gelatin nanoparticles and co-administered 
soluble CpG ODN 1826; ODN 1826: Mice treated with soluble CpG ODN 1826; CpG-
GNP: Mice treated with CpG-GNPs; control: untreated control mice. 
3.2.4 Summary 
Present data revealed that CpG-GNPs are a highly potent vaccine adjuvant. 
Whereas previous findings raised the question, if s.c. administered CpG-GNPs 
possess immunological activity at all, since no enhanced blood-levels of 
immunogenic and inflammatory cytokines could be detected (see 3.1), it was now 
demonstrated that this immune activation occurs in a local manner.  
A 
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Nevertheless, this local restriction encompassing the area around the injection site 
and the closest draining lymph nodes turned out to be sufficient to induce strongly 
enhanced specific immune against the co-administered antigen OVA. Moreover, 
the immunization efficiency with co-administered CpG-GNPs concerning the 
obtained percentage of specific CD8+ cells was significantly better than with 
soluble CpG ODN. 
In addition to these findings, it was demonstrated that the protein antigen remains 
comparably active as the soluble antigen, when it is adsorbed onto the surface of 
gelatin nanoparticles or incorporated in the particles matrix.  
3.3 Do gelatin nanoparticles induce anti-gelatin IgGs in mice? 
In all in vitro experiments that have been described in this Ph.D. thesis, gelatin 
nanoparticles behaved biologically neutral. However, since gelatin nanoparticles 
were used as carrier for an immunomodulatory adjuvant here, certain antigenicity 
concerns have been raised. To investigate these issues, we established a specific 
ELISA. Therefore, we injected dissolved gelatin in combination with FCA 
(Freund’s Complete Adjuvant) to a group of mice. Immunization with gelatin and 
FCA as adjuvant induces the production of specific anti-gelatin IgG1 and IgG2a 
antibodies. Thus, we generated mice bearing these gelatin-specific serum antibodies 
as a positve control. To detect the antibodies via ELISA, we coated well-plates with 
gelatin and incubated them with serum samples of CpG-GNP-immunized mice. 
After the CpG/OVA-immunization experiments, serum samples of all mice were 
taken and analyzed for anti-gelatin IgG1 and IgG2a in comparison to PBS as 
negative control and serum of gelatin/FCA-immunized mice as positive control. As 
depicted in Fig. 12, all serum samples of CpG/OVA-immunized mice did not 
contain significant anti-gelatin IgG. So, no undesired immunogenicity against 
gelatin was induced. Nevertheless, certain focus has to be put on this issue also in 
future.  
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Fig. 12: Serum titers of anti-gelatin IgG of all gelatin nanoparticle samples 
administered in vivo; OVA-GNP I: gelatin nanoparticles with incorporated OVA; OVA-
GNP I + CpG-GNP: gelatin nanoparticles with incorporated OVA and additional CpG-
GNP; OVA-GNP II + CpG-GNP: gelatin nanoparticles with adsorbed OVA and 
additional CpG GNP; CpG ODN: soluble CpG ODN; CpG-GNP; neg. control: PBS; 
pos. control: mice treated with gelatin and additional FCA. 
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4. CONCLUSION 
When performing first characterization experiments to investigate the in vivo 
immunological activity of CpG-GNPs, it was noteworthy that the route of 
administration was decisive for systemic secretion of immunogenic and 
inflammatory cytokines. While intravenous injection of CpG-GNPs induces high 
amounts of those cytokines in the blood stream, subcutaneously applied CpG-
GNPs do not cause this systemic kind of immune response. On the other hand, 
soluble CpG ODN induces systemic secretion of non-specific, immunogenic 
cytokines in both ways of application. Searching for explanations for this 
phenomenon, it was found that s. c. administered CpG-GNPs in contrast to 
soluble CpG ODN are not systemically distributed via the blood stream, but 
remain at the site of injection from where they are partially taken up by antigen 
presenting cells (APCs). After this cellular uptake they are transported to the closest 
draining lymph nodes, where finally TH1/CTL-mediated immune reactions against 
co-administered are initialized. 
Due to the locally restricted distribution of CpG-GNPs, the potential appearance 
of unwanted systemic immunological side effects, such as septic shocks, can be 
almost excluded for this new adjuvant formulation. This circumstance alone 
represents already an enormous improvement against soluble CpG ODN. But even 
more, CpG-GNPs seem to be slightly more effective than soluble CpG ODN, 
when applied as vaccine adjuvant. Otherwise, it was also demonstrated that CpG-
GNPs amplify only the immune reaction against the real antigen protein and did 
not cause immune responses against gelatin, the proteinaceous matrix material of 
the nanoparticles.  
Due to its TH1/CTL specificity this new adjuvant might perfectly fit the needs of 
anti-viral or anti-tumoral antigens to enable successful and efficient vaccinations, a 
field where state-of-the-art adjuvant alum has its disadvantages. 
Finally, it was successfully demonstrated that gelatin nanoparticles can also be used 
as carrier for antigens, by either entrapping them into the particle matrix or 
conjugating them onto the particle surface. This further expands the potential 
application repertoire also towards smaller antigenic substances, such as peptides, 
where particulate delivery might be advantageous.  
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Chapter V 
PEGylation   and   biodistribution   of   gelatin 
nanoparticles – Initial experiments 
1. INTRODUCTION 
1.1 Biodistribution of nanoparticles 
When developing a new drug delivery system, exact knowledge of its fate in vivo is 
essential. This is even more the case, if the drug release and effect is only desired at 
a specific target tissue or organ within the body. Nanoparticles are a promising 
colloidal carrier system and due to their small size they can be applied for specific 
cell targeting purposes. Potential targets are the brain (across the blood brain 
barrier), tumors, or sites of inflammation. Thereby, intravenous administration 
represents still the main route for these colloidal applications. Unfortunately, 
nanoparticles are, similar to other colloidal carrier systems, in general quickly 
removed from the blood stream by the mononuclear phagocytotic system (MPS), 
formerly also known as reticuloendothelial system (RES). Consequently, this 
circumstance represents the major obstacle for the realization of most targeting 
goals (Gref et al. 1994; Owens & Peppas 2006). The cells of the MPS that are 
responsible for this rapid clearance are mainly Kupffer cells in the liver and 
macrophages in spleen and lung (Kreuter 1983). But MPS cells do not recognize 
nanoparticles by themselves. They are dependent on the adsorption of opsonin 
proteins (Gref et al. 1995). The function of these blood serum components is to 
make foreign particles recognizable for phagocytotic cells. Typical opsonins that are 
adsorbed onto the surface of nanoparticles are lectins, immunoglobulins, and 
complement proteins such as C1-C5. Nevertheless, the respective opsonization 
pattern and thus the clearance of the nanoparticles from the blood circulation 
depends very strongly on the particular surface of the nanoparticles. The 
knowledge of the specific adsorption pattern appears to be very helpful when 
estimating a biodistribution profile of a new intravenously injectable colloidal 
carrier system. While searching for appropriate analytical tools, methods like two-
dimensional polyacrylamide gel electrophoresis have proven to be valuable for the 
 Chapter V. PEGylation and biodistribution of gelatin nanoparticles – Initial experiments  
- 166 - 
published by Verlag Dr. Hut, Munich, www.dr.hut-verlag.de, ISBN: 3-89963-451-9 
characterization of plasma protein absorption patterns (Blunk et al. 1993; Goeppert 
& Mueller 2005).  
In our research group, we have just recently used this method to investigate the 
adsorption profile of solid lipid nanoparticles (SLNs) that were stabilized with 
poloxamer 188 (Pluronic™ F 68) versus plain gelatin nanoparticles (Zillies et al. 
2005). Thereby, SLNs mainly adsorbed apolipoproteins on their surface, thus 
indicating a comparable adsorption pattern as polysorbate 80 or poloxamer coated 
poly (butyl 2-cyanoacrylate) nanoparticles (Douglas et al. 1986; Kreuter et al. 1995). 
Because of this opsonization profile, these nanoparticles are long circulating and 
are discussed to pass the blood brain barrier since apolipoprotein adsorption is 
postulated to induce active transfer via the LDL (low density lipoprotein) receptor 
(Kreuter et al. 2003). In contrast to that, gelatin nanoparticles adsorb mainly 
immunoglobulins, lectin, and components of the complement system. Thus, they 
are expected to be very quickly sequestered by the cells of the MPS. 
 Even though it is difficult to set up rules for the biodistribution of nanoparticles, it 
can be stated that adsorption of hydrophilic shells is beneficial for prolonged blood 
circulation. These hydrophilic chains are typically introduced by attaching 
poly(ethylene oxide) (PEO) onto the nanoparticle surface. One strategy is the 
adsorption of amphiphilic agents that contain PEO such as poloxamers and 
poloxamins (block copolymers of PEO and poly (propylene oxide)) or polysorbate 
(poly (ethylene oxide) sorbitanester). The second way is to covalently attach or 
entangle poly (ethylene glycol) (PEG) and PEG containing polymer layers. So far 
numerous approaches based on one of these concepts have been described for 
polymeric nanoparticles (for detailed information see review Owens & Peppas 
2006). Most of them prolonged the bloodstream half-lives of the nanoparticles up 
to some hours. A second beneficial feature of the hydrophilic shell is that it 
prevents cationic nanoparticles or polyplexes, which are often used in non-viral 
gene therapy (see Chapter II.), from inducing erythrocyte aggregation by sterically 
neutralizing the formulation’s zeta potential (Ogris et al. 1999). 
However, when planning to develop specific cell targeting of e.g. tumor cells, it 
would be highly desirable to achieve separation of the colloidal carrier from its 
attached PEG chains during entrance into the target cell. Nanoparticles are typically 
internalized via phagocytosis. So, acidic pH sensitive separation within the 
endosome appears as promising potential mechanism. This concept led already to 
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highly increased gene transfections in gene therapeutic experiments with pH-
sensitive PEGylated PEI/DNA polyplexes (Walker et al. 2005). 
Performing the attachment of PEG onto the surface of colloidal carriers, it is 
essential to have detailed information on the total amount of PEG that has been 
successfully grafted (Veronese 2001; Moghimi & Szebeni 2003). Moreover, this 
information is also mandatory to prove the reproducible quality of commercial 
PEGylated products. Unfortunately, accurate analytical quantification of PEG is a 
quite crucial issue, since direct spectrophotometrical detection fails due to the 
molecular structure of PEG. Some quantification methods being described in 
literature that are based on colorimetric reactions with PEG (Childs 1975; Cole et 
al. 1983; Nag et al. 1996) are quite old, but due to the lack of alternatives still 
commonly used. Although, these methods feature only low accuracy and sensitivity 
and are quite susceptible to outside influences. A more recent detection method is 
direct refractive index detection of PEG in connection with previous separation 
(Philipsen et al. 1985) via e.g. HPLC or asymmetrical flow field-flow fractionation 
(AF4). 
1.2 Real-time biodistribution analysis of gelatin nanoparticles via 
positron emission tomography (PET) 
While investigating the fate of i.v. injected nanoparticles for their respective 
biodistribution profile, radiolabeling of the nanoparticle matrix with appropriate 
radioisotopes is still most favorable for a subsequent facile and reliable in vivo/ex 
vivo quantitative analysis. 
In order to derive non-invasive real-time analytical data of radiolabeled colloidal 
carriers, positron emission tomography (PET) currently represents the method of 
choice (Oku 1999). Other common imaging techniques are the use of γ-camera or 
single photon emission computed tomography (SPECT). These techniques detect 
γ-rays that are emitted by radionuclides. However, the resolution of PET is 
superior since it detects two 511 keV γ-rays in coincidence that are produced by 
annihilation after positron emission a respective radionuclide. Thus, PET has 
become a routine tool in modern nuclear medicine diagnostics. Radioisotopes that 
are typically utilized in PET diagnostics are those with short half-lives such as 
fluorine-18 (18F; T1/2=109.7 min), carbon-11 (11C; T1/2=20.4 min), nitrogen-13 (13N, 
T1/2=10 min), oxygen-15 (15O; T1/2=2 min), iodine-124 (124I; T1/2=100.8h) and 
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copper-64 (64Cu; T1/2=12.7h). The most relevant isotope at present is 18F. Similar to 
the others, it can be produced using small cyclotrons, so called ‘baby cyclotrons’. 
Compared to other positron emitting radioisotopes 18F shows almost ideal decay 
characteristics: 96% positron branching and with 0.63 MeV a low maximum 
positron energy allowing detection in high resolution.  
The 18F-labeled glucose analogue 2-deoxy-2-[18F]-fluoro-D-glucose ([18F]FDG) is 
currently one of the most often used radiopharmaceuticals being applied for tumor 
diagnosis worldwide (Fukuda et al. 1982; Brix et al. 2002). Due to the development 
of more and more tumor-specific peptides and antibodies, 18F-labeling of these 
amino-acid-based compounds for highly specific diagnostic applications is rising 
more and more interest (for overview see Varagnolo et al. 2000; Okarvi 2001). 
 However, direct nucleophilic incorporation of 18F fails due to the presence of 
acidic functionalities in those biomolecules and the necessity of harsh reaction 
conditions that occur during 18F-labeling experiments. Electrophilic 
radiofluorination is theoretically possible when residual tyrosine groups are 
available in the protein, but bad regioselectivity, the low specific activity (only 
available in carrier added (19F-added) form) and the low finally obtained radioactive 
yields (<50%, 18F-19F) rather question the applicability of this approach. 
Consequently, the use of prosthetic groups is necessary. Preferred conjugation 
reactions being described are labeling reactions via amino-reactive conjugates, 
sulfhydryl-reactive conjugates, carboxyl-reactive couplings or photochemical 
conjugation.  
When targeting sulfhydryl groups, common strategies are selective alkylation 
reactions with activated halides and maleimides. Well established examples of 
activated halides as prosthetic groups for 18F-labeling are α-halo ketones such as 
[18F]fluorophenacyl bromide and N-(4-[18F]fluorobenzyl)-2-bromoacetamide 
(Kilbourn et al. 1987; Kuhnast et al. 2002). They react with soft nucleophiles like 
sulfhydryl groups to corresponding α-keto thioethers. Maleimide-containing 
compounds such as N-(4-[18F]fluorophenyl)maleimide (Wuest 2005) react with 
sulfhydryl groups according to a Michael-reaction to give thioethers.  
N-terminal amines and ε-amino groups of lysine residues represent the most 
commonly targeted functional group for conjugation of 18F-containing groups to 
peptides and proteins. Photochemical conjugation reactions are performed with 
azides such as 4-Azidophenacyl-[18F]fluoride (Wester et al. 1996), which react via 
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highly reactive nitrene intermediates with the amino groups. However, these 
reactions are very unspecific. 
More often used conjugation reactions via prosthetic groups and residual amino 
groups are acylations, amidations, imidations, and oxim-forming reactions (for 
overview see Okarvi 2001; Wuest 2005). The most prominent reaction being 
applied is the formation of amide linkages. These fluoroacylation reactions can 
either be introduced via previously in-situ activated carboxylic groups that have 
been activated with carbodiimide agents such as the DCC (Wuest 2005). Other 
more prominent approaches induce direct aminolysis via 18F–labeled active esters. 
Table 1: Frequently used 18F-labeled active esters for peptide and protein labeling 
via acylation 
Prosthetic group References 
*F
O
O
N
O
O
 
N-Succinimidyl 4-[18F]fluorobenzoate ([18F]SFB)  
(Vaidyanathan & Zalutsky 1992; 
Vaidyanathan & Zalutsky 1994; Wester 
et al. 1996; Wuest et al. 2003) 
O
O
N
O
O*F  
N-Succinimidyl 4-[18F] (fluoromethyl)benzoate  (Lang & Eckelman 1994) 
*F
O
O
NO2
 
4-Nitrophenyl 2-[18F]fluoropropionate ([18F]NPFP) (Guhlke et al. 1994) 
*F
N
H
O
OO
N
O
O
 6
 
N-Succinimidyl-8-[4’-[18F]fluorobenzyl)-amino] suberate (Garg et al. 1991) 
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Table 1 gives an overview of the most relevant acylation agents (Okarvi 2001; 
Wester 2003; Wuest 2005). Each of these approaches comprises advantages and 
limitations. But summarizing all relevant aspects such as low number of synthesis 
steps, short preparation time, high radiochemical yield, and good in vivo stability, N-
Succinimidyl 4-[18F]fluorobenzoate (TSTU-mediated) ([18F]SFB) and 4-Nitrophenyl 
2-[18F]fluoropropionate appear to be suitable acylation agents for 18F protein and 
peptide labeling.  
The most attractive conjugation approach, chemoselective labeling via oxime 
ligation, comprises the use of 18F-benzaldehydes, since the achievable radioactive 
yield is high and the syntheses are very quick and simple (Poethko et al. 2004). The 
principle of this approach is that aldehydes react with high efficiency and 
chemoselectivity with previously aminooxy functionalized proteins, by forming 
stable oximes.  A similar approach has been developed for using radiolabeled 
aldehydes and hydrazides to form hydrazones (Bruus-Jensen et al. 2006). 
1.3 Aim of the study 
In the present study initial experiments were performed to build a fundament for a 
potential future application of gelatin nanoparticles as highly specific and multi-
functional carrier system for intravenous injection. A first focus was to establish 
PEGylation on the surface of the nanoparticles to shield them from the 
phagocytotic clearance via the MPS. Special care was taken on the development of 
new analytical tools for the monitoring of the PEGylation process. The second aim 
of the study was to develop a strategy for radiolabeling of plain and PEGylated 
gelatin nanoparticles to track their respective biodistribution in vivo. Thereby, a first 
goal was to investigate the biodistribution profile of standard 150-200 nm sized 
plain gelatin nanoparticles and subsequently to compare the biodistribution profiles 
of plain and PEGylated particles.   
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2.  MATERIALS AND METHODS 
2.1 Reagents 
Reagent Description Supplier 
Acetone p.a. VWR International GmbH  
(Ismaning, Germany) 
Cholaminechloride 
hydrochloride 
(2-aminoethyl)-trimethyl-
ammoniumchloride hydrochloride 
Sigma-Aldrich GmbH  
(Taufkirchen, Germany) 
EDC 1-ethyl-3-(3-dimethyl-aminopropyl) 
carbodiimide hydrochloride 
Sigma-Aldrich GmbH  
(Taufkirchen, Germany) 
Gelatin type A  175 Bloom Sigma-Aldrich GmbH  
(Taufkirchen, Germany) 
Glutaraldehyde  25% Sigma-Aldrich GmbH  
(Taufkirchen, Germany) 
HCl 1 N VWR International GmbH  
(Ismaning, Germany) 
MPEG-NH2 Methoxy-poly (ethylene glycol)amine
(Mw 5 kDa) 
Nektar (Huntsville, AL, USA) 
NaOH 1 N VWR International GmbH  
(Ismaning, Germany) 
2.2 Preparation of plain and PEGylated gelatin nanoparticles 
Plain gelatin nanoparticles were produced in reference to previously established 
optimized conditions (see Chapter I). For PEGylation, 50 µL of an aqueous 
nanoparticle dispersion (20 mg/mL) were incubated for 2 h under constant shaking 
(800 rpm; 25°C; Thermomixer comfort, Eppendorf AG, Hamburg, Germany) with 
various amounts of an MPEG-NH2 solution in 0.5 M borate buffer pH 8.4 (20 
mg/mL). Thereby, MPEG-NH2 reacts with residual aldehyde groups on the 
surface of the gelatin nanoparticles. After incubation the total volume was filled up 
to 1 mL with highly purified water to get a nanoparticle concentration of 1 mg/mL. 
Aliquots of this non-purified dispersion were now taken to assess the quantity of 
conjugated MPEG-NH2 by AF4. The remaining particles were purified by 3-fold 
centrifugation and redispersion. 
 Nanoparticles being used in the AFM experiments furthermore demanded a 
cationic surface charge to enable fixation on the anionic sample grid. The 
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cationization was performed according to the previously described method with the 
cationization agent cholamine (see Chapter II- 2.2). 
2.3 Quantitative monitoring of nanoparticle PEGylation by AF4 
AF4 measurements were performed in cooperation with my colleague Jan Zillies 
on an Eclipse2 AF4 system (Wyatt Technology, Santa Barbara, CA, USA). 
Autosampler, isocratic HPLC pump, degasser, UV-, and RI-detector were parts of 
the Agilent 1100 series (Agilent Technologies, Palo Alto, CA, USA). A 
fractionation-channel height of 350 µm and a regenerated cellulose ultrafiltration 
membrane (5 kDa cut-off; Nadir Filtration, Wiesbaden, Germany) were chosen as 
experimental settings as well as a phosphate buffer pH 7.0 (50 mM Phosphate 150 
mM NaCl) as mobile phase. The flow-rate at the channel-outlet was 1 mL/min. 
PEG was quantified via the AUC of the RI signal according to a PEG-standard 
calibration curve. The amount of covalently bound PEG was assessed via the 
detected amount of unbound PEG.  
2.4 Atomic force microscopy analysis of plain and PEGylated 
cationized gelatin nanoparticles 
Size and surface morphology of cationized plain and PEGylated gelatin 
nanoparticles were analyzed by atomic force microscopy (AFM) in cooperation 
with Christian Löbbe (JPK Instruments, Berlin, Germany). Therefore, we used a 
JPK NanoWizard™ Life science version (JPK Instruments) in intermittent contact 
(ic) mode with a so called super sharp silicon (SSS) cantilever (NanoWorld, 
Schaffhausen, Switzerland). These special cantilevers were chemically etched and 
end with a slim 200 nm long and 2 nm-radius tip. Used cantilevers had a spring 
constant of about 42 N/m measured. Measurements in water were utilized with 
softer cantilevers having spring constants of about 0.2 N/m (10-15 nm-radius tip). 
In both cases the cantilever was excited close to its resonance frequency (air: ~300 
kHz; water: ~12 kHz).   
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2.5 Synthesis of 4-Nitrophenyl 2-[18F]fluoropropionate 
([18F]NPFP) 
The synthesis of [18F] NPFP according to a previously described protocol (Wester 
et al. 1996) is well established as it is a routine labeling agent in our cooperation 
partner’s facility. Consequently, the respective agent was obtained as aliquots from 
large scale batches.  
2.6 Adopted synthesis of N-succinimidyl-[18F]fluorobenzoate 
([18F]SFB) 
The synthesis of [18F]SFB was performed according to the previously described 
protocol (Wester et al. 1996) of the improved synthesis using O-(N-succinimidyl)-
N-N,N’,N’-tetramethyluronium tetrafluoroborate (TSTU) as activating reagent. In 
cooperation with Dr. Norman Koglin (Nuclear medicine, TU Munich), the original 
protocol was further optimized resulting in the following procedure: 
[18F]Fluoride was produced via the 18O-(p,n)18F nuclear reaction by bombardment 
of isotopically enriched [18O] water target with a 11-MeV proton beam at the RDS-
112 cyclotron (Siemens/CTI, Munich, Germany).  
The resulting aqueous [18F]fluoride solution was separated from [18O]H2O using an 
anion exchange cartridge. After elution with ~200 µL 1 M potassium carbonate 
solution, the aqueous [18F]fluoride solution was transferred to a 2.5 mL conical vial 
containing 500 µL of anhydrous acetonitril and 10 mg Kryptofix 2.2.2 (Merck, 
Darmstadt, Germany). The solution was azeotropically dried with 3 x 300 µL 
acetonitrile portions in a stream of argon. 
11 mg of the triflate salt of ethyl p-trimethylammonium benzoate were dissolved in 
250 µL anhydrous dimethylsulfoxide. This solution was added to the dry cryptate 
(K+[2.2.2]/18F-). Subsequently, the reaction vessel was heated at 90°C for 5 min. 
Afterwards 0.5 mL of 0.3 M sodium hydroxide were added and stirred at 90°C for 
10 min hydrolyzing the ester. This reaction was stopped by acidification with 1 mL 
of 0.3 M HCl. The reaction vessel was rinsed twice with 0.03 M HCl. The obtained 
4-[18F]fluorobenzoic acid was fixed by passing the reaction mixture through a Sep-
Pak C18 cartridge. The product was eluted from the cartridge with 2 x 2 mL ether 
and collected in a new reaction vessel. The aqueous phase was discarded. The 
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remaining organic solution was treated with 50 µL 20% tetramethylammonium 
hydroxide. Afterwards, the solvent was evaporated under a stream of argon. Drying 
was repeated three times by addition and evaporation of acetonitrile. For activation 
a solution of 10 mg TSTU, dissolved in 400 µL acetonitrile was added and heated 
for 2 min at 90°C. Instant acidification was performed by addition of 2 mL 0.1% 
TFA/H2O. Subsequently, the solution was passed through a Sep-Pak C-18 
cartridge and the column was washed with 2 mL 20% acetonitrile/0.1% TFA/H2O 
and the activated ester eluted with 50% acetonitrile/0.1% TFA/H2O. The 
acetonitrile was evaporated by rotary evaporation.  
Preparative chromatography was performed using a LiChrosorb RP-18 select B 
column (7µm, 250 x 4 mm) at a flow rate of 5 mL/min and a gradient 20→50% 
acetonitrile/H2O over 20 min. The product peak was fractionated, diluted with 
10 mL H2O and fixed on a HR-P cartridge (Macherey-Nagel, Dueren, Germany). 
The cartridge was dried under a stream of argon and [18F]SFB was eluted with 
ether. 
N
+
O
OEt [K 2.2.2.]+,18F-
DMSO
*F
O
OEt
1. OH- *F
O
OH
N
O
O
O
N
+
N (TSTU) *F
O
O N
O
O
[18F] SFB
2. HCl
 
Fig. 1: Scheme of the preparation of [18F] SFB.  
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2.7 18F-Radiolabeling of gelatin nanoparticles with [18F]SFB/ 
[18F]NPFP  
[18F]SFB dissolved in ether was transferred to a reaction cap and the ether was 
removed in a stream of argon. 100 µL of a gelatin nanoparticles dispersion in 0.5 M 
borate buffer (pH 8.0, if not differently stated) were added to the residue. 
Furthermore, 20 µL of acetone were added. The mixture was incubated for 30 min 
at 37°C under constant shaking (800 rpm). Purification was performed by 3 times 
centrifugation and redispersion of the gelatin nanoparticles. After every 
centrifugation step, the supernatant was collected and measured in a Capintec CRC 
Dose Calibrator (Capintec Inc., Ramsey, NJ, USA) to determine unbound [18F] 
fluorobenzoic acid/SFB. Finally, the particles were dispersed in physiological PBS 
(pH 7.4). 
[18F]NPFP labeling was performed according to the same protocol. 
2.8 125I/123I labeling of gelatin nanoparticles 
Radioiodination was performed according to the standard protocol being described 
by Pierce Biotechnology Inc. (Rockford, IL, USA; www.piercenet.com) with slight 
modifications. Thereby, Iodogen (1,3,4,6-tetrachloro-3a,6a-diphenylglycouril) was 
dissolved in chloroform in a concentration of 1.5 mg/mL. 100 µL of this solution 
(corresponding to 150 µg Iodogen) were added to a 2 mL Eppendorf reaction cap 
(Eppendorf AG, Hamburg, Germany) Chloroform was evaporated under gentle 
heating in a water bath and constant rotation. Thus, water-insoluble Iodogen was 
plated onto the inner surface of the cap. The Iodogen coated caps were stored at  
-20°C until usage. Gelatin nanoparticles dispersed in PBS pH 7.4 were added to the 
Iodogen coated reaction vessel. Subsequently, 10-20 µL radioiodide solution in 0.05 
N NaOH (125I: Hartmann Analytic, Braunschweig, Germany; 123I: GE/Amersham 
Health, Eindhoven, The Netherlands) were added. This mixture was incubated at 
ambient temperature under slight shaking. After 30 min, an aliquot sample was 
taken to quantify the percentage of successful 125I or 123I conjugation via thin layer 
chromatography (TLC). TLC was performed using silica gel 60 F254 TLC plates 
from Merck (Darmstadt, Germany). To separate free iodine from that being linked 
onto the nanoparticle a mixture of acetone, butanol, amonia, and water (65:20:10:5) 
was chosen as mobile phase. The resulting radioactive spots on the TLC plate were 
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quantified by an automatic TLC analyzer, Tracemaster 20 (Berthold, Wildbad, 
Germany). 
 
Fig. 2: Mechanism of radioiodide incorporation into proteins; a) formation of the 
reactive mixed halogen species by Iodogen; b) Iodination of tyrosine (to a lower 
extent also histidine and tryptophan) resulting in a mixture of monoiodinated and rare 
diiodinated tyrosyl moieties. 
2.9 Biodistribution experiments 
For biodistribution studies the radiolabeled gelatin nanoparticles dispersed in PBS 
7.4 were injected into the tail vein of Balb/c mice. Concentrations were adjusted to 
injection doses of 100µL containing nanoparticles labeled with 50 µCi radioactivity. 
During injection, the mice were slightly anesthetized via inhalation of ether. At 
selected time points after injection, organs of interest were dissected. The 
radioactivity was measured in weighted tissue samples using a γ-counter (1480 
Wizard3 gamma counter from Wallac, Turku, Finland). Results are expressed as the 
percentage injected dose per gram (%ID/g) (mean ± s.d., 3–5 animals per group) if 
not stated otherwise. 
2.10 PET imaging  
For PET imaging, respective amounts of 18F-labeled gelatin nanoparticles were 
dispersed in PBS 7.4. Similar to the biodistribution studies, the dispersions were 
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adjusted to injection doses of 100µL containing 50 µCi radioactivity. These doses 
were injected intravenously into the tail vein of white Balb/c mice that were 
anesthetized using a combination of xylazine and ketamine. Dynamic PET images 
(10-60 min after injection) of the anesthetized mice were acquired using a Philips 
MOSAIC small animal PET scanner (Philips, Hamburg, Germany).  
2.11 γ-camera imaging  
123I-labeled nanoparticles were dispersed in PBS 7.4 and adjusted to injection doses 
of 100µL containing 80-140 µCi. During injection, mice were slightly anesthetized 
with inhalation of ether. Mice were sacrificed 15 min p.i.. For acquisition of γ-
camera images mice were directly positioned on one medium energy general 
purpose collimator of a dual-headed γ-camera (Skylight, ADAC/Philips, Hamburg, 
Germany). Data acquisition was performed for 20 min. 
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3. RESULTS AND DISCUSSION 
3.1 PEGylation of gelatin nanoparticles 
3.1.1 Quantitative analysis of the PEGylation properties of gelatin 
nanoparticles via AF4 
As mentioned, PEGylation is currently a very popular method to prolong the blood 
circulation time of biomolecules or colloidal carrier systems by shielding them from 
detection by the MPS. In order to achieve pH-sensitive linkage of PEG, we chose 
MPEG-NH2 as PEGylation agent to give imines with available aldehyde groups on 
the nanoparticle surface that could be attributed to only monofunctionally bound 
glutaraldehyde. Resulting imine bonds are pH-sensitive and hydrolyze under acidic 
pH conditions. To quantify the amount of MPEG-NH2 that was finally grafted 
onto the nanoparticles, our idea was to detect the amount of free, unbound PEG 
directly with the present AF4 setup.  
The complete development and validation of the analytical method was performed 
by Jan Zillies. Data concerning these issues will be published in his thesis (Zillies 
2007).  
According to its molecular properties, the PEG signal is only detected as peak in 
the RI detector, whereas the gelatin nanoparticles appear as stronger signal within 
the UV-detector. However, gelatin nanoparticles induce also a certain RI signal. 
Consequently, particle separation from PEG as realized with the AF4 system was 
mandatory to avoid any disturbance of the PEG signal.  
Aside from the PEG quantification, it was a further goal of our analytical approach 
to determine a certain saturation-threshold dose of PEG when the nanoparticles 
are completely loaded with MPEG-NH2. Therefore, 1 mg of gelatin nanoparticles 
were incubated with increasing amounts of MPEG-NH2, ranging from 31.25 µg up 
to 1 mg MPEG-NH2.  
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Fig. 3: Exemplary fractograms of two different MPEG-NH2 concentrations (1 mg/mL: 
black; 0.25 mg/mL: grey) before and after the incubation with gelatin nanoparticles. 
Solid lines represent the fractograms before and dotted lines those after incubation. 
Analyzing the AUCs of MPEG-NH2 before and after incubation with 1 mg 
nanoparticles (Fig. 3), a certain dose dependent saturation became visible. A 
significant peak of unbound PEG could be detected when administering 1mg PEG 
per mg nanoparticles, whereas only a low signal could be detected when 0.25 mg 
PEG was administered. The amount of bound PEG was calculated by the 
following equation:  
00 )( mAUCAUCm XX ×−=  
mX = mass of MPEG-NH2 being loaded onto the nanoparticles 
m0 = initially administered mass of MPEG-NH2 
AUCX  = AUC of the RI signal being detected for the amount of residual 
free of MPEG-NH2 after incubation  
AUC0 = AUC of the RI signal being detected for the amount m0 of MPEG-
NH2 before incubation 
The so calculated values of the various amounts of PEG bound per mg 
nanoparticles are plotted versus their pertaining originally administered amounts 
per mg nanoparticles in Fig. 4. Analyzing this diagram, ~350 µg MPEG-NH2 could 
be identified as the maximum dose that could be covalently linked onto the surface 
of 1 mg gelatin nanoparticles. This complete loading can be achieved with the 
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utilized incubation settings of 1 mg gelatin nanoparticles in 50 µL highly purified 
water being incubated over 2 h with ~0.8 mg MPEG-NH2 in 50 µL 0.5 M borate 
buffer pH 8.4.  
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Fig. 4: Amount of MPEG-NH2 being loaded onto 1 mg nanoparticles in dependency 
of the originally offered amount of MPEG-NH2.  
In a final experiment we wanted to scrutinize the impact of the applied pH 
conditions during the incubation process. Successful linking was performed in 
0.5 M borate buffer pH 8.4, since alkaline conditions are beneficial for the reaction 
of aldehyde groups with primary amino groups. Hence, changing the pH towards 
acidic conditions should have negative impact on the reaction yield. Comparing the 
chromatograms of 1 mg PEG that has been incubated with 1mg nanoparticles in 
an acidic aqueous solution (pH 3.0) versus 1 mg PEG standard, both peaks were 
almost identical (data not shown). Thus, we could demonstrate that no conjugation 
occurs under these unfavorable acidic reaction conditions. Moreover, this 
experiment represents a successfully coped negative control, to prove the accuracy 
of the new established analytical method.  
For further detailed information on the performed experiments, see Jan Zillies’ 
dissertation (Zillies 2007).  
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3.1.2 Visual comparison of the surface morphology of plain and PEGylated 
gelatin nanoparticles by AFM 
Searching for other modes to characterize the nanoparticles we investigated AFM 
as an interesting method, since it is obviously dedicated for the analysis of various 
surfaces due to its measurement principle. Summarizing the microscopic 
visualization techniques it is the method of choice for the analysis of surface 
morphologies, since it allows the highest resolution.  Other groups have already 
demonstrated this as they were even able to visualize the helical structure of DNA 
(Ravi Kumar, V et al. 2004; Bakowsky 2005) via AFM. Prior measurement, the 
nanoparticles were fixed on the sample grid by electrostatic interactions. Since the 
sample grid had a negatively charged coating, the nanoparticles had to be cationized 
to ensure sufficient fixation. Certainly, it has to be mentioned that the measured 
nanoparticles were not identical to those that were analyzed via AF4 and applied in 
later in vivo biodistribution experiments. But it was supposed that this modification 
with cholamine, a low molecular weight substance (Mw 175.10 Da) should not 
have crucial impact on the particle’s morphology. Otherwise, this is a good example 
that both modifications can be performed on one nanoparticle batch. Dynamic 
light scattering (DLS) revealed that neither cationization or PEGylation nor 
cationization and PEGylation led to changes in particle homogeneity. All batches 
still had polydispersity indices below 0.1 (Table 2). 
Table 2: DLS size determination data of the applied nanoparticle batches; ZWAFM: 
plain nanoparticles; ZWAFM-PEG: PEGylated batch ZWAFM 
 plain nanoparticles cationized nanoparticles 
 size (nm) PI size (nm) PI 
ZWAFM 179.7 0.041 180.4 0.064 
ZWAFM-PEG 185.2 0.072 184.5 0.097 
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The images derived from AFM analysis of the cationized versions of ZWAFM and 
ZWAFM-PEG are depicted below (Fig. 5): 
 
 
    
Fig. 5: AFM analysis of plain (A1-A3) and PEGylated (B1-B3) gelatin nanoparticles; 
A/B 1: error channel image; A/B 2: height channel image; A/B 3: cross section of the 
height image (see black lines) 
Overview images being employed in the amplitude mode demonstrated the good 
homogeneity of the applied samples (Fig. 5-A/B1). No significant differences 
between both batches could be noticed. So, previous SEM data, where those 
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gelatin nanoparticles were assessed as homogeneous smooth spheres were 
substantiated (see Chapter I – 3.1). But analyzing height images, PEGylated 
nanoparticles seemed to possess a more indifferent surface (Fig. 5-A/B2). 
Observing the respective cross sections of these height images finally revealed 
more detailed information (Fig. 5-A/B3). Contrary to the smooth surface of plain 
gelatin nanoparticles, PEGylated nanoparticles featured a cragged surface when 
analyzing their height profile in highly purified water, which obviously indicates the 
presence of PEG-chains on the nanoparticles’ surface. 
3.1.3 Summary 
Present data indicate that PEGylation of gelatin nanoparticles with MPEG-NH2 is 
possible. Thus, the residual amino group of MPEG reacts with free aldehyde 
groups on the nanoparticle surface by forming an imine. Quantitative analysis via 
AF4 demonstrated that up to ~0.35 mg PEG can be attached onto the surface of 
1 mg nanoparticles in dependency of the amount of MPEG-NH2 being offered. 
The absence of successful conjugation while performing the incubation of gelatin 
nanoparticles and MPEG-NH2 under acidic aqueous conditions leads to the 
conclusion that the conjugation is mainly based on the covalent linkage as imine, 
since this reaction is suppressed under acidic conditions.  
AFM as second analytical tool finally completed the set of data and demonstrated 
its strength by visualizing the presence of PEG chains on the nanoparticles’ 
surface. Especially the combination of both techniques appears to be ideal to track 
the PEGylation of colloidal carrier systems, even more due to the certain lack of 
other appropriate techniques.  
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3.2 Biodistribution experiments with radiolabeled gelatin 
nanoparticles 
3.2.1 Evaluation of the applicability of prosthetic groups for radioactive 18F 
labeling of gelatin nanoparticles 
The necessity of prosthetic groups for 18F labeling of proteinaceous material has 
already been discussed. Searching for the ideal radiofluorination agent, the use of 
18F-benzaldehydes appeared very attractive, because of their fast synthesis and high 
radioactive yield. However, this process could not be applied for gelatin 
nanoparticles due to the necessary conjugation conditions, since gelatin 
nanoparticles contain free aldehyde groups according to only monofunctionally 
bound crosslinking-agent glutaraldehyde. Thus, additional aminooxy 
functionalization of the nanoparticles would induce immediate aggregation. 
Moreover, it was refrained from labeling sulfhydryl groups on the nanoparticle 
surface since none are present in the primary sequence of gelatin. Thus, previous 
introduction would have been necessary. Considering these facts and summarizing 
the pros and cons of the remaining amino-reactive prosthetic groups, it was 
decided that [18F]SFB (TSTU-mediated) and [18F]NPFP seem to be the most 
promising radiolabeling agents worth to be further investigated. To find the most 
efficient agent for gelatin nanoparticle radiolabeling, we tested the potential of both 
in parallel. Therefore, 100 µL of gelatin nanoparticle dispersion were applied (conc. 
29 mg/mL). Dynamic light scattering analysis resulted with an averaging mean size 
of 180.4 nm and 0.053 as corresponding polydispersity index for the chosen plain 
nanoparticle batch ZW1F18. Aliquots of this batch were incubated with low dose 
amounts of the respective 18F prosthetic groups (~100 µCi: [18F]SFB; ~180 µCi: 
[18F]NPFP). Fig. 6 shows the radiochemical yields (RCYs) that were achieved when 
labeling the described gelatin nanoparticles with both radioactive acylation agents at 
various pH conditions.   
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Fig. 6: Comparative study of radiolabeling efficiency of [18F]NPFP and [18F]SFB to 
evaluate their potential as 18F-labeling agents for gelatin nanoparticles at various pH 
conditions. 
The resulting RCYs of successfully labeled gelatin nanoparticles differed 
remarkably between both radioacylation agents. Whereas only 12-13% RCY could 
be achieved for labeling with [18F]NPFP, [18F]SFB was more efficiently linked onto 
the nanoparticles (40.7-46.5% RCY) and able to exceed [18F]NPFP by far. 
Moreover, the RCY was improved when using 0.5 M borate buffer at pH 8.0 and 
8.4 (45.5-46.5% RCY) instead of pH 7.6 (40.7% RCY) as conjugation medium. 
Performing size determination of the respective [18F]SFB-labeled nanoparticle 
samples (batch ZW1F18), no significant changes could be detected (Fig. 7).  
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Fig. 7: Dynamic light scattering control experiments of [18F]SFB-labeled gelatin 
nanoparticles being conjugated at various pH conditions. 
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According to these results, it was decided that [18F]SFB was the prosthetic group of 
choice for 18F-labeling of gelatin nanoparticles in high radiochemical yields. The 
second parameter we examined was the influence of the offered amount of gelatin 
nanoparticles on the achievable RCYs. Fig. 8 indicates that 18F conjugation yields of 
up to 50% can be achieved with increasing amounts of gelatin nanoparticles. 
Thereby, the underlying correlation of both parameters can be very well described 
with a logarithmical fit. Changes of the initially utilized 18F- respectively [18F]SFB-
dose did not influence this phenomenon. Thus, optimum yield was achieved above 
a concentration of 3 mg nanoparticles in 100 µL 0.5 M borate buffer (→ 
conc.=30 mg/mL). 
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Fig. 8: RCY in dependence of the offered amount of gelatin nanoparticles; 
conjugation buffer: (0.5 M borate buffer pH 8.0) 
3.2.2 Biodistribution experiments with 18F-labeled gelatin nanoparticles 
Since it was demonstrated that gelatin nanoparticles can successfully be labeled 
with [18F]SFB produced in the established small scale setup, first in vivo 
biodistribution experiments could be initiated. In this study, 2 mg 18F-labeled 
gelatin nanoparticles being dispersed in 100 µL PBS 7.4 were injected to 2 groups 
of mice containing 4 individuals each. The injected radioactive dose was ~50 µCi 
per animal. The first group was sacrificed after 30 min and the other after 60 min. 
Subsequently the biodistribution of the nanoparticles was assessed by detection of 
the accumulated radioactivity in various organs. Additionally, the biodistribution 
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was tracked online via a dynamic PET scan of one mouse (Fig. 9). Early PET 
images after 10 min revealed that the nanoparticles accumulated very quickly in 
lung and liver. This distribution pattern remained constant over 60 min. Solely 
certain radioactivity became visible in the bladder with increasing time, which might 
indicate cleavage of the radioactive agent and/or initial degradation of the 
nanoparticles. The signal in the tail region of the mouse referred to particles that 
remained at the site of injection. 
 
Fig. 9: PET images after 1-10 min (A), 21-30 min (B), and 51-60 min (C) after 
injection of 2 mg nanoparticles.  
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The quantification of the biodistribution substantiated these observations very well 
(Fig. 10). The highest concentration of radioactivity (depicted as %ID/g) was 
determined in the lungs. In addition, edema could be observed in the lung tissue of 
some mice when dissecting their organs after sacrificing. Consequently, this strong 
lung accumulation had to be attributed to the occurrence of thromboses in the lung 
capillaries which are caused by the high amount (2 mg) and concentration (20 
mg/mL) of nanoparticles that was injected.  
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Fig. 10: Biodistribution of gelatin nanoparticles in mice after injection into the tail vein 
(n=4); radioactivity concentrations are given as percent of the injected radioactive 
dose per gram tissue (%ID/g). 
However, in the small ‘lab-scale’ [18F]SFB , the radioactivity that could be linked 
onto the nanoparticles was too low for the administration of less concentrated 
nanoparticle dispersions. Therefore, upscaling from the present setup was 
necessary to obtain [18F]SFB with higher radioactivity. Simultaneously, this required 
also a higher initial radioactivity of 18F at the start of the synthesis (~ 100 mCi). 
Due to safety reasons these syntheses could no longer be manually prepared in the 
lab. Thus, the [18F]SFB synthesis had to be transferred for a large-scale setup into a 
radiation shielded hot-cell. Although scale up was carried out successfully 
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concerning the obtained [18F]SFB yield and subsequent conjugation, the resulting 
18F-labeled nanoparticles tended towards strong aggregation, thus could not be 
applied for animal experiments. Searching for reasons, the used nanoparticle batch 
(ZW1F18) could be excluded as originating factor, since no aggregation occurred 
when performing control experiments with Texas Red-X™ succinimidylester 
instead of [18F]SFB. These control-experiments were performed following the 
identical procedure as that for [18F]SFB labeling. But also the [18F]SFB could be 
almost excluded, since the molar amount administered was not significantly 
increased in comparison to the previous low scale experiments. Finally, we 
discovered the presence of an impurity peak with variable intensity in the UV-signal 
which is co-eluted at similar retention time as [18F]SFB in the preparative HPLC 
purification step. Unfortunately, the origin of this impurity could not be located so 
far and is still under investigation.  
3.2.3 Biodistribution experiments with 123I/125I-labeled gelatin nanoparticles 
While we were searching for reasons that caused the nanoparticle aggregation 
during labeling with [18F]SFB derived from large scale production, we considered 
radioiodination of the gelatin nanoparticles as an alternative strategy, since it is a 
well established method for proteins and peptides. Furthermore, 125I had been used 
in recently published biodistribution experiments with nanoparticles based on a 
gelatin-PEG co-polymer (Kaul & Amiji 2004). In order to evaluate the applicability 
of this approach, we performed initial experiments with iodine isotope 123I due to 
its shorter radioactive half-life (13h) in comparison to commonly used 125I (T1/2= 
60 d) and the possibility to image the in vivo distribution via planar γ- or SPECT-
Imaging. Furthermore, after a 6d decay period of the 123I-iodine label, the 
nanoparticles could be analyzed without considerations by DLS for changes 
concerning their average mean sizes. Moreover, we now compared for the first 
time plain with PEGylated gelatin nanoparticles. The PEGylated nanoparticles that 
were used in this experiment were prepared according to the previously described 
method, incubating 1 mg MPEG-NH2 with 1 mg plain gelatin nanoparticles in 
0.5 M borate buffer pH 8.4 to achieve a complete saturation of the free aldehyde 
groups on the nanoparticle surface. 
With respect to labeling efficiency, TLC analysis demonstrated that 123I was almost 
completely introduced into the accessible tyrosyl groups of plain and PEGylated 
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gelatin nanoparticles within 30 min (Fig. 11). No relevant amounts of free 123I could 
be measured for both, plain and PEGylated gelatin nanoparticles.  
 
Fig. 11: Quality control of 123I-labeled nanoparticles via TLC after 30 min of 
incubation; A: [123I]iodide control without nanoparticles; B: [123I]iodide reacted with 
plain nanoparticles; C: [123I]iodide reacted with PEGylated nanoparticles 
Consequently, it could be refrained from further nanoparticle purification and 
nanoparticles were only diluted with PBS 7.4, to a concentration of 1 mg/mL. 
Finally, formulations of 100 ng (corresponding to 100 µL of 1 mg/mL 
nanoparticles) were injected into the tail vein of one mouse each. 
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Fig. 12: Rough estimation of biodistribution pattern of plain and PEGylated 123I-
labeled nanoparticles; injected dose of nanoparticles: 100 ng in 100 µL PBS 7.4; time 
point of sacrification: 30 min. A: γ-camera scan; mouse a: PEGylated nanoparticles; 
mouse b: plain nanoparticles. B: Semi-quantitative analysis of the accumulated 
radioactive dose (%ID/g) in the major organs of these two mice as measured by a γ-
counter.  
The obtained data are only based on single shots and consequently without any 
statistical significance. Even though, the strong accumulation within the lung tissue 
did not occur in both mice. In addition, no edemas caused by thromboses were 
observed with this 20-fold reduced dose when dissecting the lung tissue of both 
mice. Concurrently, it could be seen that γ-camera imaging enables only visual 
distribution data of limited precision and accuracy in comparison to PET (Fig. 
12A). Again, the signal in the tail region of the mouse being treated with 
PEGylated nanoparticles referred to particles that remained at the site of injection. 
Slight radioactivity within the thyroid gland region occurs due to free 123I formed by 
in vivo-deiodination. Measuring size and homogeneity of particles in previously 
taken aliquots of the 123I-labeled nanoparticles after their radioactive decay 
demonstrate no significant changes when compared to the original nanoparticles 
(data not shown). 
In the final experiment of the present study, we investigated the biodistribution of 
125I-labeled nanoparticles over 15 and 60 min after injection. Again, both types of 
nanoparticles, plain and PEGylated were administered to two groups of mice (6 
mice each). In analogy to the previous 123I experiment, also 125I was completely 
incorporated into the nanoparticles as monitored with TLC (data not shown), so 
B 
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that no further purification of the nanoparticles was necessary to separate them 
from free iodide. This time we conjugated higher amounts of radioactive iodide 
with the nanoparticles than in the first experiment. Consequently we were able to 
administer again a lowered nanoparticle concentration of only 20 ng nanoparticles 
per mouse which was only 1% of the originally administered dose in the [18F]SFB-
study that had caused the thromboses. Screening the biodistribution of both 
batches, the accumulation within the lung was now even more reduced, thus no 
obstruction of the lung capillaries was detected. Liver and spleen, two characteristic 
tissues of the MPS were the organs containing the highest concentrations of 
radioactively labeled nanoparticles (Fig. 13). Calculating the absolute amount of 
recovered radioactivity of the originally injected dose, the liver was identified as the 
predominant site that contains nanoparticles with ~50% of the originally injected 
radioactive nanoparticles. This observation was made for both, PEGylated and 
plain gelatin nanoparticles.  
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Fig. 13: Biodistribution of plain and PEGylated gelatin nanoparticles in mice after 
injection into the tail vein; radioactivity concentrations are given as percent of the 
injected radioactive dose per g (%ID/g). A: Biodistribution after 15 min; B: 
Biodistribution after 60 min.  
A first observation made was that the radioactive dose within liver and spleen was 
significantly reduced after 60 min (Fig. 13B) in comparison to 15 min (Fig. 13A). 
Furthermore, significant radioactivity could be detected within samples of the urine 
after 60 min. Obviously, the MPS already begins to degrade the nanoparticles at 
this time point. Similar findings were made when analyzing the data that were 
obtained with 100-fold more concentrated [18F]SFB-labeled nanoparticles, but less 
pronounced (see 3.3.2). One reason for the distinct appearance of this 
phenomenon is the lower administered dose of nanoparticles, since it is most likely 
that degradation activity underlies zero-order-kinetics due to saturation of the 
respective degradation enzymes. 
The second conclusion that can be drawn from these data is that the goal of 
prolonged blood circulation of PEGylated gelatin nanoparticles was not achieved 
with the present setup. Possible reasons might be that the length of the grafted 
PEG-chains (Mw. 5 kDa) was not appropriate, since literature suggests using PEG 
chains of higher molecular weights to achieve prolonged blood circulation. 
However, prolonged circulation effect was observed by other researcher’s when 
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preparing nanoparticles based on gelatin-PEG co-polymer containing a 5 kDa PEG 
(Kaul & Amiji 2004).  
Another aspect might be that the linkage of MPEG-NH2 with free aldehyde groups 
represents only a reversible balance reaction, since the imine function is easily 
hydrolyzed under acidic conditions. If this is the case, PEG needs to be linked onto 
the nanoparticles in a more stable way. One possible approach would be to add 
cyanoborohydride (NaCNBH3) during the condensation reaction. NaCNBH3 
induces the reduction of the imine giving a stable amine bond. But the use of this 
approach is due to the high toxicity of NaCNBH3 questionable. Other approaches 
of MPEG-NH2 linkage would be direct conjugation with previously activated 
carboxyl groups, or the utilization of different functional groups. However, both 
approaches do not allow quick cleavage of the nanoparticles when entering the cell, 
which was the original idea behind the present approach. The applicability of the 
highly promising technique to introduce pH-triggered linkage via acylhydrazides or 
pyridylhydrazines (Walker et al. 2005) appears also questionable for gelatin 
nanoparticles due to the complex synthesis that might facilitate particle-aggregation. 
Another interesting approach might be the linkage via reducible disulfide bonds 
that would be cleaved within the reductive intracellular milieu of the target cell. 
Therefore, introduction of sulfhydryl groups onto the gelatin nanoparticles is 
necessary. Respective methods using cysteine or cystaminiumdichloride have been 
described in literature (Coester 2000; Weber et al. 2000). 
3.2.4 Summary  
It has been demonstrated in the present study that gelatin nanoparticles can be 
linked with 18F prosthetic groups or radioactive iodide to enable the study of their 
in vivo biodistribution noninvasively by PET or SPECT. Moreover, [18F]SFB could 
be characterized as a promising prosthetic group for this purpose. Small-scale 
synthesis and labeling reaction for gelatin nanoparticles were established. However, 
the initial radioactivity at the start of the synthesis that can be utilized in the small-
scale setup was too low to allow the application of appropriate nanoparticle 
concentrations that do not cause thromboses in the lung capillaries. Preparation of 
‘large-scale’ [18F]SFB-conjugated nanoparticles failed so far due to nanoparticle 
aggregation. Although the exact reason could not be identified yet, the effect is 
most likely induced by the introduction of impurities during [18F]SFB synthesis. 
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Thus, radioactive iodine isotopes which are well established for radioactive protein 
and peptide labeling were chosen as alternative radiolabeling agent for gelatin 
nanoparticles. Both, plain and PEGylated gelatin nanoparticles could be almost 
quantitatively labeled with 123I/125I, so high amounts of radioactivity could be 
introduced to the gelatin nanoparticles. This higher radioactivity introduced 
allowed to lower the concentration that was injected to the tail vein of mice by two 
orders of magnitude. Consequently, quick accumulation of the nanoparticles in the 
main organs of the MPS could be already observed after 15 min. PEGylated 
nanoparticles were unable to improve the blood circulation time. Reasons might be 
in vivo instability of the PEG-linkage via an imine bond, or too low molecular 
weight of the applied PEG chains. Consequently, different approaches such as 
reducible disulfide linkage and different sized PEG chains should be evaluated in 
future. Furthermore, the impact of the applied particle size should be studied. 
Finally, surfactant coating with e.g. polysorbate, in analogy to the findings with 
solid lipid nanoparticles (Zillies et al. 2005) and poly (butyl 2-cyanoacrylate) 
nanoparticles (Douglas et al. 1986; Kreuter et al. 1995) should be evaluated as 
alternative strategy to change the opsonization profile of gelatin nanoparticles.  
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4. CONCLUSION 
This chapter gives another outlook on possible future projects with gelatin 
nanoparticles.  
Aside from successful PEGylation experiments, special attention was paid to the 
development of innovative and precise analytical tools for the assessment of the 
quality and quantity of PEG chains grafted onto the nanoparticles. Thereby, AF4 
and AFM were demonstrated as complementing instruments for the quantification 
and visualization of successful linkage. The obtained results are of high quality and 
suggest transferring both methods as state-of-the-art for various other colloidal 
systems as the number of existing techniques is rather limited.  
As second focus, radioactive labeling of gelatin nanoparticles was performed to 
enable the analysis of their biodistribution. Moreover, 18F labeling was established, 
which allows real-time tracking of the nanoparticles’ biodistribution by PET. 
Thereby, [18F]SFB could be identified as a prosthetic group for 18F labeling. Initial 
biodistribution revealed that plain gelatin nanoparticles behave like most other non-
modified nanoparticles and are quickly cleared from the blood stream by the MPS. 
The first PEGylation approach grafting a 5 kDa PEG-chains via a pH-sensitive and 
reversible imine bonds onto the surface of gelatin nanoparticles did not succeed in 
prolonged blood circulation in comparison to plain gelatin nanoparticles.  
Nevertheless, the analytical setup is prepared for further investigations. The next 
steps should include the evaluation of various nanoparticle batches with various 
surface modifications concerning their circulation in the blood stream. In addition 
to this, targeting ligands for e.g. cancer cells should be attached onto the particle 
surface, thus resulting in a new application of gelatin nanoparticles as highly 
specific colloidal delivery system or diagnostic tracer.  
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Final summary and conclusions of this thesis 
The present work highlights the potential of gelatin nanoparticles as delivery 
system for nucleotide-based drugs.  
Detailed analysis of the original manufacturing process and exact characterization 
of the effect of process parameters on the later nanoparticle quality, as described in 
Chapter I, allowed significant improvement of the two-step desolvation technique. 
Now it is possible to prepare standardized homogeneous colloidal spheres in a 
range between 100 and 300 nm with excellent reproducibility. Another essential 
result was the analytical determination of the optimum molecular weight 
constitution of the gelatin raw material to prepare homogeneous and stable 
nanoparticles. Our partners at Gelita AG prepared specific gelatin batches that 
allow to refrain from the first fractionating desolvation step in the preparation 
procedure. Now, stable gelatin nanoparticles can be directly generated by a simple 
single desolvation process.  
In Chapter II, surface modification strategies were investigated to enable the 
electrostatic loading of nucleotide-based drugs onto the nanoparticle surface. 
Among the various tested modification agents, cholamine, containing a terminal 
quaternary amino group that induces a pH independent cationic charge on the 
nanoparticle surface, was selected as the most promising one for further 
investigations. The first application examined in vitro, was the use as gene delivery 
system. In this study it could be demonstrated that cationized gelatin nanoparticles 
are able to successfully transfect murine melanoma cells. However, transfection 
occurred with a little delay and achieved results were unable to top the efficiency of 
the current ‘gold standard’ PEI-polyplexes. But, gelatin nanoparticles were also 
shown to be a biocompatible carrier, as they did not induce significant cytotoxicity 
in contrast to other non-viral delivery systems. Consequently, this simple approach 
promises high potential.  
The most auspicious and advanced results were obtained with immunogenic CpG 
ODNs (Chapter III and Chapter IV). In these studies, short single-stranded 
ODNs were attached onto the surface of cholamine-modified gelatin nanoparticles. 
During first in vitro experiments with murine myeloid dendritic cells (MDCs), 
phagocytotic uptake and enhanced induction of TH1/CTL-polarizing cytokines in 
comparison to soluble CpG ODNs could be observed. Comparing the activation 
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kinetics of particulate bound CpG ODN with soluble CpG ODN, no delay could 
be observed. Hence, CpG interacts most likely with the receptor when still being 
attached onto the nanoparticle surface. Admittedly, those experiments with murine 
MDCs can only be seen as model setup because TLR9, the specific receptor for 
CpG motifs is not present in this cell-type in humans. Thus, the setup was 
successfully transferred to primary human B cells and plasmacytoid dendritic cells 
(PDCs), the two cell-types that have exclusively expressed TLR9 in humans and 
non-human primates.  
For humans three different classes of CpG ODNs (CpG-A – CpG-C) exist. In vitro 
experiments on PDCs and B cells with all three ODN types being loaded onto 
gelatin nanoparticles led to novel insights on the different activation prerequisites 
of both CpG-ODN-sensitive cell-types. Particulate presentation of CpG motifs is 
rather counterproductive for the activation of B cells. In PDCs, activation 
conditions were found to be completely contrary to B cells. They are stimulated 
best by particulate CpG ODN presentation. Hence, optimized nanoparticulate 
presentation led to strongly enhanced induction of CpG-C. Even CpG-B, which 
does not activate PDCs in soluble form, was now able to induce slightly more IFN-
α than the original ‘gold standard’, soluble CpG-A. Furthermore, it was proven that 
the high efficiency of CpG-A has to be attributed to the fact that the sequence of 
CpG-A facilitates the formation of colloidal particulate aggregates in physiological 
media. 
Due to the success in vitro, CpG formulations were then transferred to in vivo trials 
in mice (Chapter IV). In first characterization studies, comparing the subcutaneous 
and intravenous administration route, it could be observed that only i.v. 
administration of CpG-GNPs induces systemic immune activation, whereas soluble 
CpG ODN is active after both types of injection. The explanation is that 
particulate bound CpG ODN basically remained at the site of administration after 
s.c. injection. Solely a few nanoparticles could be detected in the draining lymph 
nodes that were closest to the site of injection.  
However, for an application as adjuvant for vaccines, the absence of unspecific 
systemic immunoactivation is highly advantageous, because the systemic effect of 
soluble CpG ODNs potentially is a source of immunological side effects.  
While performing immunization experiments with the model antigen ovalbumin 
(OVA) and CpG ODN-loaded gelatin nanoparticles as additional adjuvant, this 
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local restriction of the immunological effect turned out to be sufficient to achieve 
enhanced immunization. The obtained specific IgG titers were comparable and the 
activation of specific CD8+ cells was significantly better than that achieved with 
soluble CpG ODN as adjuvant, which is currently investigated in various clinical 
trials. Thus, these preclinical data suggest the development of CpG ODN-loaded 
gelatin nanoparticles towards clinical trials as new adjuvant for vaccine 
formulations. Due to it’s TH1/CTL specificy, this new formulation might be ideal 
for anti-viral and anti-tumoral antigens, a field where standard adjuvant alum has its 
weaknesses. 
Finally, it was demonstrated that the immunological activity of OVA remains 
identical with soluble OVA, when adsorbed onto the surface of cationized gelatin 
nanoparticles or incorporated into the matrix of plain nanoparticles. These might 
be potential options when particulate delivery and presentation of an antigen 
peptide is advantageous.  
 
Summarizing the applications presented in this work, gelatin nanoparticles are a 
versatile carrier that can be used for both, transfection with large double-stranded 
pDNAs as well as for short single-stranded ODNs. However, the optimum 
payloads of both applications differ remarkably. Whereas best gene transfections 
were obtained with 0.5% (w/w) payload, best activation of the immune system 
were achieved with 5-10% (w/w) CpG ODN loaded onto nanoparticles, a payload 
where pDNA loaded nanoparticles were unstable and aggregated.  
Additionally, it was interesting to see that the optimum nanoparticle size depends 
also on the respective target. Best gene transfections on murine melanoma cells 
were obtained with small gelatin nanoparticles (~150 nm). In contrast to that, best 
dendritic cell activation occurred with ~300 nm large CpG ODN loaded 
nanoparticles. This fits perfectly with the preferably phagocytosed size of antigen 
presenting cells.  
Comparing the results of gene transfection with the ones of CpG delivery it is 
noticeable that the same carrier platform showed different success. Whereas the 
gene transfection efficiency of cationized gelatin nanoparticles was lower than that 
of PEI-polyplexes, it is known that PEI rather reduces the immunological effect of 
CpG ODNs when delivered as polyplexes. An explanation for this phenomenon is 
that TLR9, the receptor of CpG ODNs, is located within the endosomal 
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compartment. Consequently good transfection reagents, such as PEI, that are 
known to promote a quick endosomal escape, are inappropriate for this purpose. 
On the other hand cholamine-modified nanoparticles apparently comprise a rather 
delayed escape from the endosome.  
Special attention was paid in this work to safety and biocompatibility of gelatin 
nanoparticles. During gene delivery studies, cationized gelatin nanoparticles were 
demonstrated as highly biocompatible, low cytotoxic transfection system in 
contrast to other very efficient non-viral carriers such as cationic liposomes and 
PEI-polyplexes. CpG delivery experiments proved that gelatin nanoparticles 
themselves are an immunologically inert delivery system. The immunogenic effect 
of CpG ODNs led only to efficient immunization against the co-administered 
protein antigen but did not induce the production of anti-gelatin IgGs. 
In the final Chapter V, first PEGylations of the nanoparticle surface were 
performed to achieve prolonged circulation within the blood-stream. The major 
focus here was to establish new analytical tools for quantitative and qualitative 
monitoring of the coupling reaction. AF4 and AFM demonstrated to be highly 
valuable to characterize the successful PEGylation of nanoparticles, since existing 
alternatives are limited. 
In the second part of this chapter, radiolabeling was applied to track the 
biodistribution of gelatin nanoparticles. Aside from radioiodination, 18[F]-coupling 
via prosthetic groups was evaluated for real-time monitoring of the biodistribution 
with positron emission tomography (PET). N-Succinimidyl 4-[18F]fluorobenzoate 
([18F]SFB) was identified as ideal prosthetic group for gelatin nanoparticle labeling. 
Initial biodistribution experiments showed typical quick elimination via the 
mononuclear phagocytotic system (MPS).  
However, no significantly prolonged blood circulation could be achieved using 
PEGylated nanoparticles in a first approach. Nevertheless, various other potential 
PEGylation strategies exist and should be evaluated. If one of these PEGylation 
approaches succeeds, a future application as parenteral carrier system for tumor 
targeting seems possible. The target specificity would occur, since long-circulating 
gelatin nanoparticles are expected to accumulate at the target site due to the 
enhanced permeability and retention (EPR) effect, a phenomenon which allows 
colloidal carriers to penetrate deep into the leaky vasculature surrounding solid 
tumor cells. Aside from this passive targeting approach, covalent coupling of a 
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tumor-specific ligand onto the nanoparticle surface would allow additional active 
targeting. In combination with the established radiolabeling, diagnostic as well as 
therapeutic applications seem feasible.  
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List of abbreviations 
AF 4  Asymmetrical flow field-flow fractionation 
AFM Atomic force microscopy 
APC  Antigen presenting cell 
AUC  Area under the curve 
BSA Bovine serum albumin 
CD Cluster of differentiation 
CLSM  Confocal laser scanning microscopy 
CMV  Cytomegalovirus 
CpG Cytosine-phosphate-guanosine 
CpG motif 
 
Cytosine-phosphate-guanosine dinucleotide in a particular 
sequence context 
CpG ODN Synthetic ODN containing CpG motifs 
CpG-A CpG ODN 2216 
CpG-B CpG ODN 2006 
CpG-C CpG ODN M362 
CpG-GNP CpG ODN loaded cationized gelatin nanoparticle 
CTL Cytotoxic T lymphocytes 
DC Dendritic cell 
DLS Dynamic light scattering 
DMEM Dulbeco's modified eagles medium 
DMSO Dimethyl sulfoxide 
DNA  Deoxyribonucleic acid 
DOPC 1,2-Dioleoyl-sn-glycero-3-phosphocholine 
DOTAP 1,2-Dioleoyl-3-trimethylammonium-propane chloride 
dsRNA Double-stranded RNA 
EDC 1-Ethyl-3-(3-dimethyl-aminopropyl) carbodiimide hydrochloride
EGF Epidermal growth factor 
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ELISA  Enzyme-linked immunosorbent assay 
FACS  Fluorescence-activated cell sorting 
FCA Freund's complete adjuvant 
FCS Fetal calf serum 
FDA US Food and Drug Administration  
FITC Fluoresceine-isothiocyanate 
GM-CSF  Granulocyte-macrophage colony stimulating factor 
GNP Gelatin nanoparticle 
GRAS Generally recognized as safe 
GTA Glutaraldehyde 
HBG  HEPES-buffered glucose 
HBS  HEPES-buffered saline 
hmw High molecular weight 
HPLC  High pressure liquid chromatography 
ID Injected dose 
IEP Isoelectric point 
IFN Interferon 
Ig Immunoglobulin 
IL Interleukin 
lmw Low molecular weight 
LPS  Lipopolysaccharide 
MACS  Magnetic-activated cell sorting 
MALS Multi-angle light scattering  
MDC Myeloid dendritic cell 
MHC Major histocompatibility complex 
MPS  Mononuclear phagocytotic system 
mRNA Messenger ribonucleic acid 
Mw Molecular weight 
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N/P-ratio  Molar ratio of PEI nitrogen to DNA phosphate 
NF-κB  Nuclear factor kappa B 
NK cells Natural killer cells 
NPFP 4-Nitrophenyl 2-fluoropropionate 
OD  Optical density 
ODN  Oligodesoxynucleotide 
OVA Ovalbumin 
PACA Poly(alkylcyanoacrylate)  
PAMP  Pathogen-associated molecular pattern 
PBMC  Peripheral blood mononuclear cell 
PBS  Phosphate-buffered saline 
PCA Poly(cyanoacrylate)  
PCL Poly(ε-caprolactone)  
pCMVLuc  
 
Plasmid encoding for luciferase under control of the CMV 
promoter/enhancer 
PCS Photon correlation spectroscopy  
PDC Plasmacyoid dendritic cell 
pDNA plasmid DNA 
PE  Phycoerythin 
PEA Poly(ester-anhydride)  
PEG  Polyethyleneglycol 
PEI Polyethylenimine 
PEO Polyethyleneoxide 
PET Positron emission tomography 
PI Polydispersity index  
PLA Polylactide 
PLG Polyglycolide 
PLGA Poly(D,L-lactide-co-glycolide)  
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PRR  Pattern recognition receptor 
QELS Quasi-elastic light scattering 
RCY Radiochemical yield 
RES  Reticuloendothelial system 
RGD Rayleigh-Gans-Debye 
RLU  Relative light units 
RNA  Ribonucleic acid 
SE-HPLC Size exclusion HPLC 
SEM  Scanning electron microscopy 
SFB N-Succinimidyl 4-fluorobenzoate 
SLN Solid lipid nanoparticle 
SLS static light scattering 
SPECT Single photon emission computed tomography 
TEPA  Tetraethylenpentamine 
TETA Triethylentetramine 
TH cells T helper cells 
TLC Thin-layer chromatography  
TLR Toll-like receptor 
TNF Tumor necrosis factor 
TSTU 
 
O-(N-succinimidyl)-N-N,N’,N’-tetramethyluronium 
tetrafluoroborate 
W/O Water in oil 
ζ potential Zeta potential 
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